

- Vidgen, E., 530
 Vieira, N.E., 908
 Vierhapper, H., 680
 Vilardell, E., 644
 Villa, P., 538
 Villas-Boas Weffort, R.F., 706
 Viñas, O., 984
 Virgilio-Menopause-Health Group, 5
 Virvidakis, K., 1059
 Viswanathan, V., 1220
 Vittone, J., 89
 Von Eckardstein, A., 1039
 Vosmeer, S., 723
 Voudiklari, S., 1059
 Vuksan, V., 530
- Wada, S., 793
 Wadden, T.A., 857
 Wagner, D., 619
 Wagner, J.D., 698
 Wagner, T.L., 1380
 Wajchenberg, B.L., 159
 Waldhäusl, W., 680
 Walker, J.A., 504, 954, 1275
 Walker, M., 914, 1333
 Waltenbaugh, C., 926
 Walters, J.M., 1448
 Walzem, R., 431
 Wang, J.W.-C., 154
 Wang, P., 454, 625
 Wang, P.S., 154
 Wanner, C., 726
 Ward, G.M., 1448
 Wareham, N.J., 1171
- Warnaar, S.O., 1343
 Wasilewska-Dziubińska, E., 1384
 Wasserman, D.H., 1327
 Wastney, M.E., 330
 Watkinson, A.L., 1101
 Weaver, J.A., 884
 Webster, J.D., 23, 796
 Wehrenberg, W.B., 382
 Weiss, S.T., 1266
 Wellby, M.L., 1429
 Wernerman, J., 756
 Wessel, K., 763
 Westerterp, K.R., 420, 968, 1324
 Whitesell, L.R., 168
 Wiebke, G.A., 179
 Wingrove, C., 1137
 Winocour, P.D., 1406
 Wittert, G., 1399
 Wolever, T.M.S., 530, 805
 Wolfe, R.R., 573, 943
 Wong, N.C.N., 1132
 Wu, H.P., 1211
- Yabuta, K., 146
 Yagui, K., 1044
 Yajnik, C.S., 1
 Yamaguchi, M., 981
 Yamaguchi, T., 1044
 Yamakita, J., 1162
 Yamakita, J.-i., 544, 801, 1339, 1473
 Yamamoto, M., 997, 1166
 Yamamoto, T., 544, 801, 1162, 1339, 1473
 Yamasaki, T., 518
 Yang, C., 1113
- Yanizawa, Y., 199
 Yarasheski, K.E., 306
 Yasuda, K., 997
 Yasunari, K., 287, 1032
 Yasunobu, Y., 355
 Yatzkan, Y., 730
 Yergey, A.L., 908
 Yokoi, H., 880
 Yokokawa, K., 287, 1032
 Yokoyama, J., 1458
 Yoo, H.J., 634
 Yoshida, S., 370
 Yoshikawa, J., 287, 487, 1032
 Yoshimori, K., 793
 Yoshioka, S., 716
 Young, A.A., 67
 Young, T.-K., 154
 Yurgalevitch, S.M., 217
- Zachwieja, J.J., 306
 Zammam, H.Y., 1199
 Zatelli, M.C., 107
 Zech, L.A., 333, 1215, 1231
 Zhang, B., 273
 Zhang, L., 698
 Zhang, X.-J., 943
 Ziegler, T.R., 691
 Zimet, R.J., 1206
 Zinker, B.A., 1327
 Ziogas, G., 1178
 Zmuda, J.M., 217, 1206
 Zou, L., 114
 Zung, A., 1246
 Zvereva, S., 504, 954, 1275
 Zylberberg, G., 711

SUBJECT INDEX

- A, *see* Androstenedione
 AAs, *see* Amino acids
 Abdominal adipose tissue (AT)
 adult GH deficiency and intraabdominal AT, 813, 815
 CAT scan of distribution of, and its correlation with anthropometry and insulin secretion in healthy Asian Indians, 1220-1224
 dietary soy protein and ERT effects on, in ovariectomized subjects, 701
 in obesity-susceptible and obesity-resistant subjects, 212
 sex hormones inhibiting LPL activity in, in men, 179-185
 Absorptiometry, dual-energy x-ray, pre- and post-HD changes in body composition of subjects on chronic HD as assessed by, 1059-1062
 ACE, *see* entries beginning with terms: Angiotensin-converting enzyme
 [1-¹⁴C]Acetate, insulin effects on incorporation of, into lipids and glycogen, in fetal hepatocytes, 346-351
 Acetic acid, effects of time of day and glucose tolerance status on concentrations of, 805-811
 Acetyl-L-carnitine, association of, with muscle glucose and lipid metabolism, effects of hyperinsulinemia on, 1454-1457
 Acetyl coenzyme A (CoA) carboxylase, insulin inhibition of AMP-activated PK in heart resulting in FA oxidation and activation of, 1270-1274
- Acidification, inhibition of endosomal, in normal cells, compared with insulin and insulin receptor metabolic derangements in NIDDM, 1259-1265
 Acidosis, lactic, *see* Lactic acidosis
 Aciduria, mild orotic, nutritional and metabolic effects of, during supplementation with arginine after injury, 785-792
 Acquired immunodeficiency syndrome, *see* HIV-infected men
 Acromegaly, measurement of IGF-I and IGFBP-3 to determine clinical activity index in, 494-498
 ACTH, *see* Corticotropin
 Actinomycin D, effects of, on levels of GHR and GHBP mRNA during 3T3-L1 preadipocyte differentiation, 117
 Activated protein C, myocardial infarction with, homocysteinemia, high PAI-1 activity, and resistance to, 1470-1472
 Acute hyperinsulinemia
 NO production stimulated by, 406-409
 plasma CETP activity and plasma FFAs and, 1166-1170
 serum T concentrations in obese and non-obese men with, 526-529
 Acute insulin resistance, glucocorticoid-induced, in adipocytes, RU38486 effects on, 997-1002
 Acute protein-sparing effects of ethanol in postabsorptive conditions but not in anabolic conditions, 750-755
 Acyltransferase, lecithin:cholesterol, in FED, 474-483

- ADA (adenosine deaminase), effects of adenosine hydrolysis by, on effects of progesterone on glucose metabolism in adipocytes, 595-604
- Adenine dinucleotide phosphate, erythrocyte nicotinamide, in NIDDM, polyol pathway activation, GSH redox status and, 1195
- Adenoma cells, GH-secreting, inhibitory effects of galanin, GHRH, octreotide, and TRH on GH release in, compared, 425-430
- Adenosine, progesterone effects on glucose metabolism in adipocytes modulated by, 595-604
- Adenosine deaminase (ADA), effects of adenosine hydrolysis by, on effects of progesterone on glucose metabolism in adipocytes, 595-604
- Adenosine diphosphate (ADP), platelet aggregation induced by, in Graves' disease and primary hypothyroidism, 1129
- Adenosine monophosphate, *see* AMP
- Adenosine triphosphatase, *see* ATPase
- Adenosine triphosphate, *see* ATP
- Adipocytes
- acute glucocorticoid-induced insulin resistance in, RU 38486 effects on, 997-1002
 - progesterone effects on adenosine and glucose metabolism in, 595-604
 - wortmannin converting insulin but not oxytocin, from antilipolytic to lipolytic agent in presence of forskolin in, 62-66
- Adipose tissue (AT; body fat)
- androgenic status and plasma prothrombin factors in men, irrespective of, 1287-1293
 - dietary soy protein and ERT effects on, in ovariectomized subjects, 701
 - exercise effects on, in men and women, 1182; *see also* Adipose tissue in obese exercising men
 - in hypercholesterolemia, 629
 - in older women, long-term BW maintenance and, 886
 - reduced PTPase in, and improved insulin sensitivity following weight loss in obesity, 1140-1145
 - skeletal muscle, in critical illness, 759, 760
 - in small-cell lung cancer subjects, TEE and, 1413
 - in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and EPA-E on, 1461, 1462
 - VLDL subfraction composition and metabolism in, 605-610
 - white, lipogenesis in, after starvation-refeeding cycles, 10-17
 - see also* Abdominal adipose tissue; Adipocytes; Adipose tissue, leptin and; Adipose tissue blood flow; Adipose tissue in obesity; Subcutaneous adipose tissue; Visceral adipose tissue
- Adipose tissue (AT; body fat), leptin and
- AT and effects of HF diet composition on leptin concentrations, 421
 - serum leptin and AT in HIV-infected men, 303-305
- Adipose tissue blood flow (ATBF) in SCI subjects, 388-392
- Adipose tissue (AT; body fat) in obese exercising men
- and increase in HDL-C with endurance training, 557
 - without weight loss, HDL metabolism and, 218
- Adipose tissue (AT; body fat) in obesity
- femoral, in obese men, sex hormones inhibiting LPL activity in, 179-185; *see also* Adipose tissue in obese exercising men
 - visceral AT effects on insulin secretion, insulin sensitivity, and energy expenditure in obesity, 123-129
- ADMA (asymmetrical dimethylarginine), serum, in nondialyzed subjects with chronic renal insufficiency, 1024-1031
- Adolescents, obese, relationship of serum IGFBP-3, serum PICP, and serum IGF-I to sex, pubertal development, growth, insulin, and nutritional status of, 862-872
- ADP (adenosine diphosphate), platelet aggregation induced by, in Graves' disease and primary hypothyroidism, 1129
- Adrenal(s), radiation dose received by, from apo tracers, 1237
- Adrenal hyperplasia, congenital, complicated by CPP, GnRH therapy of linear growth during infancy due to, 513-517
- Adrenal masses, function of 17-OHP, DHEAS, and ACTH in, 107-113
- Adrenal steroidogenic abnormalities, ovarian and, in hirsute women without hyperandrogenemia, 902-907
- Adrenaline, *see* Epinephrine
- α_2 (alpha₂)-Adrenergic agonists, effects of imidazolines, G-protein and, on insulin secretion in beta cells, 1146-1149
- Adrenergic blockade, effects of portal, on gluconeogenic effects of epinephrine and NE on liver, 458-465
- β (beta)-Adrenergic receptor, brain, beef tallow-induced binding of, in obese subjects, 18-22
- β_3 (beta₃)-Adrenergic receptor, Trp64Arg missense mutation of, in Japanese subjects, prevalence of, 199-202
- Adrenocorticotrophic hormone, *see* Corticotropin
- Adults, *see* Growth hormone, deficiency of, in adults; Men; Normal adult subjects; Women and specific conditions
- Advanced glycation end products (AGEs), serum, as predictors of IDDM-induced changes in renal morphology, 661-664
- Aerobic exercise, sequential effects of weight loss and, on CV disease risk factors in obese middle-aged and older men, 1441-1447
- Afferent stimulation, peripheral, of decentralized sympathetic neurons, lipolysis in SCI activated by, 1465-1469
- African Americans, *see* Race and ethnicity
- AGE(s) (advanced glycation end products), serum, as predictors of changes in renal morphology in IDDM, 661-664
- Age
- abdominal AT/insulin secretion correlation and, 1221
 - ACE gene, insulin resistance and, 396, 397
 - of acromegalic subjects, 495
 - of adrenal mass subjects, 109
 - androgenic status and plasma prothrombin factors in men irrespective of, 1287-1293
 - and association between IGT and Ca homeostasis, 1173-1175
 - of bulimic subjects, 485
 - of cirrhotic subjects, 841
 - of critically ill subjects, 757
 - of ECD subjects, 1218
 - effects of, on response to PTH in HP and PHP, 1246-1251
 - of epileptic subjects on anticonvulsant therapy, 961
 - and exercise, *see* Age, exercise and
 - of FCPD subjects, 2
 - gestational, of premature infants, serum cortisol and cortisone levels and, 520
 - GH and, *see* Age, GH and
 - of glucose-tolerant offspring of NIDDM subjects, 881
 - of Graves' disease subjects, *see* Age of Graves' disease subjects
 - and handgrip strength, 1267, 1268
 - of HD subjects, *see* Age of HD subjects
 - of heart failure patients, daily energy requirements and, 1296
 - of HIV-infected men, total EE and, 1325
 - of HL deficiency subjects, stanozolol effects on serum Lps and, 993
 - of hypercholesterolemic subjects, *see* Age of hypercholesterolemic subjects
 - of hyperinsulinemic subjects, *see* Age of hyperinsulinemic subjects
 - of hyperlipidemic subjects, niceritol effects on plasma Lp(a) and, 356
 - of hypertensive subjects, *see* Age, hypertension and
 - of IDDM subjects, *see* Age of IDDM subjects
 - of IGT subjects, 668, 670, 915
 - insulin resistance and, *see* Age, insulin resistance and
 - leptin concentrations and, *see* Age, leptin concentrations and
 - of liver transplant recipients, 1004
 - of male offspring of CAD parents, 506, 956

Age (*Continued*)

- maternal, preeclampsia and, 964
- of mitochondrial DM subjects, *see* Age of mitochondrial DM subjects
- of multiple myeloma subjects, 1344
- of NIDDM subjects, *see* Age of NIDDM subjects
- of obese subjects, *see* Age of obese subjects
- of postmenopausal women, *see* Age of postmenopausal women
- of premenopausal women, *see* Age of premenopausal women
- and quantitative genetics of SHBG, 990
- race and, and hepatic insulin extraction and clearance, 55, 56
- and relationship between RMR and FFM composition, 1226
- and relationship between serum TGs, serum urate, and FE_{UA} , 1086, 1087
- of SCD children, 1242, 1243
- of SCI subjects, 389, 1466
- and serum Lp(a) levels in endometriosis, 736
- of severe malaria subjects, 1436
- of small-cell lung cancer subjects, TEE and, 1413
- and smoking cessation effects, 712
- of TCP subjects, 442
- and time of day and glucose tolerance status effects on serum SCFAs, 806
- and Trp64Arg missense mutation of β_3 -adrenergic receptor, 200, 202
- of Turner's syndrome subjects, 909, 1483
- of underweight subjects with and without cancer, 141
- visceral AT accumulation and uric acid metabolism correlation and, 1163
- see also entries beginning with terms:* Elderly, Middle-aged, Older, Young
- Age, exercise and
 - and effects of moderate exercise on insulin- and non-insulin mediated glucose uptake, 205
 - by hypercholesterolemic subjects, lovastatin and simvastatin effects on skeletal muscle injury and, 1207
 - see also* Age of obese exercising men
- Age, GH and
 - adult GH deficiency effects on serum leptin, 813
 - correlation of basal GH levels with HDL-C in women, 1040
 - of GH-secreting adenoma subjects, 426
- Age, hypertension and
 - in CHD; ACE gene and, 1212
 - mitogen effects on lymphoblast NHE-1 phosphorylation and PKC activity and, 299
- Age, insulin resistance and
 - LDL particle size and, 1276
 - relationship between, 1282, 1284
- Age, leptin concentrations and
 - HF diet and, 421
 - and plasma leptin concentration in heart failure subjects, 451
 - relationship of plasma leptin to age, race, and body composition in women, 1399-1405
- Age of Graves' disease subjects
 - hyperthyroidic, 1185
 - and of primary hypothyroidism subjects, 1129
- Age of HD subjects
 - of chronic HD subjects, pre- and post-HD body composition changes and, 1060
 - and of chronic renal disease and CAPD subjects, 37
- Age of hypercholesterolemic subjects
 - hyperamylinemic, 1158
 - and lovastatin and simvastatin effects on skeletal muscle injury during exercise, 1207
 - and plasma CETP activity in acute hyperinsulinemia, 1167, 1168
 - pravastatin effects on RBC deformability and, 289
- Age of hyperinsulinemic subjects
 - hyperamylinemic, 1158
 - and plasma CETP activity in acute hyperinsulinemia, 1167, 1168
- Age of IDDM subjects
 - C and plasma apo H levels and, 523
 - and changes in renal morphology, 662
 - with diarrhea and constipation, 731
 - GAD antibodies and GH secretion and, 383
 - intracellular Ca and [3H]PdBu binding to intact platelets and, 950
 - and tolrestat effects on NRBA, 635
- Age of mitochondrial DM subjects
 - with M3243A \rightarrow G mutation and, 794
 - with tRNA^{Leu(UUR)} 3243 mutation, 1020
- Age of NIDDM subjects, 1260
 - C and plasma apo H levels and, 523
 - with or without CHD and hypertension, ACE gene and, 1212
 - day-to-day variation in insulin sensitivity and, 375
 - with diabetic nephropathy and retinopathy, 978, 979
 - with hyperinsulinemia and hypofibrinolysis, 1075
 - hypertensive NIDDM, 1317
 - intracellular Ca and [3H]PdBu binding to intact platelets and, 950
 - non-obese, with diabetic nephropathy, insulin resistance and, 1014, 1016
 - obese, heparin effects on hemostatic abnormalities and, 931
 - peripheral vasoconstrictor responses to SNS activation and, 236
 - polyol pathway activation and GSH redox status and, 1195
 - and tolrestat effects on NRBA, 635
- Age of non-obese men
 - with acute hyperinsulinemia, serum T concentrations in, 527
 - and increase in HDL-C with endurance training, 557
- Age of non-obese subjects
 - with and without cancer, 141
 - with NIDDM and diabetic nephropathy, insulin resistance and, 1014, 1016
 - see also* Age of non-obese men
- Age of obese exercising men
 - and increase in HDL-C with endurance training, 557
 - without weight loss, HDL metabolism and, 218
- Age of obese men
 - with acute hyperinsulinemia, serum T concentrations in, 527
 - hypertensive, and effects of diltiazem or quinapril on insulin sensitivity, glucose effectiveness, and beta cell function, 174
 - sex hormone effects on LPL activity and, 180
 - see also* Age of obese exercising men
- Age of obese subjects
 - hypertensive and normotensive, lipolytic sensitivity and, 1081
 - insulin secretion, insulin sensitivity, EE and, 124
 - with NIDDM, heparin effects on hemostatic abnormalities and, 931
 - race, sex and, and insulin-mediated FFA suppression, 401
 - see also* Age of obese men; Age of obese women
- Age of obese women
 - NPY, leptin, galanin release and, 1385
 - with PCOS, and NTX effects on insulin and GH secretion, 538
 - premenopausal, hyperinsulinemia, sex hormones and, 1253, 1255
 - on weight-reducing diet and exercising, BMC changes and, 858
- Age of postmenopausal women
 - elderly, lipolysis and, 1313
 - SHBG and, 7
- Age of premenopausal women
 - obese, hyperinsulinemia, sex hormones and, 1253, 1255
 - SHBG and, 7
 - VDR alleles and bone mineral density and, 225
- Aggregation, platelet, in Graves' disease and hypothyroidism, 1128-1131

- Aging
 DHEAS and, *see* Aging, DHEAS and
 effects of, on beta cell function and survival, 242-246
 effects of endurance training and, on gluconeogenesis, 414-419
 and erythrocyte membrane sialic acid in IDDM, 59-61
 implications of Cr decrease in hair, sweat, and serum samples due to,
 for prevention of cardiovascular disease, 469-473
 in NIDDM, *see* Aging, NIDDM and
 role of, in metabolic disorders, 310
 whole-body metabolism of zinc in, computer model of, 330-331
see also Older subjects
- Aging, DHEAS and
 aging effects on DHEAS in relation to fasting insulin levels and body
 composition, BIA in assessment of, 826-832
 role of DHEAS in relationship between insulin resistance and aging,
 1281-1286
- Aging, NIDDM and
 effects of NIDDM/aging interaction on insulin action, 890-896
 and erythrocyte membrane sialic acid in NIDDM, 59-61
 implications of Cr decrease in hair, sweat, and serum samples due to
 aging for prevention of NIDDM, 469-473
- AGT (angiotensinogen) gene, polymorphism of, in NIDDM, 976-980
- AIDS (acquired immunodeficiency syndrome), *see* HIV-infected men
- Alanine
 cortisol and estradiol effects on, 248
 DCA effects on, 269
 in isonitrogenous diet, 786, 790, 791
 plasma, *see* Plasma alanine
 portal adrenergic blockade effects on, 459-460
 skeletal muscle, in critical illness, 760
- Alanine aminotransferase (ALT)
 in cirrhosis, 841
 liver transplantation and, 1004
 in small-cell lung cancer subjects, TEE and, 1413
- Albumin
 in chronic renal disease, HD, and CAPD subjects, 37
 and liver transplantation, 1004
 plasma, *see* Plasma albumin
 serum, *see* Serum albumin
 in small-cell lung cancer subjects, TEE and, 1413
see also Albuminuria
- Albuminuria, 979-983
 microalbuminuria in NIDDM with diabetic nephropathy and retinopa-
 thy, 979, 980
 in STZ-DM, troglitazone effects on, 981-983
see also Proteinuria; Urinary excretion of albumin
- Alcohol intake
 and handgrip strength, 1267, 1268
 by IGT subjects, 668, 915
 by male offspring of CAD parent, 506
 plasma insulin, physical activity and, 1420, 1421
 smoking and, 713
see also Ethanol
- Aldose reductase inhibition
 effects of, on glucose flux, DAG formation, PKC, and phospholipase
 A₂ activation in STZ-DM, 41-47
 with tolrestat, effects of, on NRBA in IDDM and NIDDM, 634-638
- Alkaline phosphatase (ALP), MMI and 1 α (OH)D₃ effects on, in Graves'
 disease, 1185
- Allele(s)
 and Trp64Arg missense mutation of β_3 -adrenergic receptor, 201
 vitamin D receptor, and BMD in premenopausal women, race and,
 224-226
see also Allele(s), ACE gene
- Allele(s), ACE gene
 and for ACE gene polymorphism in NIDDM, 978
 insertion allele at ACE gene locus associated with insulin resistance,
 395-399
- Allopurinol, effects of benzbromarone and, on plasma uridine concen-
 trations, 1473-1476
- Alloxan-induced diabetes mellitus (DM), catabolism of prothrombin
 and antithrombin in, 1406-1411
- ALP (alkaline phosphatase), MMI and 1 α (OH)D₃ effects on, in Graves'
 disease, 1185
- Alpha₂ (α_2)-adrenergic agonists, effects of imidazolines, G-protein and,
 on insulin secretion in beta cells, 1146-1149
- Alpha (α) cells, function of, in IRH, 639-643
- 1 alpha (α)-hydroxyvitamin D₃ [1 α (OH)D₃], effects of, on levels of
 serum thyroid hormones in hyperthyroidism with untreated
 Graves' disease, 1184-1188
- Alpha (α)-ketoglutarate (KG) in isonitrogenous diet, 785-792
- Alpha (α)-keto- δ -guanidinovaleric acid, *see* Serum α -keto- δ -guanidino-
 valeric acid
- Alpha-ketoisocaproate, *see* α -Ketoisocaproate
- Alpha (α) lipoic acid (LA), effects of, on glycemia and muscle GLUT4
 transporter content in STZ-DM, 763-768
- Alpha-lipoprotein, *see* High-density lipoprotein
- Alpha-tocopherol, *see* α -Tocopherol; D- α -Tocopherol
- ALT, *see* Alanine aminotransferase
- Ambulatory peritoneal dialysis, *see* Continuous ambulatory peritoneal
 dialysis
- Amide, *see* Glucagon-like peptide-1 (7-36) amide; Glucagon-like
 peptide-1 (7-36) amide gene
- Amino acids (AAs)
 GH modulating oxidation of, in surgical subjects, 23-28
 handling of, in uremia, 611-618
 skeletal muscle concentration of, in critical illness, 758-760
see also specific amino acids
- Ammonium (NH₄), plasma, after exercise, 1340
- AMP (adenosine monophosphate)
 cyclic, progesterone effects on, 595-604
 insulin inhibition of AMP-activated PK in heart resulting in acetyl
 CoA carboxylase and FA oxidation, 1270-1274
- Amylin
 dose-response for glucagonostatic effects of, 67-70
 fasting, in hyperinsulinemia-associated hyperamylinemic glucose-
 tolerant and insulin-resistant subjects, 1158
 IAPP, effects of, on insulin secretion in beta cells, 1044-1051
- Anabolic conditions, acute protein-sparing effects of ethanol in postab-
 sorptive but not in, 750-755
- Androgenic status
 hirsute women without hyperandrogenemia, adrenal and ovarian
 steroidogenic abnormalities and, 902-907
 and plasma prothrombin factors in men, irrespective of age, obesity,
 and AT distribution, 1287-1293
see also specific hormones
- Androstenedione (A; Δ^4 -DIONE)
 in obese hyperinsulinemic women, 1255
 serum, effects of long-term RU486 therapy on, 292-296
see also Androstenedione in PCOS
- Androstenedione (A; Δ^4 -DIONE) in PCOS
 long-term NTX therapy effects on, 540
 with severe hirsutism, effects of triptorelin with desogestrel-
 containing OCs on, 439
- Anesthesia, lactate-induced insulin resistance in heart and skeletal
 muscles during, 684-690
- ANF (atrial natriuretic factor), effects of, on CGRP, 818-825
- Angiotensin II (Ang II), ET-1 production in VSMCs and, 488, 490

- Angiotensin-converting enzyme gene, *see* Allele(s), ACE gene; Polymorphism, ACE gene, in NIDDM
- Angiotensin-converting enzyme (ACE) inhibitor(s), quinapril as, effects of, on insulin sensitivity, glucose effectiveness, and beta cell function in obese hypertensive men, 173-178
- Angiotensinogen (AGT) gene, polymorphism of, in NIDDM, 976-980
- 1,5-Anhydroglucitol in IDDM and NIDDM, intracellular Ca and [³H]PdBu binding to intact platelets and, 950
- Anorexia nervosa, NPY, leptin, and galanin release in, 1384-1389
- ANPs, *see* Atrial natriuretic peptides
- Anthropometry
- CAT scan of abdominal AT distribution and its correlation with insulin secretion and, in healthy Asian Indians, 1220-1224
 - impact of variables of, on PAI-1, fibrinogen, and FVII in IGT, 670
 - see also specific anthropometric data*
- Antibodies
- to GAD, GH secretion and, in IDDM, 382-387
 - to IL-6, therapy of multiple myeloma with, 1343-1348
- Anticonvulsant therapy, total plasma Hcy in epileptic patients on, 959-962
- Antidiabetic drugs, effects of, on arterial contraction, 1199-1205
- Antihypertensive therapy
- of hypertensive NIDDM, Na⁺/H⁺ and Na⁺/Li⁺ CT activity and, 1316-1323
 - see also specific antihypertensive agents*
- Antilipolytic agent, wortmannin as, converting insulin but not oxytocin from, to lipolytic agent in presence of forskolin, 62-66
- Antioxidants
- PKC-signaled increases in TGF- β in mesangial cells inhibited by, 918-925
 - vitamin E lowering effects on TGs and, associated with prevention of abnormal reactivity and morphology of aorta in STZ-DM, 872-879
- Antithrombin, catabolism of prothrombin and, in alloxan-induced DM and in normal subjects, 1406-1411
- Antithrombin III (ATIII)
- plasma levels of, and androgenic status in men, 1287-1293
 - thrombin-, in obese NIDDM subjects, heparin effects on, 932
- Antithyroid drugs for Graves' disease and primary hypothyroidism, 1129
- Aorta, abnormal reactivity and morphology of, in STZ-DM, antioxidant and TG-lowering effects of vitamin E associated with prevention of, 872-879
- Aortic cholesteryl ester, ERT and dietary soy protein effects on CV disease risk factors and, in ovariectomized subjects, 698-705
- Apo(s), *see* Apolipoprotein(s)
- Apolipoprotein(s) (apo)
- plasma, smoking cessation effects on, 713
 - see also specific apolipoproteins*
- Apolipoprotein A-I (apo A-I)
- and basal GH levels in women correlated with HDL-C, 1040, 1041
 - diet effects on, *see* Apolipoprotein A-I, diet effects on
 - in FED, 476, 478, 481
 - in HL deficiency, stanozolol effects on serum Lps and, 993, 994
 - in obesity, *see* Apolipoprotein A-I in obesity
 - plasma, *see* Plasma apolipoprotein A-I
 - and SLDL particles in children, 147
 - serum fasting, in young women with endometriosis, 736
 - smoking cessation effects on, 713, 714
- Apolipoprotein A-I (apo A-I), diet effects on
- CHO effects on expression of, in young and older subjects, 1132-1136
 - of diet high in vegetables, fruit, and nuts on, 533
 - dietary fat restriction effects on, 434
- Apolipoprotein A-I (apo A-I) in obesity
- with NIDDM, heparin effects on hemostatic abnormalities and, 931
 - in obese exercising men without weight loss, 219, 220
- Apolipoprotein A-II (apo A-II)
- and basal GH levels in women correlated with HDL-C, 1040, 1041
 - in FED, 476, 478
 - in HL deficiency, stanozolol effects on serum Lps and, 993, 994
 - in obese exercising men without weight loss, HDL metabolism and, 219, 220
 - plasma, and plasma CETP activity in acute hyperinsulinemia, 1167, 1168
 - serum fasting, in young women with endometriosis, 736
- Apolipoprotein A-IV (apo A-IV) in FED, 476, 478
- Apolipoprotein B (apo B)
- and basal GH levels in women correlated with HDL-C, 1040, 1041
 - diet effects on, *see* Apolipoprotein B, diet effects on
 - in ECD, 1218
 - in HL deficiency, stanozolol effects on serum Lps and, 993, 994
 - intestinal, mRNA of, in FHBL without truncation of, 1095-1100
 - kinetics of VLDLs of, [³H]leucine in study of, 335-341
 - in obesity, *see* Apolipoprotein B in obesity
 - plasma, and plasma CETP activity in acute hyperinsulinemia, 1167
 - PP hemorrhheology and metabolism of, in familial hypertriglyceridemia, 1299-1304
 - and SLDL particles in children, 147
 - serum fasting, in young women with endometriosis, 736
 - smoking cessation effects on, 713, 714
- Apolipoprotein B (apo B), diet effects on
- of diet high in vegetables, fruit, and nuts on, 533, 534
 - dietary fat restriction effects on, 434
- Apolipoprotein B (apo B) in obesity
- with NIDDM, heparin effects of hemostatic abnormalities and, 931
 - in obese exercising men without weight loss, 219
- Apolipoprotein B (apo B) phenotype in persistent hypobetalipoproteinemia, 630
- Apolipoprotein B:AI (apo B:AI), effects of diet high in vegetables, fruit, and nuts on, 533
- Apolipoprotein B-48 (apo B-48), synthesis of, in FHBL without apo B truncation, 1095-1100
- Apolipoprotein E (apo E)
- genotype of, in persistent hypobetalipoproteinemia, 630
 - Lp(a) binding to HSPGs enhanced by LPL and improved by saturation with, 650-655
- Apolipoprotein H (apo H; β_2 -glycoprotein I), plasma, in IDDM and NIDDM, C levels correlated with, 522-525
- Apolipoprotein (apo) tracers, determination of radiation dose received from, 1231-1239
- Applesauce in soy protein diet, 699
- Arginic acid, serum, in nondialyzed patients with chronic renal insufficiency, 1026, 1028
- Arginine (ARG)
- metabolism of, in tumor-bearing subjects on TPN, 370-373
 - plasma, *see* Plasma arginine
 - serum, *see* Serum arginine
 - skeletal muscle, in critical illness, 760
 - supplementation with, after injury, nutritional and metabolic effects of mild orotic aciduria during, 785-792
 - Trp64Arg missense mutation of β_3 -adrenergic receptor in Japanese subjects, prevalence of, 199-202
 - see also* D-Arginine; L-Arginine; Arginine-vasopressin; Dimethylarginine
- D-Arginine (ARG), lack of effects of, on insulin-mediated glucose uptake, 1068-1073

- L-Arginine (ARG)
 amylin effects on glucagon response to, 68, 69
 on insulin-mediated glucose uptake, 1068-1073
- Arginine-vasopressin (AVP), ET-1 production in VSMCs and, 488-490
- Arterial contraction, effects of antidiabetic drugs on, 1199-1205
- Arterial epinephrine (EPI), prolonged exercise in DM and, 1328-1329
- Arterial pressure, *see* Blood pressure
- Arterialized venous blood of hand and foot in assessment of glucose metabolism, 1364-1366
- Ascorbic acid (vitamin C), intake of, with diet high in vegetables, fruit, and nuts, 532
- Asian Indians, healthy, CAT scan of abdominal AT distribution and its correlation with anthropometry and insulin secretion in, 1220-1224
- Asparagine
 plasma, *see* Plasma asparagine
 skeletal muscle, in critical illness, 760
- Aspartate
 plasma, *see* Plasma aspartate
 skeletal muscle, in critical illness, 760
- Aspartate transaminase (AST)
 liver transplantation and, 1004
 in severe malaria, 1436
- Aspartic acid in isonitrogenous diet, 786, 790, 791
- AST, *see* Aspartate transaminase
- Asymmetrical dimethylarginine (ADMA), serum, in nondialyzed subjects with chronic renal insufficiency, 1024-1031
- AT, *see* Adipose tissue
- ATBF (adipose tissue blood flow) in SCI subjects, 388-392
- Atherogenic risk in male offspring of parents with early CAD, LDL particle size as marker for, 954-958
- Athletes, *see* Exercise
- ATP (adenosine triphosphate)
 pyrimidine degradation induced by consumption of, 1339-1341
 skeletal muscle, in critical illness, 759, 761
- ATPase (adenosine triphosphatase)
 Ca²⁺/, and Mg²⁺/, in diabetic cardiomyopathy, 73
 Na⁺/K⁺, activity of erythrocyte membrane, in IDDM and NIDDM, aging and, 59-61
- ATRA (all-*trans*-retinoic acid), effects of, on insulin secretion from RINm5F cells, 656-660
- Atrial natriuretic factor (ANF), effects of, on CGRP, 818-825
- Atrial natriuretic peptides (ANPs)
 effects of long-acting, on CGRP, 818-825
 ET-1 production in VSMCs modulated by, 487-493
- Atrophy of unweighted muscle, insulin effects on, 673-679
- ATIII, *see* Antithrombin III
- Autofeedback, negative GH, on GH-releasing effects of hexarelin, 83-88
- AVP (arginine-vasopressin), ET-1 production in VSMCs and, 488-490
- Basal growth hormone (GH), HDL-C correlated with, in women, 1039-1044
- BCAAs (branched-chain amino acids), *see* Amino acids
- Beef tallow
 brain β -adrenergic receptor binding induced by, in obese subjects, 18-22
 in soy protein diet, 699
- Benzbromarone, effects of allopurinol and, on plasma uridine concentrations, 1473-1476
- BEP (beta endorphin), effects of naloxone-induced opioid withdrawal on, 131
- Beta (β)-adrenergic receptor, binding of brain, induced by beef tallow diet in obese subjects, 18-22
- Beta (β) cells
 aging effects on function and survival of, 242-246
 insulin secretion in, *see* Beta cells, insulin secretion in
 and insulin sensitivity, *see* Beta cells, insulin sensitivity and
 in obese hypertensive men, effects of diltiazem or quinapril on, 173-178
 partial preservation of, by vanadium, in STZ-DM, 769-777
 purified and nonpurified, respiratory chain activity and mitochondrial DNA content of, 984-987
- Beta (β) cells, insulin secretion in
 IAPP/amylin effects on, 1044-1051
 imidazolines, α_2 -adrenergic agonists, and G-protein effects on, 1146-1149
- Beta (β) cells, insulin sensitivity and
 in hyperlipidemia, troglitazone effects on, 273-281
 in obesity, secretion kinetics of, 127-128
 in TCP, 441-444
- Beta (β) endorphin (BEP), effects of naloxone-induced opioid withdrawal on, 131
- Beta (β)-glycoprotein I (apo H), plasma, in IDDM and NIDDM, C levels correlated with, 522-525
- Beta (β)-hydroxy-5-androsten-17-one, *see* Dehydroepiandrosterone sulfate
- Beta (β)-hydroxybutyrate (BOHB), portal adrenergic blockade effects on, 461
- BF, *see* Blood flow
- BIA (body impedance analysis), aging effects on DHEAS in relation to fasting insulin level and body composition assessed with, 826-832
- Bicarbonate (HCO₃)-urea method measuring TEE in small-cell lung cancer subjects, 1412-1417
- Bilirubin
 liver transplantation and, 1004
 serum, in severe malaria subjects, 1436
 in small-cell lung cancer subjects, TEE and, 1413
- Biochemical parameters
 longitudinal changes in skeletal muscle, in critical illness, 756-762
see also specific biochemical data
- Biology, mitochondrial, 306-308
- Biphosphate, *see* Fructose 2,6-biphosphate
- BK (bradykinin), effects of, on insulin, glucagon, and somatostatin secretion, in pancreatic islets, 1113-1115
- Bladder and bladder wall, radiation dose received by, from apo tracers, 1235-1238
- Blood Cu (copper) enzyme, effects of Cu supplementation on CV disease risk and, in men, 1380-1383
- Blood flow (BF)
 adipose tissue, in SCI subjects, 388-392
 hepatic, effects of portal adrenergic blockade on, 459, 460
 during ischemia in STZ-DM, 170
 measurement of cutaneous, to determine peripheral vasoconstrictor response to SNS activation in NIDDM, 235-241
- Blood glucose
 in cirrhosis, 842
 in exercising transgenic subjects, 1352-1353
 fasting, *see* Fasting blood glucose
 GH therapy effects on, in Turner's syndrome, 1484
 hypothyroidism effects on, 155
 incretin effects on, 262
 in NIDDM, *see* Blood glucose in NIDDM
 physical activity and, 1420
 in STZ-DM, *see* Blood glucose in STZ-DM
- Blood glucose in NIDDM
 aging and, 892, 893
 with obesity, and heparin effects on hemostatic abnormalities, 931

- Blood glucose in STZ-DM
CS-045 effects on, 982
 α LA effects on, 764
- Blood insulin
in cirrhosis, 842
 α LA effects on, in STZ-DM, 764
- Blood lactic acid, ethanol and fructose effects on, compared, 546
- Blood phosphate, ethanol and fructose effects on, compared, 546
- Blood pressure (BP)
abdominal AT/insulin secretion correlation and, 1221
acute hyperinsulinemia effects on, 407
and androgenic status in men, 1289
in children, SLDL particles and, 147
in chronic renal disease, HD, and CAPD subjects, 37
during exercise, 283
in hypobetalipoproteinemia, 627, 630
in IDDM, *see* Blood pressure in IDDM
of IGT subjects, 668, 915
insulin resistance, *see* Blood pressure, insulin resistance and LANP, vessel dilator, kaliuretic peptide, and ANF effects on, 820
of male offspring of CAD parents, 506, 956
in NIDDM, *see* Blood pressure in NIDDM
portal adrenergic blockade effects on, 459, 460
in STZ-DM, *see* Blood pressure in STZ-DM
see also Hypertension; Normotensive subjects, obese
- Blood pressure (BP), insulin resistance and
ACE gene, and, 396, 397
LDL particle size and, 1276
- Blood pressure (BP) in IDDM, 662
intracellular Ca and [3 H]PdBu binding to intact platelets and, 950
- Blood pressure (BP) in NIDDM
with diabetic nephropathy, *see* Blood pressure in NIDDM with diabetic nephropathy
intracellular Ca and [3 H]PdBu binding to intact platelets and, 950
peripheral vasoconstrictor responses to SNS activation and, 236
Trp64Arg missense mutation of β_3 -adrenergic receptor and, 202
- Blood pressure (BP) in NIDDM with diabetic nephropathy
in non-obese subjects, 1014
and retinopathy and, 978, 979
- Blood pressure (BP) in STZ-DM
CS-045 effects on, 982
during ischemia, 170
- Blood pyruvic acid, ethanol and fructose effects on, compared, 546
- Blood urea nitrogen (BUN) in hypercholesterolemia, pravastatin effects on RBC deformability and, 289
- BMC, *see* Bone mineral content
- BMD, *see* Bone mineral density
- BMI, *see* Body mass and body mass index
- BNPs (brain natriuretic peptides), ET-1 production in VSMCs modulated by, 487-493
- Body composition
aging effects on DHEAS in relation to fasting insulin level and, BIA in assessment of, 826-832
of chronic HD subjects, pre- and post-HD changes in, as assessed by DEXA, 1059-1062
endurance exercise effects on, in lean and obese men, 558
GHRH 1-29 effects on, 91
and insulin secretion, insulin sensitivity, and EE, 124, 125
leptin and, *see* Body composition, leptin and
of obese women, 859, 970
see also Adipose tissue; Body mass and body mass index; Fat-free mass; Fat mass; Muscle mass
- Body composition, leptin and
body composition relationship to GH deficiency effects on serum leptin in adults, 812-817
- Body composition, leptin and (*Continued*)
relationship of body composition, age, and race to plasma leptin, 1399-1405
- Body fat, *see* Adipose tissue
- Body impedance analysis (BIA), aging effects on DHEAS in relation to fasting insulin level and body composition assessed with, 826-832
- Body mass and body mass index (BMI)
abdominal AT/insulin secretion correlation and, 1221, 1222
aging effects on DHEAS in relation to fasting insulin level and, 828-830
and androgenic status in men, 1289
of bulimic women, 485
of children, SLDL particles and, 147
of chronic renal disease, HD, and CAPD subjects, 37
of cirrhotic subjects, 841
and correlation between visceral AT accumulation and metabolism of uric acid, 1163, 1164
diet effects on, *see* Body mass and body mass index, diet effects on
of ECD subjects, 1218
exercise and, *see* Body mass and body mass index, exercise and
of FCPD subjects, 2
GH and, *see* Body mass and body mass index, GH and
of glucose-tolerant offspring of NIDDM subjects, 881
of gout subjects, 802
and handgrip strength, 1267, 1268
of heart failure patients, daily energy requirements and, 1296
of HIV-infected men, total EE and, 1325
of hyperinsulinemic subjects, *see* Body mass and body mass index of hyperinsulinemic subjects
of hypertensive subjects, *see* Body mass and body mass index of hypertensive subjects
of IDDM subjects, *see* Body mass and body mass index of IDDM subjects
and IGT, *see* Body mass and body mass index, IGT and
of infants with CAH with and without CPP, 526
insulin resistance and, *see* Body mass and body mass index, insulin resistance and
insulin secretion and, *see* Body mass and body mass index, insulin secretion and
leptin and, *see* Body mass and body mass index, leptin and
of liver transplant recipients, 1004
of male offspring of CAD parents, 506, 956
of mitochondrial DM subjects, *see* Body mass and body mass index of mitochondrial subjects
of multiple myeloma subjects, 1344
of NIDDM subjects, *see* Body mass and body mass index of NIDDM subjects
of non-obese subjects, *see* Body mass and body mass index of non-obese subjects
of normotensive obese subjects, lipolytic sensitivity and, 1081
of obese subjects, *see* Body mass and body mass index of obese subjects
of older women, long-term BW maintenance and, 886
PCOS and, *see* Body mass and body mass index of PCOS women
of postmenopausal women, *see* Body mass and body mass index of postmenopausal women
of premenopausal women, *see* Body mass and body mass index of premenopausal women
and quantitative genetics of SHBG, 990
race and, and hepatic insulin extraction and clearance, 55, 56
and relationship between RMR and FFM composition, 1226
of SCD children, 1242-1244
of small-cell lung cancer subjects, TEE and, 1413
smoking cessation effects on, 712, 714

- Body mass and body mass index (BMI) (*Continued*)
 of TCP subjects, 442
 time of day and glucose tolerance status effects on serum SCFAs and, 806
 and Trp64Arg missense mutation of β 3-adrenergic receptor, 200, 201
 of Turner's syndrome subjects, 909, 1483
 of underweight subjects with and without cancer, 141
- Body mass and body mass index (BMI), diet effects on
 dietary soy protein and ERT effects on BMI of ovariectomized subjects, 701
 HF diet effects on leptin concentrations on, 421
- Body mass and body mass index (BMI), exercise and
 exercise effects on BMI, 1179
 and lovastatin and simvastatin effects on skeletal muscle injury during exercise in hypercholesterolemia, 1207
 and moderate exercise effects on insulin- and non-insulin mediated glucose uptake, 205
see also Body mass and body mass index, exercise and, in men
- Body mass and body mass index (BMI), exercise and, in men
 exercise effects on BMI, 1179
 of obese exercising men without weight loss, HDL metabolism and, 218
 plasma insulin, physical activity and, 1420
- Body mass and body mass index (BMI), GH and, 915
 and adult GH deficiency effects on serum leptin, 813, 815
 and basal GH levels in women correlated with HDL-C, 1040, 1041
- Body mass and body mass index (BMI), IGT and, 668, 670
 IGT/Ca homeostasis association and, 1174, 1175
- Body mass and body mass index (BMI), insulin resistance and
 ACE gene and, 396, 397
 LDL particle size and, 1276, 1278
 relationship between, 1282
- Body mass and body mass index (BMI), insulin secretion and
 insulin sensitivity, EE and, 124
 and long-term NTX therapy effects on insulin secretion in obese women and non-obese women with and without PCOS, 539
- Body mass and body mass index (BMI), leptin and
 HF diet effects on leptin concentrations on, 421
 relationship between BMI and plasma leptin levels in women, 1403, 1404
- Body mass and body mass index (BMI) of hyperinsulinemic subjects
 hyperamylinemic, 1158
 and plasma CETP activity in acute hyperinsulinemia, 1167, 1168
- Body mass and body mass index (BMI) of hypertensive subjects
 with or without CHD, ACE gene and, 1212, 1213
 obese, lipolytic sensitivity and, 1081
- Body mass and body mass index (BMI) of IDDM subjects
 C and plasma apo H levels and, 523
 GAD antibodies and GH secretion and, 383
- Body mass and body mass index (BMI) of mitochondrial DM subjects
 prevalence of M3243A→G mutation and, 794
 tRNA^{Leu(UUR)} 3243 mutation and, 1020
- Body mass and body mass index (BMI) of NIDDM subjects, 1260
 C and plasma apo H levels and, 523
 with or without CHD and hypertension, ACE gene and, 1212, 1213
 day-to-day variation in insulin sensitivity and, 375
 diabetic nephropathy, *see* Body mass and body mass index of NIDDM subjects with diabetic nephropathy
 heparin effects on hemostatic abnormalities and, 931
 peripheral vasoconstrictor responses to SNS activation and, 236
- Body mass and body mass index (BMI) of NIDDM subjects with
 diabetic nephropathy
 non-obese, and insulin resistance, 1014, 1016
 and retinopathy and, 978, 979
- Body mass and body mass index (BMI) of non-obese subjects
 with and without cancer, 141
 and long-term NTX therapy effects on insulin secretion in non-obese women with PCOS, 539
 of non-obese men, effects of acute hyperinsulinemia on serum T concentrations and, 527
- Body mass and body mass index (BMI) of obese men
 and acute hyperinsulinemia effects on serum T concentrations, 527
 of obese exercising men without weight loss, HDL metabolism and, 218
 of obese hypertensive men, diltiazem or quinapril effects on insulin sensitivity, glucose effectiveness, and beta cell function and, 174
 sex hormone effects on LPL activity and, 180
- Body mass and body mass index (BMI) of obese subjects
 following weight loss, reduced AT PTPase and improved insulin sensitivity and, 1141
 of obese women, *see* Body mass and body mass index of obese women
 race, sex and, and insulin-mediated FFA suppression and fasting TG levels, 401, 402
see also Body mass and body mass index of obese men
- Body mass and body mass index (BMI) of obese women
 FM loss effects on, during weight reduction, 969
 and NPY, leptin, and galanin release, 1385
 with PCOS, and long-term NTX therapy effects on insulin and GH secretion, 539
 premenopausal, hyperinsulinism, sex hormones and, 1253, 1255
- Body mass and body mass index (BMI) of PCOS women
 metformin effects and, 455
 obese and non-obese, and long-term NTX therapy effects on insulin and GH secretion, 539
- Body mass and body mass index (BMI) of postmenopausal women
 plasma leptin and, 1479
 SHBG and, 7, 8
- Body mass and body mass index (BMI) of premenopausal women
 obese, hyperinsulinism, sex hormones and, 1253, 1255
 SHBG and, 7, 8
- Body weight (BW)
 of cardiomyopathic subjects, 72
 of chronic HD patients, pre- and post-HD changes in, 1060
 and clofibrate-induced hyperoxaluria, 136-137
 and correlation between visceral AT accumulation and metabolism of uric acid, 1163
 of critically ill subjects, 757
 diet effects on, *see* Body weight, diet effects on
 energy requirements for long-term maintenance of, in older women, 884-889
 exercise and, *see* Body weight, exercise and
 of heart failure subjects, plasma leptin concentrations, EE and, 451
 of HIV-infected men, total EE and, 1325
 of HL deficiency patients, stanozolol effects on serum Lps and, 993
 and IGF-I and IGF-BPs following graded uninephrectomy, 30
 indomethacin and flurbiprofen effects on, in T-cell leukemia, 361-362
 of infants with CAH with and without CPP, 526
 mitochondrial tRNA^{Leu(UUR)} 3243 mutation in DM and, 1020
 muscle unweighting effects on, 675
 of NIDDM subjects, *see* Body weight of NIDDM subjects
 of postmenopausal women, *see* Body weight of postmenopausal women
 of premenopausal women, *see* Body weight of premenopausal women
 race and, and hepatic insulin extraction and clearance, 55, 56
 and relationship between RMR and FFM composition, 1226
 of SCI subjects, 389, 1466
 and serum Lp(a) levels in endometriosis, 736

- Body weight (BW) (*Continued*)
 of severe malaria subjects, 1436
 of small-cell lung cancer subjects, TEE and, 1413
 smokeless nicotine effects on, 1010
 smoking cessation effects on, 714
 in STZ-DM, *see* Body weight in STZ-DM
 of TAK-044- and hydrazaline-treated malignant hypertension subjects, 1033
 time of day and glucose tolerance status effects on serum SCFAs and, 806
 of Turner's syndrome subjects, 909, 1483
see also Non-obese subjects; Obesity; Underweight subjects; Weight gain; Weight loss in obesity
- Body weight (BW), diet effects on
 of diet high in vegetables, fruit, and nuts, 533, 534
 dietary fat restriction effects, 434
 dietary protein effects on BW of burned children, 575
 dietary soy protein and ERT effects on BW of ovariectomized subjects, 701
 and insulin resistance induced by HF diet, 101
 of protein-restricted diet, 692-693
 of TPN in tumor-bearing subjects, 372
- Body weight (BW), exercise and
 lovastatin and simvastatin effects on, during exercise by hypercholesterolemic subjects, 1207
 and moderate exercise effects on insulin- and non-insulin-mediated glucose uptake, 205
 plasma insulin, physical activity and, in men, 1420, 1421
 of transgenic subjects, 1351
- Body weight (BW) of NIDDM subjects
 day-to-day variation in insulin sensitivity and, 375
 with hyperinsulinemia and hypofibrinolysis, 1075
 hypertensive NIDDM, 1317
 spontaneous NIDDM, and effect of lard, olive oil, safflower oil, and EPA-E on, 1460
- Body weight (BW) of postmenopausal women
 elderly, lipolysis and, 1313
 SHBG and, 7, 8
- Body weight (BW) of premenopausal women
 SHBG and, 7, 8
 VDR alleles, bone mineral density and, 225
- Body weight (BW) in STZ-DM
 CS-045 effects on, 982
 vitamin E effects on, 874
- BOHB (β -hydroxybutyrate), portal adrenergic blockade effects on, 461
- Bone(s), radiation dose from apo tracers received by, 1237
- Bone density, effects of triptorelin with desogestrel-containing oral contraceptives on, in PCOS with severe hirsutism, 437-440
- Bone marrow, red, radiation dose received from apo tracers by, 1235-1237
- Bone mineral content (BMC)
 of chronic HD patients, pre- and post-HD changes in, 1060
 in obese women, *see* Bone mineral content in obese dieting women
- Bone mineral content (BMC) in obese dieting women
 changes in, 857-861
 FM loss and, 969
- Bone mineral density (BMD)
 in chronic HD patients, pre- and post-HD changes in, 1060
 in obese exercising women on weight-reducing diet, 858, 859
 vitamin D receptor alleles and, in premenopausal women, race and, 224-226
- Bone turnover in girls with Turner's syndrome, estrogen therapy effects on Ca absorption, Ca retention and, 908-913
- Bovine retinal endothelial cells, *see* Insulin-like growth factor-binding protein(s) in BRECs, production of
- BP, *see* Blood pressure
- Bradykinin (BK), effects of, on insulin, glucagon, and somatostatin secretion, in pancreatic islets, 1113-1115
- Brain β (beta)-adrenergic receptor, beef tallow-induced binding of, in obese subjects, 18-22
- Brain natriuretic peptides (BNPs), ET-1 production in VSMCs modulated by, 487-493
- Bran, wheat, in soy protein diet, 699
- Branched-chain amino acids, *see* Amino acids
- BRECs (bovine retinal endothelial cells), *see* Insulin-like growth factor-binding protein(s) in BRECs, production of
- BRL 49653, systemic FA supply and utilization, and tissue lipid availability reduced by, in NIDDM, 935-942
- 8-Bromo cyclic guanosine monophosphate (cGMP), effects of, on ET-1 production in VSMCs, 492
- Bulimia nervosa, IVGTT in, 484-486
- BUN (blood urea nitrogen) in hypercholesterolemia, pravastatin effects on RBC deformability and, 289
- Burned children, effects of dietary protein intake on urea and protein metabolism in, 573-578
- Butter in soy protein diet, 699
- Butyric acid, effects of time of day and glucose tolerance status on concentrations of, 805-811
- BW, *see* Body weight
- C, *see* Cholesterol
- Ca (and Ca^{2+} ; calcium)
 activation of MAPK in hepatocytes by Ca-dependent pathway, 548-555
 dietary, *see* Dietary Ca
 estrogen therapy effects on absorption and retention of, and on bone turnover in girls with Turner's syndrome, 908-913
 hypothyroidism effects on, 155
 IGT and altered homeostasis of, 1171-1777
 oscillatory signaling by, in somatostatin-producing pancreatic cells, 366-369
 urinary excretion of creatinine and, in early pregnancy, preeclampsia development and, 1107-1108
 vascular myocyte NHE-1 activation induced by, 250-256
see also Ca^{2+} /ATPase; Ca channel blocker(s); $[\text{Ca}^{2+}]_i$; Calcific pancreatitis
- Ca^{2+} /ATPase (calcium/adenosine triphosphatase) in diabetic cardiomyopathy, 73
- Ca (calcium) channel blocker(s), diltiazem as, effects of, on insulin sensitivity, glucose effectiveness, and beta cell function in obese hypertensive men, 173-178
- $[\text{Ca}^{2+}]_i$ (cytosolic Ca; intracellular Ca), $[\text{^3H}]\text{PdBu}$ and, binding to intact platelets in young IDDM and NIDDM subjects, 949-953
- Cachexia, T-cell leukemia-induced, PGs in, 359-365
- CAD, *see* Coronary artery disease, male offspring of parents with
- CAH (congenital adrenal hyperplasia) complicated by CPP, GnRH agonist therapy of linear growth during infancy due to, 513-517
- Calcific pancreatitis, tropical, beta cell function and insulin sensitivity in, 441-444
- Calcitonin gene-related peptide (CGRP), LANP effects on, 818-825
- Calcium, *see* Ca
- Caloric diet and intake
 of burned children, 575
 with diet high in vegetables, fruit, and nuts, 532, 534
 GH and, *see* Caloric diet and intake, GH and
see also Energy intake; Thermic effect of the meal
- Caloric diet and intake, GH and
 effects of GH and nitrogen-free hypocaloric diet on postoperative protein synthesis, 796-800

- Caloric diet and intake, GH and (*Continued*)
 nitrogenous caloric diet, leucine kinetics during fasting and feeding using GH and, 23-28
- cAMP (cyclic adenosine monophosphate), progesterone effects on, 595-604
- Cancer
 underweight and non-obese subjects with, insulin secretion, insulin sensitivity, and glucose production in, 140-145
see also Tumor(s)
- CAPD, *see* Continuous ambulatory peritoneal dialysis
- Carbachol, insulinotropic sensitivity to glucose and, in HF diet-induced insulin resistance, 97-106
- Carbohydrate(s) (CHO)
 kinetics of, stable isotopically labeled tracers in study of, 322-329
 metabolism of, in HGPS, 854, 855
see also Carbohydrate intake and specific carbohydrates
- Carbohydrate (CHO) intake
 daily requirements in, for long-term BW maintenance in older women, 885
 with diet high in vegetables, fruit, and nuts, 532
 in exercise, 1180
 in NIDDM, *see* Carbohydrate intake in NIDDM
 plasma insulin, physical activity and, 1420
 smoking cessation effects on, 713
 with soy protein diet, 699
- Carbohydrate (CHO) intake in NIDDM
 effects of, on apo A-I expression in young and older subjects, 1132-1136
 metformin effects on oxidation of, 229, 230
- Carbon dioxide, *see* $^{13}\text{CO}_2$ APE; Energy expenditure; PaCO_2
- Carboxykinase, *see* Phosphoenolpyruvate carboxykinase
- Carboxylase, CoA acetyl, insulin inhibition of AMP-activated PK in heart resulting in FA oxidation and activation of, 1270-1274
- Cardiac ventricles
 in malignant hypertension, TAK-044 and hydralazine effects on, in malignant hypertension, compared, 1036
 weight of, in diabetic cardiomyopathy, 72
- Cardiomyopathy, diabetic, MLC phosphorylation in, 71-75
- Cardiovascular (CV) disease
 implications of age-related Cr decrease in hair, sweat, and serum samples for prevention of, 469-473
 serum Ca concentrations and mortality due to, 1171-1177
see also Coronary heart disease; Diabetic cardiomyopathy
- Cardiovascular (CV) disease, risk factors for
 dietary soy protein and ERT decrease aortic cholesteryl ester content and, in ovariectomized subjects, 698-705
see also Cardiovascular disease, risk factors for, in men
- Cardiovascular (CV) disease, risk factors for, in men
 Cu supplementation effects on blood Cu enzyme and, 1380-1383
 sequential effects of aerobic exercise and weight loss on, in middle-aged and older men, 1441-1447
see also Coronary artery disease, male offspring of parents with
- Carnitine, acetyl-L-, association of, with muscle glucose and lipid metabolism, effects of hyperinsulinemia on, 1454-1457
- Carnosine, plasma and skeletal muscle, in critical illness, 760
- Casein
 in protein-restricted diet, 692
 in soy protein diet, 698-704
- CAT (computed axial tomography) of abdominal AT distribution and its correlation with anthropometry and insulin secretion in healthy Asian Indians, 1220-1224
- Catecholamines
 effects of portal adrenergic blockade on gluconeogenic effects of, on liver, 458-465
see also Epinephrine; Norepinephrine
- Cell biology, *see* Kinetic modeling in molecular cell biology
- Cell differentiation, 3T3-L1 preadipocyte, induction of mRNA for GHR gene during, 114-118
- Cell-mediated oxidation of LDLs, glitazide effects on monocyte adhesion to endothelial cells and, 1150-1156
- Cellular fluorescence produced by Nile red staining, insulin effects on, 351
- Cellulose in protein-restricted diet, 692
- Central precocious puberty (CPP) complicating CAH, linear growth during infancy due to, and GnRH agonist therapy of, 513-517
- Ceruloplasmin (Cp), erythrocyte plasma, Cu supplementation effects on, in men, 1380-1383
- CETP, *see* Cholesteryl ester transfer protein
- cGMP (cyclic guanosine monophosphate), 8-bromo, effects of, on ET-1 production in VSMCs, 492
- CGRP (calcitonin gene-related peptide), LANP effects on, 818-825
- CHD (coronary heart disease), I/D polymorphism of ACE gene in hypertension, NIDDM and, 1211-1214
- Children, 1241-1251
 burned, effects of dietary protein intake on urea and protein metabolism in, 573-578
 IDDM, mitochondrial DNA mutation A32443G in, 445-450
 obese, relationship of serum IGFBP-3, serum PICP, and serum IGF-I to sex, pubertal development, growth, insulin, and nutritional status of, 862-872
 response of, to PTH, 1246-1251
 with SCD, GH secretion, IGF-I, and IGFBP-3 concentrations in, 1241-1245
 SLDLs in, 146-148
see also Coronary artery disease, male offspring of parents with; Infants; Parents, NIDDM, of glucose-tolerant offspring; Turner's syndrome, girls with
- Chloride (Cl), skeletal muscle, in critical illness, 760
- CHO(s), *see* Carbohydrate(s)
- Cholesterol (C)
 and androgenic status in men, 1289
 in chronic renal disease, HD, and CAPD subjects, 38
 Cu supplementation effects on, 1382
 dietary, *see* Dietary cholesterol
 in elderly postmenopausal women, lipolysis and, 1313
 in familial hypertriglyceridemia, 1301, 1302
 in FED, 476, 478
 heparin effects on concentrations of, 654
 in HL deficiency, stanozolol effects on serum Lps and, 993, 994
 in IDDM, levels of, correlated with plasma apo H, 522-525
 in NIDDM, *see* Cholesterol in NIDDM
 in obese men, *see* Cholesterol in obese men
 plasma, in STZ-DM, 874
 RE kinetics and PP production of, 585, 586
 and relationship between serum TGs, serum urate, and FE_{UA} , 1086, 1087
 serum, *see* Serum cholesterol
 in SLOS, 844-850
 total, *see* Total cholesterol
see also Cholesterol acyltransferase; High-density lipoprotein-cholesterol; Hypercholesterolemia; Intermediate-density lipoprotein-cholesterol; Low-density lipoprotein-cholesterol
- Cholesterol (C) acyltransferase, lecithin:, in FED, 474-483
- Cholesterol (C) in NIDDM
 with or without CHD and hypertension, ACE gene and, 1213
 diabetic nephropathy and retinopathy and, 979
 levels of, correlated with plasma apo H in, 522-525
 TRG effects on, in normolipidemic non-obese subjects, 194

- Cholesterol (C) in obese men
and effects of sex hormones on LPL activity, 180
elderly and middle-aged men, sequential effects of aerobic exercise
and weight loss on, 1444
- Cholesteryl ester(s)
aortic, ERT and dietary soy protein effects on, in ovariectomized
subjects, 698-705
in FED, 477
see also Cholesteryl ester transfer protein
- Cholesteryl ester transfer protein (CETP)
NO-1886 elevates plasma HDL-C levels by increasing LPL and
without effect on activity of, 257-260
plasma, decrease in plasma FFAs and acute hyperinsulinemia effects
on activity of, 1166-1170
- Choline in protein-restricted diet, 692
- Cholinergic blockade with PZP, effects of, on nocturnal TSH and GH
secretion in IDDM, 1305-1311
- Cholinergic system-opioid interaction, physiological effects of, on GH
neuroregulation, 740-744
- Chromatography, enrichment of very low stable isotopically labeled
tracers measured with GC/MS, and its application to measure-
ment of muscle protein synthesis, 943-948
- Chromium (Cr), implications of age-related decrease of, in hair, sweat,
and serum samples for prevention of cardiovascular disease and
NIDDM, 469-473
- Chronic dietary protein restriction, tissue-specific effects of gastros-
tomy and, on IGF-I pathway in liver and colon, 691-697
- Chronic excessive interleukin-6 (IL-) production in multiple myeloma,
effects of modulation of, on T₃ and T₄, 1343-1348
- Chronic hemodialysis (HD), pre- and post-hemodialysis changes in
body composition of subjects on, as assessed by DEXA,
1059-1062
- Chronic renal disease, PAI-1 in CAPD, HD and, 36-40
- Chronic renal insufficiency, serum and urine guanidino compounds in
nondialyzed subjects with, 1024-1031
- Cigarette smoking, *see* Smoking
- Cirrhosis, insulin effects on nonoxidative glucose metabolism in,
840-843
- Citrulline
as marker of renal insufficiency and proximal tubular dysfunction,
611-618
plasma, in isonitrogenous diet, 790, 791
- CK (creatine kinase), serum, effects of simvastatin and lovastatin on
skeletal muscle, during exercise, 1206-1210
- Cl (chloride), skeletal muscle, in critical illness, 760
- Classification of hyperuricemia by plasma uridine level, 802, 803
- Clinical activity index in acromegaly, IGF-I and IGFBP-3 measurement
to determine, 494-498
- Clinical presentation, *see specific conditions*
- Clofibrate, hyperoxaluria and increased oxalate synthesis due to,
135-139
- Clonidine, effects of, on insulin secretion by beta cells, 1146-1149
- CNPs (C-natriuretic peptides), ET-1 production in VSMCs modulated
by, 487-493
- ¹³CO₂ APE (atom percent excess), ethanol effects on levels of, 751-752
- CoA, *see* Coenzyme A carboxylase; HMG-CoA reductase
- Coenzyme A (CoA) carboxylase, acetyl, insulin inhibition of AMP-
activated PK in heart resulting in FA oxidation and activation of,
1270-1274
- Collaboration in kinetic modeling in molecular cell biology, 1494-1495
- Collagen, platelet aggregation induced by, in Graves' disease with
primary hypothyroidism, 1129
- Colon
effects of chronic dietary protein restriction and gastrectomy on
IGF-I pathway in, 691-697
- Colon (*Continued*)
temperature of, effects of indomethacin and flurbiprofen on, in T-cell
leukemia, 360-361
- Combined endothelin (ET) type A/type B receptor antagonist, renopro-
tective effects of TAK-044 as, in malignant hypertension,
1032-1038
- Compartmental model of RE kinetics during PP lipemia, 584-594
- Computed axial tomography (CAT) of abdominal AT distribution and its
correlation with anthropometry and insulin secretion in healthy
Asian Indians, 1220-1224
- Computer models
in exploration of whole-body metabolism, 330-332
see also Kinetic modeling in molecular cell biology
- Congenital adrenal hyperplasia (CAH) complicated by CPP, GnRH
agonist therapy of linear growth during infancy due to, 513-517
- Connecting peptides, *see* C-peptides
- Constipation in IDDM and NIDDM, substance P content of rectal
mucosa in, 730-734
- Continuous ambulatory peritoneal dialysis (CAPD)
oxidation of Lps from patients on, 833-839
PAI-1 in chronic renal disease, HD and, 36-40
- Continuous insulin infusion, short-term, effects of, on hypofibrinolysis
with hyperinsulinemia in NIDDM, 1074-1079
- Contraceptives, *see* Oral contraceptives
- Copper, *see* Cu
- Corn oil in protein-restricted diet, 692
- Cornstarch in protein-restricted diet, 692
- Coronary artery disease (CAD), male offspring of parents with
decreased glucose tolerance in, as maturational abnormality, 504-512
with early CAD, LDL particle size as marker for atherogenic risk in
offspring, 954-958
- Coronary heart disease (CHD), I/D polymorphism of ACE gene in
hypertension, NIDDM and, 1211-1214
- Corticosteroids, *see* Glucocorticoids and *specific corticosteroids*
- Corticotropin (ACTH; adrenocorticotrophic hormone)
effects of naloxone-induced opioid withdrawal on, 131
function of 17-OHP, DHEAS and, in adrenal masses, 107-113
galanin levels after exercise-induced secretion of, in men, 282-286
increases receptor-specific uptake of native LDL, native Lp(a),
oxidized Lp(a), but not of oxidized LDL in HepG2 cells,
726-729
- Cortisol
effects of naloxone-induced opioid withdrawal on, 131
as nongenetic factor for hyperhomocyst(e)inemia, 247-249
plasma, portal adrenergic blockade effects on, 459
PZP effects on, 1309
serum, *see* Serum cortisol
in underweight and non-obese subjects with and without cancer, 141
- Cortisone, serum, in premature infants, 518-521
- Countertransport (CT) activity, Na⁺/H⁺ and Na⁺/Li⁺, in hypertensive
NIDDM, 1316-1323
- Cp (ceruloplasmin), erythrocyte plasma, Cu supplementation effects on,
in men, 1380-1383
- C-peptides (connecting peptides)
ethanol effects on, 752-754
fasting, *see* Fasting C-peptides
in hyperinsulinemia, 1253, 1254
in mitochondrial DM, 794
natriuretic, ET-1 production in VSMCs modulated by, 487-493
plasma, *see* Plasma C-peptides
race and ethnicity determining concentrations of serum insulin and,
53-58
serum, *see* Serum C-peptides
in underweight and non-obese subjects with and without cancer, 141

- CPK (creatine phosphokinase) in hypercholesterolemia, and lovastatin and simvastatin effects on skeletal muscle injury during exercise, 1207, 1208
- CPP (central precocious puberty) complicating CAH, GnRH agonist therapy of linear growth during infancy due to, 513-517
- Cr (chromium), implications of age-related decrease of, in hair, sweat, and serum samples for prevention of cardiovascular disease and NIDDM, 469-473
- 9CRA (9-*cis*-retinoic acid), effects of, on insulin secretion from RINm5F cells, 656-660
- C-reactive protein (CRP) in small-cell lung cancer subjects, TEE and, 1413
- Creatine
 inborn error of synthesis of, GAMT deficiency and, 1189-1193
 serum, *see* Serum creatine
 skeletal muscle, in critical illness, 761
- Creatine kinase (CK), serum, effects of simvastatin and lovastatin on skeletal muscle, during exercise, 1206-1210
- Creatine phosphokinase (CPK) in hypercholesterolemia, and lovastatin and simvastatin effects on skeletal muscle injury during exercise, 1207, 1208
- Creatinine
 in chronic renal disease, HD, and CAPD, 37
 in hypertensive NIDDM, 1317
 and liver transplantation, 1004
 of multiple myeloma subjects, 1344
 in non-obese subjects with diabetic nephropathy, insulin resistance and, 1014, 1016
 and relationship between serum TGs, serum urate, and FE_{UA} , 1086, 1087
 serum, *see* Serum creatinine
 in uremia, 613, 615
 see also Creatinine, urinary excretion of; Creatininemia
- Creatinine, urinary excretion of
 and Ca, in early pregnancy, preeclampsia development and, 1107-1108
 with isonitrogenous diet, 787
 in nondialyzed chronic renal insufficiency subjects, 1026, 1028, 1029
- Creatininemia
 in NIDDM, peripheral vasoconstrictor responses to SNS activation and, 236
 in uremia, 613
- Critical illness, longitudinal changes in biochemical parameters of skeletal muscle during, 756-762
- CRP (C-reactive protein) in small-cell lung cancer subjects, TEE and, 1413
- Cryopreservation of pancreatic islets, 644-649
- CS-045, *see* Troglitazone
- CT (countertransport) activity, Na^+/H^+ and Na^+/Li^+ , in hypertensive NIDDM, 1316-1323
- C-terminal propeptide, serum type I procollagen, serum IGF-I, and serum IGFBP-3 in obese children and adolescents, relationship of, to sex, pubertal development, growth, insulin, and nutritional status of, 862-872
- Cu (copper)
 effects of supplementation with, on blood Cu enzyme and CV disease risk in men, 1380-1383
 hepatic iron overload with hypercholesterolemia, hypertriglyceridemia, and Cu deficiency, 377-381
 intake of, with diet high in vegetables, fruit, and nuts, 532
 lipid peroxide generation in LDLs promoted by, 835
- Cutaneous blood flow (BF), measurement of, to determine peripheral vasoconstrictor response to SNS activation in NIDDM, 235-241
- CV disease, *see* Cardiovascular disease
- Cyanocobalamin (vitamin B₁₂), intake of, with diet high in vegetables, fruit, and nuts, 532
- Cyclic adenosine monophosphate (cAMP), progesterone effects on, 595-604
- Cyclic guanosine monophosphate (cGMP), 8-bromo, effects of, on ET-1 production in VSMCs, 492
- 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), effects of progesterone on cAMP and glycerol in presence of, 595, 596, 598, 602
- Cysteine in isonitrogenous diet, 786
- Cysteine protease inhibitor, E64d as membrane-permeable, effects of, on PTH action in osteoblasts, 1090-1094
- Cystine, *see* Plasma cystine
- Cytosolic calcium ($[Ca^{2+}]_i$), $[^3H]PdBu$ and, binding to intact platelets in young IDDM and NIDDM subjects, 949-953
- DAG, *see* Diacylglycerol
- Daily energy requirements of heart failure patients, 1294-1298
- Day-to-day variation in insulin sensitivity in NIDDM, 374-376
- DCA (dichloroacetate) inhibiting glutamine oxidation via transamination by decreasing pyruvate availability, 268-272
- Deaminase, adenosine, effects of adenosine hydrolysis by, on progesterone effects on glucose metabolism in adipocytes, 595-604
- Decarboxylase, glutamic acid, GH secretion and antibodies to, in IDDM, 382-387
- Decentralized sympathetic neurons, lipolysis in SCI activated by peripheral afferent stimulation of, 1465-1469
- Dehydrocholesterol- Δ^7 -reductase, fibroblast, measuring activity of, to identify SLOS homozygotes and heterozygotes, 844-850
- Dehydroepiandrosterone sulfate (β -hydroxy-5-androsten-17-one; DHEAS)
 aging and, *see* Aging, DHEAS and
 function of 17-OHP, ACTH and, in adrenal masses, 107-113
 in obese hyperinsulinemic women, 1255
 plasma levels of, and androgenic status in men, 1287-1293
 see also Dehydroepiandrosterone sulfate in hirsutism, triptorelin effects on; Dehydroepiandrosterone sulfate in PCOS
- Dehydroepiandrosterone sulfate (β -hydroxy-5-androsten-17-one; DHEAS) in hirsutism, triptorelin effects on
 effects of triptorelin with desogestrel-containing OCs in severe hirsutism, 439
 in hirsutism without hyperandrogenemia, 905
- Dehydroepiandrosterone sulfate (β -hydroxy-5-androsten-17-one; DHEAS) in PCOS
 with and without obesity, effects of long-term NTX therapy on, 540
 with severe hirsutism, effects of triptorelin with desogestrel-containing OCs on, 439
- Dehydrogenase
 fibroblast lathosterol-5-, in SLOS, 848
 glucose-6-phosphate, Cu deficiency effects on, 378
 lactate, clofibrate effects on, 137
- 2-Deoxyglucose (2-DOG), α LA effects on, in STZ-DM, 766, 767
- $[^3H]$ 2-Deoxyglucose (2-DOG), RU38486 effects on insulin-induced uptake of, 988
- Deoxyribonucleic acid, *see* DNA
- Desogestrel, effects of triptorelin with oral contraceptives containing, on hair, bone density, and hormone profile in PCOS with severe hirsutism, 437-440
- Development, *see* Growth and development
- DEXA (dual-energy x-ray absorptiometry), pre- and post-HD changes in body composition of subjects on chronic HD as assessed by, 1059-1062
- $[^3H]$ Dexamethasone, RU38486 effects on, 998-999
- Dextrin in soy protein diet, 699
- DG-5128, effects of, on insulin secretion by beta cells, 1146-1149

DHEAS, *see* Dehydroepiandrosterone sulfate

Diabetes mellitus (DM)

alloxan-induced, catabolism of prothrombin and antithrombin in, 1406-1411

fibrocalculus pancreatic, effects of oral MCTs on hepatic ketogenesis and, 1-4

hepatic and nonhepatic splanchnic tissue contribution to NE increase during prolonged exercise in, 1327-1332

see also Insulin-dependent diabetes mellitus; Mitochondrial diabetes mellitus, mutations in; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus *and entries beginning with term:* Diabetic

Diabetic cardiomyopathy, MLC phosphorylation in, 71-75

Diabetic nephropathy of NIDDM

insulin resistance in non-obese NIDDM subjects, 1013-1018

lack of relationship between AGT and ACE gene polymorphism and, 976-980

Diabetic retinopathy with NIDDM, lack of relationship between AGT and ACE gene polymorphism and, 976-980

Diacylglycerol (DAG)

in MCs exposed to high glucose concentrations, D- α -tocopherol effects on, 781, 782

in STZ-DM, aldose reductase inhibition effects on formation of, 41-47

Diagnosis

of GH deficiency in adults, 680-683

see also specific conditions

Dialysis, *see* Continuous ambulatory peritoneal dialysis; Hemodialysis

Diarrhea in IDDM and NIDDM, substance P content of rectal mucosa in, 730-734

Dichloroacetate (DCA) inhibiting glutamine oxidation via transamination by decreasing pyruvate availability, 268-272

Diet

high in vegetables, fruit, and nuts, effects of, on serum lipids, 530-537 of male offspring of CAD patient, 506

see also Fasting; Fed state, leucine in; Food intake; Nutritional status; Nutritional therapy; Refeeding; Starvation; Thermic effect of the meal *entries beginning with terms:* Dietary, Postprandial *specific food groups, specific food substances, and types of diet*

Dietary Ca (calcium)

in diet high in vegetables, fruit, and nuts, 532

in soy protein diet, 699

Dietary carbohydrates, *see* Carbohydrate intake

Dietary cholesterol (C)

in high-vegetable, fruit, and nuts diet, nuts, 532, 534

insulin resistance and, 99

normal intestinal absorption of dietary fat and, intestinal apo B mRNA levels, and apo B-48 synthesis in FHBL without apo B truncation, 1095-1100

in soy protein diet, 699

see also Total cholesterol, diet effects on

Dietary Cu (copper) in diet high in vegetables, fruit, and nuts, 532

Dietary fat

daily requirements in, for long-term BW maintenance in older women, 885

with diet high in vegetables, fruit, and nuts, 532

effects of, on composition of plasma membrane FAs, 19-20

effects of modification of, on fibrinogen, factor VII, and PAI-I activity in IGT, 666-672

effects of restriction of, on plasma Lp particle size in postmenopausal women, 431-436

intake of, by exercising subjects, 1180

normal intestinal absorption of cholesterol and, intestinal apo B mRNA levels, and apo B-48 synthesis in FHBL without apo B truncation, 1095-1100

Dietary fat (*Continued*)

plasma insulin, physical activity and, 1420

see also High-fat diet *and specific dietary fats*

Dietary Na (sodium) with diet high vegetable, fruit, and nuts, 532

Dietary P (phosphorus) with diet high in vegetables, fruit, and nuts, 532

Dietary protein intake

daily, for long-term BW maintenance in older women, 885

with diet high in vegetables, fruit, and nuts, 532, 534

effects of, on urea and protein metabolism in burned children, 573-578

effects of ERT and soy, on CV risk factors and on aortic cholesteryl ester content in ovariectomized subjects, 698-705

in exercise, 1180

by IGT subjects on modified diet, 668

plasma insulin, physical activity and, 1420

by smokers, 713

tissue-specific effects of gastrostomy and chronic restriction of, on IGF-I pathway in liver and colon, 691-697

Diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl] benzylphosphonate (NO-1886) elevates plasma HDL-C levels by increasing LPL and without effect on CETP activity, 257-260

Dihydrotestosterone, plasma, effects of, on LPL activity in obese men, 181, 183

1,25-Dihydroxyvitamin D [$1,25-(OH)_2D$], and association between IGT and altered Ca homeostasis, 1171-1177

Diltiazem, effects of, on insulin sensitivity, glucose effectiveness, and beta cell function in obese hypertensive men, 173-178

Dimethylarginine, serum symmetrical and asymmetrical, in nondiabetic subjects with chronic renal insufficiency, 1024-1031

Dinucleotide phosphate, erythrocyte nicotinamide adenine, in NIDDM, polyol pathway activation and GSH redox status and, 1195

Δ^4 -DIONE, *see* Androstenedione

Diphosphate, adenosine, platelet aggregation induced by, in Graves' disease and primary hypothyroidism, 1129

Dismutase, erythrocyte superoxide, Cu supplementation effects on, in men, 1380-1383

DM, *see* Diabetes mellitus

DNA (deoxyribonucleic acid)

BREC, insulin and GF effects on synthesis of, 1369-1370

content of insulin, in beta cells, effects of aging on, 244

mitochondrial, *see* Mitochondrial DNA

skeletal muscle concentration of, in critical illness, 758, 759

2-DOG, *see* 2-Deoxyglucose; [3H]2-Deoxyglucose

Dose, radiation, from apo tracers, 1231-1239

Dose-response for glucagonostatic effects of amylin, 67-70

DPCPX (8-cyclopentyl-1,3-dipropylxanthine), effects of progesterone on cAMP and glycerol in presence of, 595, 596, 598, 602

Dried egg yolk in soy protein diet, 699

Dual-energy x-ray absorptiometry (DEXA), pre- and post-HD changes in body composition of subjects on chronic HD as assessed by, 1059-1062

E₂, *see* Estradiol

Early coronary artery disease (CAD), LDL particle size as marker for atherogenic risk in male offspring of parents with, 954-958

Early pregnancy, urinary excretion of Ca and creatinine in, preeclampsia development and, 1107-1108

Eating disorders, *see* Anorexia nervosa; Bulimia nervosa

EC(s), *see* Endothelial cells

ECD (Erdheim-Chester disease), LDL levels in, 1215-1219

EE, *see* Energy expenditure

Egg yolk, dried, in soy protein diet, 699

Eicosapentaenoic acid ethyl ester (EPA-E), effects of, on insulin resistance in spontaneous NIDDM, 1458-1464

- Elderly men
 effects of GHRH 1-29 injections in, 89-96
 longitudinal changes in testosterone, LH, and FSH in, 410-413
 obese, sequential effects of aerobic exercise and weight loss on CV disease risk factors in, 1441-1447
see also Aging
- Elderly women
 energy requirements for long-term BW maintenance in, 884-889
 postmenopausal, lipolysis in, 1312-1315
see also Aging
- Electrolytes
 skeletal muscle, in critical illness, 759, 760
see also specific electrolytes
- Endometriosis, serum Lp(a) levels in young women with, 735-739
- β (beta) Endorphin (BEP), effects of naloxone-induced opioid withdrawal on, 131
- Endosomal acidification, inhibition of, in normal cells, insulin and insulin receptor metabolic derangements in NIDDM compared with, 1259-1265
- Endothelial cells (ECs)
 bovine retinal, *see* Insulin-like growth factor-binding protein(s) in BRECs, production of
 gliclazide effects on cell-mediated LDL oxidation and monocyte adhesion to, 1150-1156
- Endothelin (ET) type A/type B receptor antagonist, combined, renoprotective effects of TAK-044 as, in malignant hypertension, 1032-1038
- Endothelin-1 (ET-1)
 production of, in VSMCs modulated by atrial, brain, and C-type natriuretic peptides, 487-493
 venous plasma, lack of association between hyperinsulinemia and altered levels of, in healthy subjects, 1137-1139
- Endurance exercise
 effects of aging and, on gluconeogenesis, 414-419
 by men, *see* Endurance exercise by men
- Endurance exercise by men
 with constant energy intake by identical twins, changes over time in EE and related hormones in, 499-503
 by lean and obese men, increase in HDL-C in, compared, 556-561
- Energy expenditure (EE)
 changes over time in related hormones and, in endurance training identical twins, constant energy intake and, 499-503
 in obesity, effects of visceral AT on, 123-129
 plasma leptin concentrations and, in heart failure subjects, 450-453
 resting, *see* Resting energy expenditure
 total, *see* Total energy expenditure
- Energy intake
 constant, identical twins changes over time in EE and related hormones in, 499-503
 and exercise, 1180
 of heart failure subjects, daily requirements in, 1294-1298
 by IGT subjects on modified diet, 668
 plasma insulin, physical activity and, 1420
 with protein-restricted diet, 692-693
 requirements in, for long-term BW maintenance in older women, 884-889
see also Diet
- EPA-E (eicosapentaenoic acid ethyl ester), effects of, on insulin resistance in spontaneous NIDDM, 1458-1464
- EPI, *see* Epinephrine
- Epileptic patients on anticonvulsant therapy, total plasma Hcy in, 959-962
- Epinephrine (EPI; adrenaline)
 effects of, on HL secretion by hepatocytes, 76-82
- Epinephrine (EPI; adrenaline) (*Continued*)
 effects of, on insulin-stimulated posttransport muscle glucose metabolism, 1101-1106
 effects of portal adrenergic blockade on gluconeogenic effects of, on liver, 458-465
 exercise and, *see* Epinephrine, exercise and
 lipolytic sensitivity to, in obese normotensive and hypertensive subjects, 1080-1084
 in SCI subjects, 389
- Epinephrine (EPI; adrenaline), exercise and
 effects of prolonged exercise in DM on arterial EPI, 1328-1329
 galanin levels after exercise-induced secretion of, in men, 282-286
- Erdheim-Chester disease (ECD; symmetrically excessive xanthomatosis), LDL levels in, 1215-1219
- ERT (estrogen replacement therapy), effects of dietary soy protein and, on aortic cholesteryl ester content and risk factors for CV disease in ovariectomized subjects, 698-705
- Erythrocyte(s) [red blood cell(s)], pravastatin effects on deformability of, in hypercholesterolemia, 287-291
- Erythrocyte(s) [red blood cell(s)] ceruloplasmin (Cp), plasma, Cu supplementation effects on, in men, 1380-1383
- Erythrocyte [red blood cell(s)] membrane sialic acid in IDDM and NIDDM, aging and, 59-61
- Erythrocyte [red blood cell(s)] NADPH (nicotinamide adenine dinucleotide phosphate) in NIDDM, polyol pathway activation, GSH redox status and, 1195
- Erythrocyte [red blood cell(s)] Na^+/H^+ (sodium/hydrogen) and Na^+/Li^+ (sodium/lithium), CT activity of, in hypertensive NIDDM, 1319-1321
- Erythrocyte [red blood cell(s)] sorbitol in NIDDM, polyol pathway activation and GSH redox status and, 1195
- Erythrocyte [red blood cell(s)] superoxide dismutase (SOD), Cu supplementation effects on, in men, 1380-1383
- Erythropoietin in chronic renal disease, HD, and CAPD subjects, 37
- E64d (membrane-permeable cysteine protease inhibitor), effects of, on PTH action in osteoblasts, 1090-1094
- Estradiol (E_2)
 in CAH complicated by CPP, effects of GnRH agonist therapy on, 514
 mild hyperthyroidism effects on, in young men, 1425
 as nongenetic factor for hyperhomocyst(e)inemia, 247-249
 in obese hyperinsulinemic women, 1255
 in PCOS, *see* Estradiol in PCOS
 plasma, effects of, on LPL activity in obese men, 181, 183
 in premenopausal and postmenopausal women, SHBG and, 8
- Estradiol (E_2) in PCOS
 long-term NTX therapy effects on, 540
 with severe hirsutism, effects of triptorelin with desogestrel-containing OCs on, 439
- Estrogen
 in premenopausal and postmenopausal women, SHBG and, 5-9
see also Estrogen therapy
- Estrogen therapy
 effects of, on Ca absorption, Ca retention, and bone turnover in girls with Turner's syndrome, 908-913
 ERT, effects of dietary soy protein and, on aortic cholesteryl ester content and risk factors for CV disease in ovariectomized subjects, 698-705
- Estrone, plasma, effects of, on LPL activity in obese men, 181, 183
- ET, *see* Endothelin-1; Endothelin type A/type B receptor antagonist
- Ethanol
 acute protein-sparing effects of, in postabsorptive but not in anabolic conditions, 750-755

Ethanol (*Continued*)

effects of F and, on plasma uridine and purine bases, compared, 544-547

see also Alcohol intake

Ethnicity, *see* Race and ethnicity

Excessive interleukin-6 (IL-6) production, chronic, in multiple myeloma, effects of modulation of, on T₃ and T₄, 1343-1348

Excessive xanthomatosis, symmetrically, LDL levels in, 1215-1219

Exercise

association between IGT, Ca homeostasis and, 1174

effects of, on plasma uridine and purine bases, 1339-1341

endurance, *see* Endurance exercise

handgrip, *see* Handgrip exercise

by heart failure patients, daily energy requirements and, 1296

moderate, effects of, on insulin- and non-insulin-mediated glucose uptake in normal subjects, 203-209

by obese women on weight-reducing diet, BMC changes in, 857-861

prolonged, *see* Prolonged exercise

simvastatin and lovastatin inducing skeletal muscle injury during, 1206-1210

by transgenic subjects, GLUT4 transporter overexpression and, 1349-1357

see also Men, exercising; Women, exercising

Extrapaneatic action of truncated GLP-1 amide in NIDDM, 745-749

F (fructose), effects of ethanol and, on plasma uridine and purine bases, compared, 544-547

FA(s), *see* Fatty acid(s)

Factor VII (FVII)

effects of dietary fat modification on fibrinogen, PAI-1 activity and, in IGT, 666-672

in obese NIDDM subjects, heparin effects on, 932

plasma levels of, and androgenic status in men, 1287-1293

FAEEs (fatty acid ethyl esters), synthesis of, by perfused heart, 926-929

Familial hypertriglyceridemia, PP hemorrhheology and apo B metabolism in, 1299-1304

Familial hypobetalipoproteinemia (FHBL) without apo B truncation, normal intestinal dietary fat and cholesterol absorption, intestinal apo B mRNA levels, and apo B-48 synthesis in, 1095-1100

Familial non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), genetic susceptibility loci in IDDM and, 48-52

Fasting

GH and, *see* Fasting, leucine kinetics during, GH and

lipolysis sensitivity and response to, in normotensive and hypertensive obese subjects, 1080-1084

pituitary neuromedin B in STZ-DM and in, TSH secretion and, 149-153

see also entries beginning with term: Fasting

Fasting, leucine kinetics during, GH and

and hypocaloric N-free diet effects on postoperative leucine kinetics in fasting, 796-800

with moderate nitrogenous and caloric diet, 23-28

Fasting amylin in hyperinsulinemia-associated hyperamylinemia glucose-tolerant and insulin-resistant subjects, 1158

Fasting apolipoprotein A-I (apo A-I), serum, in young women with endometriosis, 736

Fasting apolipoprotein A-II (apo A-II), serum, in young women with endometriosis, 736

Fasting apolipoprotein B (apo B), serum, in young women with endometriosis, 736

Fasting blood glucose

incretin effects on, 262

α LA effects on, in STZ-DM, 764

in NIDDM, day-to-day variation in insulin sensitivity and, 375

Fasting blood glucose (*Continued*)

in persistent hypobetalipoproteinemia, 630

truncated GLP-1 amide infusion effects on, 747

Fasting blood insulin, α LA effects on, in STZ-DM, 764

Fasting C-peptides (connecting peptides; FCPs)

abdominal AT/insulin secretion correlation and, 1222, 1223

in hyperinsulinemia-associated hyperamylinemic glucose-tolerant and insulin-resistant subjects, 1158

plasma, *see* Fasting plasma C-peptides

race and hepatic insulin extraction and clearance and, 55, 56

Fasting glucose

and abdominal AT/insulin secretion correlation, 1222

glucose tolerance and, *see* Fasting glucose, glucose tolerance and

insulin resistance, *see* Fasting glucose, insulin resistance and

in myocardial infarction, 1471

in NIDDM, polyol pathway activation and GSH redox status and, 1195

sequential effects of aerobic exercise and weight loss on, in obese elderly and middle-aged men, 1444

see also Fasting blood glucose; Fasting plasma glucose; Fasting serum glucose

Fasting glucose, glucose tolerance and

in glucose-tolerant offspring of NIDDM subjects, 881

in hyperinsulinemia-associated hyperamylinemic glucose-tolerant and insulin-resistant subjects, 1158

in IGT, effects of fibrinogen, PAI-1, and FVII on fasting glucose levels, 670

Fasting glucose, insulin resistance and

in hyperamylinemic glucose-tolerant and insulin-resistant subjects, 1158

LDL particle size and, 1276

Fasting glycemia

in NIDDM, peripheral vasoconstrictor responses to SNS activation and, 236

see also Fasting glucose

Fasting high-density lipoprotein cholesterol (HDL-C), serum, in young women with endometriosis, 736

Fasting high-density lipoprotein₂-cholesterol (HDL₂-C), serum, in young women with endometriosis, 736

Fasting high-density lipoprotein₃-cholesterol (HDL₃-C), serum, in young women with endometriosis, 736

Fasting insulin

and abdominal AT/insulin secretion correlation, 1222, 1223

aging effects on DHEAS in relation to body composition and level of, BIA in assessment of, 826-832

and androgenic status in men, 1289

and association between IGT and Ca homeostasis, 1175

in bulimia, 485

glucose tolerance and, *see* Fasting insulin, glucose tolerance and

handgrip strength and, 1267, 1268

insulin resistance, *see* Fasting insulin, insulin resistance and

plasma, *see* Fasting plasma insulin

sequential effects of aerobic exercise and weight loss on, in obese elderly and middle-aged men, 1444

serum, in NIDDM, day-to-day variation in insulin sensitivity and, 375

Fasting insulin, glucose tolerance and

in glucose-tolerant offspring of NIDDM subjects, 881

in hyperinsulinemia-associated hyperamylinemic glucose-tolerant and insulin-resistant subjects, 1158

in IGT, effects of fibrinogen, PAI-1, and FVII on levels of, 668, 670

Fasting insulin, insulin resistance and

in hyperamylinemic glucose-tolerant and insulin-resistant subjects, 1158

LDL particle size and, 1276

- Fasting lipids, effects of endurance exercise by lean and obese men on, 558
- Fasting plasma C-peptides (connecting peptides)
and abdominal AT/insulin secretion correlation, 1221
in NIDDM with hyperinsulinemia and hypofibrinolysis, effects of short-term continuous insulin infusions on, 1076
- Fasting plasma glucose (FPG)
and abdominal AT/insulin secretion correlation, 1221
in IDDM, *see* Fasting plasma glucose in IDDM
insulin resistance and, 396, 397, 1282
in IRH, 640
in NIDDM, *see* Fasting plasma glucose in NIDDM
- Fasting plasma glucose (FPG) in IDDM
intracellular Ca and [³H]PdBu binding to intact platelets and, 950
tolrestat effects on, 635
- Fasting plasma glucose (FPG) in NIDDM
in hypertensive NIDDM, 1317
intracellular Ca and [³H]PdBu binding to intact platelets and, 950
tolrestat effects on, 635
- Fasting plasma insulin (FPI)
and abdominal AT/insulin secretion correlation, 1221
in IDDM, intracellular Ca and [³H]PdBu binding to intact platelets and, 950
insulin resistance and, 396, 397, 1282
in IRH, 640
in NIDDM, *see* Fasting plasma insulin in NIDDM
in surgical subjects, 798-799
- Fasting plasma insulin (FPI) in NIDDM
in hypertensive NIDDM, 1317
intracellular Ca and [³H]PdBu binding to intact platelets and, 950
- Fasting plasma triglycerides (TGs), relationship of sex differences between insulin-mediated suppression of FFAs and levels of, in obese African American subjects, 400-405
- Fasting serum apolipoprotein A-I (apo A-I) in young women with endometriosis, 736
- Fasting serum apolipoprotein A-II (apo A-II) in young women with endometriosis, 736
- Fasting serum apolipoprotein B (apo B) in young women with endometriosis, 736
- Fasting serum cholesterol (C)
in NIDDM, Trp64Arg missense mutation of β_3 -adrenergic receptor and, 202
total, *see* Fasting serum total cholesterol
- Fasting serum glucose
following weight loss by obese subjects, 1141
pituitary, in STZ-DM, 152
race and hepatic insulin extraction and clearance and, 55, 56
- Fasting serum high-density lipoprotein-cholesterol (HDL-C) in young women with endometriosis, 736
- Fasting serum high-density lipoprotein₂-cholesterol (HDL₂-C) in young women with endometriosis, 736
- Fasting serum high-density lipoprotein₃-cholesterol (HDL₃-C) in young women with endometriosis, 736
- Fasting serum insulin
following weight loss by obese subjects, 1141
in NIDDM, day-to-day variation in insulin sensitivity and, 375
- Fasting serum low-density lipoprotein-cholesterol (LDL-C) in young women with endometriosis, 736
- Fasting serum total cholesterol (TC)
in NIDDM, Trp64Arg missense mutation of β_3 -adrenergic receptor and, 202
in young women with endometriosis, 736
- Fasting serum triglycerides (TGs)
in NIDDM, Trp64Arg missense mutation of β_3 -adrenergic receptor and, 202
- Fasting serum triglycerides (TGs) (*Continued*)
in young women with endometriosis, 736
- Fasting triglycerides (TGs)
in CAD patients, 955
insulin resistance, LDL particle size and, 1276, 1278
plasma, relationship of sex differences between insulin-mediated suppression of FFAs and levels of, in obese African American subjects, 400-405
serum, *see* Fasting serum triglycerides
- Fat, *see* Adipose tissue; Dietary fat *entries beginning with terms:* Fat, Fatty element: Lip- and specific fats
- Fat-free mass (FFM)
of chronic HD patients, pre- and post-HD changes in, 1060
EE and, *see* Fat-free mass, EE and
in elderly postmenopausal women, lipolysis and, 1313
exercise and, *see* Fat-free mass, exercise and
of heart failure patients, daily energy requirements and, 1296
of HIV-infected men, total EE and, 1325
in hyperinsulinemia-associated hyperamylinemia glucose-tolerant and insulin-resistant subjects, 1158
in NIDDM subjects, day-to-day variation in insulin sensitivity and, 375
of premenopausal and postmenopausal women, SHBG and, 7, 8
RMR and composition of, 1225-1230
in SCI subjects, 389, 1466
- Fat-free mass (FFM), EE and
in heart failure subjects, plasma leptin concentrations and, 451
insulin secretion, insulin sensitivity and, 124
- Fat-free mass (FFM), exercise and
increase in HDL-C with endurance training by lean and obese men, 557
in obese exercising women on weight-reducing diet, 858, 860
- Fat mass (FM)
aging effects on DHEAS in relation to fasting insulin level and, 828-830
of chronic HD patients, pre- and post-HD changes in, 1060
in elderly postmenopausal women, lipolysis and, 1313
of heart failure subjects, *see* Fat mass in heart failure subjects
insulin secretion, insulin sensitivity, EE and, 124
in obese women, *see* Fat mass in obese women on weight-reducing diet
RMR, FFM composition and, 1226
in SCI subjects, 389, 1466
- Fat mass (FM) in heart failure subjects
daily energy requirements and, 1296
plasma leptin concentrations and, 451
- Fat mass (FM) in obese women on weight-reducing diet and exercising, BMC changes and, 858, 860
loss of, 968-975
- Fatty acid(s) (FAs)
in elderly postmenopausal women, lipolysis and, 1313
free, *see* Free fatty acids
insulin inhibition of AMP-activated PK in heart resulting in activation of acetyl CoA carboxylase activation and oxidation of, 1270-1274
monounsaturated, *see* Monounsaturated fatty acid intake
in NIDDM, *see* Fatty acid(s) in NIDDM
in normotensive and hypertensive obese subjects, lipolysis and, 1082
plasma membrane, effects of dietary fat on composition of, 19-20
polyunsaturated, *see* Polyunsaturated fatty acid(s)
saturated, *see* Saturated fatty acid(s)
serum short-chain, effects of time of day and glucose tolerance status on concentrations of, 805-811

- Fatty acid(s) (FAs) in NIDDM
 BRL 49653 effects on supply and utilization of systemic, 935-942
 lard, EPA-E, olive oil, and safflower oil effects on, in spontaneous NIDDM, 1459
- Fatty acid ethyl esters (FAEEs), synthesis of, by perfused heart, 926-929
- Fatty acid synthase, insulin effects on, in fetal hepatocytes, 350-351
- FBSs (fibroblasts), dehydrocholesterol- Δ^7 -reductase activity measurement in, to identify of SLOS homozygotes and heterozygotes, 844-850
- FCPD (fibrocaculous pancreatic diabetes), effects of oral MCTs on hepatic ketogenesis in, 1-4
- Fe (iron)
 hypertriglyceridemia, hypercholesterolemia, and overload of hepatic, in Cu deficiency, 377-381
 intake of, on diet high in vegetables, fruit, and nuts, 532
- FE_{UA} (fractional urate excretion), relationship between serum TGs, serum urate and, 1085-1089
- FED (fish-eye disease), HDL abnormalities in, 474-483
- Fed state, leucine in
 GH and hypocaloric N-free diet effects on postoperative leucine kinetics, 796-800
 splanchnic versus whole-body KIC production from, 164-167
- Femoral adipose tissue (AT) in men, sex hormones inhibiting LPL activity in, 179-185
- Fetal hepatocytes, time-dependent effects of insulin on lipid synthesis in, 345-354
- Fetal and maternal modulators of lipid metabolism, preeclampsia development correlated with, 963-967
- FFAs, *see* Free fatty acids
- FFM, *see* Fat-free mass
- FHBL (familial hypobetalipoproteinemia) without apo B truncation, normal intestinal dietary fat and cholesterol absorption, intestinal apo B mRNA levels, and apo B-48 synthesis in, 1095-1100
- Fiber intake
 on diet high in vegetables, fruit, and nuts, 532, 534
 by IGT subjects on modified diet, 668
- Fibrinogen
 effects of dietary fat modification on FVII, PAI-1 activity and, in IGT, 666-672
 in familial hypertriglyceridemia, 1302
 in obese NIDDM subjects, heparin effects on, 932
 plasma levels of, and androgenic status in men, 1287-1293
- Fibroblasts (FBSs), dehydrocholesterol- Δ^7 -reductase activity measurement in, to identify of SLOS homozygotes and heterozygotes, 844-850
- Fibrocaculous pancreatic diabetes (FCPD), effects of oral MCTs on hepatic ketogenesis in, 1-4
- Fibronectin in MCs exposed to high glucose concentrations, D- α -tocopherol effects on, 781
- Fish-eye disease (FED), HDL abnormalities in, 474-483
- Fish oil, *see* n-3 Polyunsaturated fatty acid(s); n-6 Polyunsaturated fatty acids
- Fitness, *see* Exercise
- Fluorescence, cellular, produced by Nile red staining, insulin effects on, 351
- Flurbiprofen, effects of, in T-cell leukemia, 359-365
- FM, *see* Fat mass
- Folacin (folic acid), intake of, with diet high in vegetables, fruit, and nuts, 532
- Folate in epileptic patients on anticonvulsant therapy, total plasma Hcy and, 959-962
- Follicle-stimulating hormone (FSH)
 in CAH complicated by CPP, effects of GnRH agonist therapy on, 514
 longitudinal changes in, in healthy older men, 410-413
- Follicle-stimulating hormone (FSH) (*Continued*)
 in premenopausal and postmenopausal women, SHBG and, 8
see also Follicle-stimulating hormone in PCOS
- Follicle-stimulating hormone (FSH) in PCOS
 long-term NTX therapy effects on, 540
 metformin effects on, 455
 with severe hirsutism, effects of triptorelin with desogestrel-containing OCs on, 439
- Food intake
 effects of sex and, on GH neuroregulation, physiological role of opioid-cholinergic system and, 740-744
 and IGF-I and IGF-BPs following graded uninephrectomy, 30
 indomethacin and flurbiprofen effects on, in T-cell leukemia, 361-362
 and insulin resistance, 101
 in STZ-DM, *see* Food intake in STZ-DM
see also Diet
- Food intake in STZ-DM
 CS-045 effects on, 982
 vanadium therapy and, 771
- Foot, arterialized venous blood of, in assessment of glucose metabolism, 1364-1366
- Forskolin, wortmannin converting insulin but not oxytocin from antilipolytic to lipolytic agent in presence of, 62-66
- F2,6-P₂, *see* Fructose 2,6-biphosphate
- F3P (fructose-3-phosphate), polyol pathway metabolism and production of, in heart of STZ-DM subjects, 1333-1338
- FPG, *see* Fasting plasma glucose
- FPI, *see* Fasting plasma insulin
- Fractional synthetic rate (FSR) of protein, lipids, and CHOs, determination of, 326-327
- Fractional urate excretion (FE_{UA}), relationship between serum TGs, serum urate and, 1085-1089
- Free fatty acids (FFAs; nonesterified fatty acids)
 exercise and, *see* Free fatty acids, exercise and
 GH therapy effects on, in Turner's syndrome, 1484
 HF diet and, *see* Free fatty acids, HF diet and
 insulin-mediated suppression of, in obese subjects, race, sex and, 400-405
 during ischemia in STZ-DM, 170
 in NIDDM, *see* Free fatty acids in NIDDM
 plasma, *see* Plasma free fatty acids
 portal adrenergic blockade effects on, 461
 in SCI subjects, 389
 smokeless nicotine effects on, 1010
- Free fatty acids (FFAs; nonesterified fatty acids), exercise and
 in obese exercising men without weight loss, HDL metabolism and, 219-220
 serum, *see* Serum free fatty acids, exercise and
 in transgenic subjects, 1351-1354
- Free fatty acids (FFAs; nonesterified fatty acids), HF diet and
 effects on FFAs, 421-423
 and insulin resistance induced by HF diet, 99
- Free fatty acids (FFAs; nonesterified fatty acids) in NIDDM
 metformin effects on, 229
 in non-obese subjects with diabetic nephropathy, insulin resistance and, 1014
 plasma, NE effects on, 1450
 serum, *see* Serum free fatty acids, exercise and
 TRG effects on, in normolipidemic non-obese NIDDM subjects, 194
- Free radicals, quenching of, as treatment of mitochondrial disorders, 315-316
- Free testosterone (T) in obese hyperinsulinemic women, 1255

- Free thyroxine (T_3) in Graves' disease
 MMI and $1\alpha(OH)D_3$ effects on hyperthyroidism in untreated Graves' disease, 1185
 and primary hypothyroidism, 1129
- Free triiodothyronine (T_4) in Graves' disease
 MMI and $1\alpha(OH)D_3$ effects on hyperthyroidism and untreated Graves' disease, 1185
 and primary hypothyroidism, 1129
- Fructosamine
 dietary soy protein and ERT effects on, in ovariectomized subjects, 701
 in IDDM, intracellular Ca and $[^3H]PdBu$ binding to intact platelets and, 950
 in NIDDM, *see* Fructosamine in NIDDM
- Fructosamine in NIDDM
 intracellular Ca and $[^3H]PdBu$ binding to intact platelets and, 950
 peripheral vasoconstrictor responses to SNS activation and, 236
- Fructose (F)
 effects of, on apo A-I expression in young and older subjects, 1132-1136
 effects of ethanol and, on plasma uridine and purine bases, compared, 544-547
- Fructose 2,6-biphosphate ($F_{2,6-P_2}$)
 effects of aging and endurance training on expression of, 414-419
 troglitazone effects on, in absence or presence of insulin, 718, 719
- Fructose-3-phosphate (F_{3P}), polyol pathway metabolism and production of, in heart of STZ-DM subjects, 1333-1338
- Fruit, effects of diet high in vegetables, nuts and, on serum lipids, 530-537
- FVII, *see* Factor VII
- FSH, *see* Follicle-stimulating hormone
- FSR (fractional synthetic rate) of protein, lipids, and CHOs, determination of, 326-327
- G, *see* Glucagon
- GAA (guanidinoacetic acid), *see* Serum guanidinoacetic acid
- GAD (glutamic acid decarboxylase) antibodies, GH secretion and, in IDDM, 382-387
- Galanin (GAL)
 inhibitory effects of, on GH release in GH-secreting adenoma cells, inhibitory effects of octreotide, GHRH, and TRH compared with, 425-430
 levels of after exercise-induced pituitary hormone secretion in men, 282-286
 release of NPY, leptin and, in obese women and anorexic women, 1384-1389
- Gamma (γ)-globulin (IgG), liver transplantation and, 1004
- Gamma (γ)-guanidinobutyric acid (GBA), serum, in nondialyzed patients with chronic renal insufficiency, 1026, 1028
- GAMT (guanidinoacetate methyltransferase) deficiency, guanidino compounds in, 1189-1193
- Gas chromatography/mass spectrometry (GC/MS), very low stable isotopically labeled tracers enrichment measured with, and its application to muscle protein synthesis measurement, 943-948
- Gastric inhibitory polypeptide (GIP), regulation of thyroid hormones in secretion of, 154-158
- Gastrointestinal (GI) tract
 radiation dose received from apo tracers by, 1237
see also Intestines and entries beginning with element: Gastr-
- Gastrostomy, tissue-specific effects of chronic dietary protein restriction and, on IGF-I pathway in liver and colon, 691-697
- GBA (γ -guanidinobutyric acid), serum, in nondialyzed patients with chronic renal insufficiency, 1026, 1028
- GC/MS (gas chromatography/mass spectrometry), very low stable isotopically labeled tracers enrichment measured with, and its application to muscle protein synthesis measurement, 943-948
- Gene(s)
 ACE, *see* Allele(s), ACE gene; Polymorphism, ACE gene, in NIDDM
 LANP effects on CGRP, 818-825
see also DNA; Gene expression; Mutation; RNA and entries beginning with term: Polymorphism
- Gene expression
 GHR, during 3T3-L1 preadipocyte differentiation, 114-118
 incretin, in intestines of IDDM and NIDDM subjects, 261-267
 insulin, and insulin resistance induced by HF diet, 103
see also mRNA
- Genetic susceptibility loci in NIDDM and IDDM, 48-52
- Genetics
 of PAI-1, fibrinogen, and FVII in IGT, 668-670
 quantitative, of serum SHBG, 989-991
see also Allele(s); Children; Gene(s); Genetic susceptibility loci; Genotype; Heterozygotes; Homozygotes; Phenotype; Twins and entries beginning with terms: Congenital, Familial
- Genotype
 for ACE and AGT gene polymorphisms, 978, 979
 apo E, in persistent hypobetalipoproteinemia, 630
 in Trp64Arg missense mutation of β_3 -adrenergic receptor, 201
- Gestational age of premature infants, serum cortisol and cortisone levels and, 520
- GFs (growth factors), *see* entries beginning with terms: Insulin-like growth factor
- GH, *see* Growth hormone
- Ghanaian population, hepatic insulin extraction, insulin clearance, and concentrations of C-peptides in, 53-58
- GHBPs, *see* Growth hormone-binding proteins
- GHR (growth hormone receptor) gene, expression of, during 3T3-L1 preadipocyte differentiation, 114-118
- GHRH, *see* Growth hormone-releasing hormone, GH and; Growth hormone-releasing hormone 1-29
- GHRP-6 (growth hormone-releasing peptide 6), GH release in response to, in IDDM, 706-710
- GI tract, *see* Gastrointestinal tract
- GIP (gastric inhibitory polypeptide), regulation of thyroid hormones in secretion of, 154-158
- Girls, *see* Sex; Turner's syndrome, girls with
- GlcUA (glucuronate) technique, secreted, measuring effects of G6Pase flux on hepatic glucose phosphorylation, cycling, disposal, and net balance, 1390-1398
- Gliclazide, effects of, on cell-mediated LDL oxidation and on monocyte adhesion to endothelial cells, 1150-1156
- Globulin
 gamma-, liver transplantation and, 1004
see also Sex hormone-binding globulin
- GLP-1, *see* Glucagon-like peptide-1 (7-36) amide; Glucagon-like peptide-1 (7-36) amide gene
- Glucagon (G; hyperglycemic factor; hyperglycemic-glycogenolytic factor)
 BK effects on secretion of, in pancreatic islets, 1113-1115
 ethanol effects on, 752-754
 immunoreactive, GLP-1 amide effects on, in NIDDM, 747
 and insulin resistance induced by HF diet, 98-99, 101, 102
 in IRH, 640
 plasma, *see* Plasma glucagon
 PZP effects on, 1309
 secretion of, correlated with plasma leptin in women in postmenopausal women, 1477-1481
see also Glucagon-like peptide-1 (7-36) amide

- Glucagon-like peptide-1 (7-36) (GLP-1) amide
 absence of short-term effects of hyperglycemia and, on plasma leptin levels, 723-725
 extrapancreatic action of truncated, in NIDDM, 745-749
- Glucagon-like peptide-1 (7-36) (GLP-1) amide gene, expression of, in intestines of IDDM and NIDDM subjects, 261-267
- Glucagonostatic effects of amylin, dose-response for, 67-70
- Glucocorticoids
 acute insulin resistance induced by, in adipocytes, RU38486 effects on, 997-1002
 effects of, on lipogenesis, 349-350
- Gluconeogenesis
 effects of aging and endurance training on, 414-419
 gluconeogenic effects of epinephrine and NE on liver, effects of portal adrenergic blockers on, 458-465
 glucose production and, in PP, starved normal and STZ-DM subjects, 1358-1363
- Glucose
 abdominal AT/insulin secretion correlation and, 1222
 in adipocytes, progesterone effects on metabolism of, 595-604
 arterialized venous blood of hand and foot in assessing metabolism of, 1364-1366
 blood, *see* Blood glucose
 in chronic renal disease, HD, and CAPD subjects, 37
 dietary soy protein and ERT effects on, in ovariectomized subjects, 701
 differential effects of oxovanadiums and insulin on metabolism of, 562-572
 effects of, on apo A-I expression in young and older subjects, 1132-1136
 in elderly postmenopausal women, lipolysis and, 1313
 ethanol effects on, 752-754
 fasting, *see* Fasting glucose
 in girls with Turner's syndrome, GH therapy effects on, 1482-1488
 hepatic, *see* Hepatic glucose production
 HF diet effects on, 422
 in HGPS, 855
 high-energy phosphate generation in catabolism of, 308
 in hyperinsulinemia, 1253, 1254
 in hypobetalipoproteinemia, 627
 in IDDM, insulinotropic polypeptide gene expression in intestines of subjects with, dependent on, 261-267
 IGF-I effects on utilization of, in TNF-treated subjects, 1052-1058
 IGFBP production in BRECs and, 1373-1374
 insulin secretion and sensitivity, and production of, in underweight and non-obese subjects with and without cancer, 140-145
 insulin and uptake of, *see* Glucose uptake, insulin-mediated
 insulinotropic sensitivity to carbachol and, in HF diet-induced insulin resistance, 97-106
 in limb and trunk dystrophy, 160-161
 moderate exercise effects on non-insulin-mediated uptake of, in normal subjects, 203-209
 muscle, *see* Muscle glucose metabolism
 in NIDDM, *see* Glucose in NIDDM
 nonoxidative metabolism of, in cirrhosis, insulin effects on, 840-843
 in obese men, *see* Glucose in obese men
 plasma, *see* Plasma glucose
 portal adrenergic blockade effects on, 459, 461
 in premenopausal and postmenopausal women, SHBG and, 8
 and relationship between serum TGs, serum urate, and FE_{UA} , 1086, 1087
 in SCI subjects, 389
 serum, *see* Serum glucose
 in STZ-DM, *see* Glucose in STZ-DM
- Glucose (*Continued*)
 D- α -tocopherol effects on MCs exposed to high concentrations of, 779-784
see also 2-Deoxyglucose; [3H]2-Deoxyglucose; [U - ^{14}C]Glucose; Glucose-6-phosphatase mRNA; Glucose-6-phosphate dehydrogenase; Glucose tolerance; Glucose uptake, insulin-mediated; GLUT4 transporter; Hepatic glucose-6-phosphatase and *entries beginning with elements*: Gluc-, Glyc-
 [U - ^{14}C]Glucose, insulin effects on incorporation of, into lipids and glycogen in fetal hepatocytes, 346-351
 Glucose intolerance, *see* Impaired glucose tolerance
 Glucose in NIDDM
 decreased effectiveness of, but not of insulin resistance in glucose-tolerant offspring of Japanese NIDDM subjects, 880-883
 GLP-1 amide effects on, 747, 748
 glucose-dependent insulinotropic polypeptide gene expression in intestines of NIDDM subjects, 261-267
 metformin effects on utilization of, 227-233
 NE effects on insulin secretion and effectiveness of, 1448-1453
 plasma, BRL 49653 effects on, 937
 Glucose in obese men
 and effects of sex hormones on LPL activity, 180
 in obese hypertensive men, effects of diltiazem or quinapril on, 173-178
 Glucose-6-phosphatase, *see* Glucose-6-phosphatase mRNA; Hepatic glucose-6-phosphatase
 Glucose-6-phosphatase (G6Pase) mRNA (messenger ribonucleic acid), TNF- α effects on, 579-583
 Glucose-6-phosphate dehydrogenase (G6PD), Cu deficiency effects on, 378
 Glucose in STZ-DM
 aldose reductase inhibition effects on flux of, 41-47
 myocardial uptake of, during ischemia, 168-172
 Glucose tolerance
 decrease of, in male children of CAD parent, as maturational abnormality, 504-512
 impaired, *see* Impaired glucose tolerance
 in NIDDM, *see* Glucose tolerance in NIDDM
 smokeless nicotine associated with hypertension but not with deterioration of, 1008-1012
 time of day and glucose tolerance status effects on concentrations of serum SCFAs, 805-811
see also Intravenous glucose tolerance test; Oral glucose tolerance test; Parents, NIDDM, of glucose-tolerant offspring
 Glucose tolerance in NIDDM
 aging effects on, 891-892
 GLP-1 amide effects on, 747
 Glucose uptake, insulin-mediated
 L-arginine but not D-arginine stimulates, 1068-1073
 kinetic analysis of insulin action on glucose production and, 1116-1127
 moderate exercise effects on, in normal subjects, 203-209
 Glucuronate (GlcUA) technique, secreted, measuring effects of G6Pase flux on hepatic glucose phosphorylation, cycling, disposal, and net balance, 1390-1398
 GLUT4 transporter
 muscle content of, α LA effects on glycemia and, in STZ-DM, 763-768
see also mRNA, GLUT4
 Glutamate
 plasma, *see* Plasma glutamate
 portal adrenergic blockade effects on, 461, 464
 in purified and unpurified islet cells, 985
 skeletal muscle, in critical illness, 760

- Glutamic acid decarboxylase (GAD) antibodies, GH secretion and, in IDDM, 382-387
- Glutamic acid in isonitrogenous diet, 786, 790, 791
- Glutamine
- DCA inhibiting oxidation of, via transamination by decreasing pyruvate availability, 268-272
 - metabolism of, in tumor-bearing subjects on TPN, 370-373
 - plasma, *see* Plasma glutamine
 - portal adrenergic blockade effects on, 461, 464
 - skeletal muscle, in critical illness, 760
- Glutathione (GSH), polyol pathway activation and redox status of, in NIDDM, 1194-1198
- Glycemia
- fasting and PP, in NIDDM, peripheral vasoconstrictor responses to SNS activation and, 236
 - α LA effects on muscle GLUT4 transporter content and, in STZ-DM, 763-768
 - see also* Glucose; Hyperglycemia; Hypoglycemia
- Glycerol
- HF diet effects on, 422
 - interstitial, *see* Interstitial glycerol in SCI
 - portal adrenergic blockade effects on, 460
 - production of, by PP, starved normal and STZ-DM subjects, 1360, 1361
 - progesterone effects on, 597-598
 - rate of appearance of, and lipolysis sensitivity and response to fasting in obese normotensive and hypertensive subjects, 1080-1084
- Glycerol-3-phosphate in purified and unpurified islet cells, 985
- Glycine
- cortisol and estradiol effects on, 248
 - in isonitrogenous diet, 786
 - plasma, *see* Plasma glycine
 - portal adrenergic blockade effects on, 461, 464
 - skeletal muscle, in critical illness, 760
- Glycogen
- effects of GLUT4 transporter overexpression in exercising transgenic subjects on regulation of, 1349-1357
 - hepatic, *see* Hepatic glycogen
 - insulin effects on incorporation of [1-¹⁴C]acetate into, in fetal hepatocytes, 346-351
 - in NIDDM, metformin effects on synthesis of, 230
 - troglitazone effects on, in presence or absence of insulin, 719, 720
- Glycogen synthase (GS) gene, polymorphism of, in Russian NIDDM subjects, 121-122
- Glycogenic effects of insulin in fetal hepatocytes, lipogenic effects compared with, 345-354
- Glycogenolysis in liver, effects of VMH stimulation on, in vivo microdialysis in study of, 897-901
- β (beta)₂-Glycoprotein I (apo H), plasma, in IDDM and NIDDM, C levels correlated with, 522-525
- Glycosylated Hb (hemoglobin), TRG effects on, in normolipidemic non-obese NIDDM subjects, 194
- Glyoxylate, clofibrate synthesis from, 136, 137
- GMP (guanosine monophosphate), 8-bromo cyclic, effects of, on ET-1 production in VSMCs, 492
- GnRH, *see* Gonadotropin-releasing hormone
- Gonadal axis in idiopathic hirsutism in women, triptorelin effects on, 902-907
- Gonadotropin-releasing hormone (GnRH)
- therapy of CAH complicated by CPP with agonist of, 513-517
 - triptorelin as analog of, effects of desogestrel-containing oral contraceptives with, on hair, bone density, and hormone profile in PCOS with severe hirsutism, 437-440
- Gout, plasma uridine in
- allopurinol and benzbromarone effects on plasma uridine, 1473-1476
 - level of, as marker of uric acid overproduction, 801-804
- G6Pase, *see* Hepatic glucose-6-phosphatase; Glucose-6-phosphatase mRNA
- G6PD (glucose-6-phosphate dehydrogenase), Cu deficiency effects on, 378
- G-protein, effects of imidazolines, α_2 -adrenergic agonists and, on insulin secretion in beta cells, 1146-1149
- Graded uninephrectomy, effects of, on renal IGF-I, serum IGF-I, and IGFBPs, compensatory renal growth and, 29-35
- Graves' disease
- 1 α (OH)D₃ effects on levels of serum thyroid hormones in hyperthyroidism with untreated, 1184-1188
 - platelet aggregation alterations in primary hypothyroidism and, 1128-1131
- Growth and development, 504-517
- compensatory renal, effects of graded uninephrectomy on, 29-35
 - decreased glucose tolerance in male offspring of parent with CAD as abnormality of, 504-512
 - linear, during infancy due to CAH complicated by CPP, GnRH agonist therapy of, 513-517
 - of obese children and adolescents, relationship of serum IGFBP-3, serum PICP, and serum IGF-I to sex, insulin, nutritional status and, 862-872
 - see also* Acromegaly; Hyperplasia; Idiopathic short stature
- Growth factors, *see entries beginning with terms:* Insulin-like growth factor
- Growth hormone (GH)
- in acromegaly, 495
 - during fasting, *see* Fasting, leucine kinetics during, GH and levels of basal, in women, correlated with HDL-C, 1039-1044
 - neuoregulation by, physiological role of opioid-cholinergic interaction in, and effects of sex and food intake on, 740-744
 - surgery and, *see* Surgery, GH and
 - therapy with, *see* Growth hormone, therapy with
 - in underweight and non-obese subjects with and without cancer, 141
 - see also* Growth hormone, deficiency of, in adults; Growth hormone, release and secretion of; Growth hormone-binding proteins; Growth hormone receptor gene; Growth hormone-releasing hormone, GH and; Growth hormone-releasing hormone 1-29
- Growth hormone (GH), deficiency of, in adults
- GHRH stimulation test to determine, in healthy subjects and pituitary macroadenoma subjects, 680-683
 - relationship of body composition to GH deficiency effects on serum leptin, 812-817
- Growth hormone (GH), release and secretion of
- in GH-secreting adenoma cells, inhibitory effects of galanin, octreotide, and TRH on, compared, 425-430
 - in IDDM, *see* Growth hormone, release and secretion of, in IDDM
 - IGF-I, IGFBP-3 and, in SCD children, 1241-1245
 - mild hyperthyroidism effects on insulin and, and on sex hormones in healthy young men, 1424-1428
 - negative GH autofeedback on GH-releasing effects of hexarelin, 83-88
 - in obesity, *see* Obesity, GH release and secretion in
 - see also* Growth hormone-releasing hormone, GH release and secretion and
- Growth hormone (GH), release and secretion of, in IDDM
- GAD antibodies and, 382-387
 - PZP effects on nocturnal TSH secretion and GH secretion, 1305-1311 in response to
 - GHRP-6, 706-710

- Growth hormone (GH), therapy with
 in girls with Turner's syndrome, effects of, on glucose turnover and insulin clearance, 1482-1488
 of HGPS with NT and, 851-856
- Growth hormone-binding proteins (GHBPs)
 GHRH 1-29 effects on, 91
 mRNA of, induced during 3T3-L1 preadipocyte differentiation, 115-116
- Growth hormone receptor (GHR) gene, mRNA expression for, during 3T3-L1 preadipocyte differentiation, 114-118
- Growth hormone-releasing hormone (GHRH), GH and
 GH deficiency determination with GHRH stimulation test in healthy subjects and pituitary macroadenoma subjects, 680-683
 in HPGS, 853
see also Growth hormone-releasing hormone, GH release and secretion and
- Growth hormone-releasing hormone (GHRH), GH release and secretion and
 inhibitory effects of GHRH on GH release in GH-secreting adenoma cells, galanin inhibitory effects compared with, 425-430
 in PCOS with and without obesity, 541
- Growth hormone-releasing hormone 1-29 (GHRH 1-29), effects of, in healthy elderly men, 89-96
- Growth hormone-releasing peptide 6 (GHRP-6), GH response to, in IDDM, 706-710
- GS (glycogen synthase) gene, polymorphism of, in Russian NIDDM subjects, 121-122
- GSA (guanidinosuccinic acid), *see* Serum guanidinosuccinic acid
- GSH (glutathione), polyol pathway activation and redox status of, in NIDDM, 1194-1198
- Guanidine, *see* Serum guanidine
- Guanidino compounds
 in GAMT deficiency, 1189-1193
 serum, *see* Serum guanidino compounds
 urine, in nondialyzed subjects with chronic renal insufficiency, 1024-1031
- Guanidinoacetate methyltransferase (GAMT) deficiency, guanidino compounds in, 1189-1193
- Guanidinoacetic acid, *see* Serum guanidinoacetic acid
- γ (gamma)-Guanidinobutyric acid (GBA), serum, in nondialyzed patients with chronic renal insufficiency, 1026, 1028
- Guanidinosuccinic acid, *see* Serum guanidinosuccinic acid
- Guanosine monophosphate (GMP), 8-bromo cyclic, effects of, on ET-1 production in VSMCs, 492
- Guidelines for collaboration in kinetic modeling in molecular cell biology, 1494-1495
- GVA, *see* Serum α -keto- δ -guanidinovaleric acid
- Hair
 effects of triptorelin with desogestrel-containing oral contraceptives on, in PCOS with severe hirsutism, 437-440; *see also* entries beginning with term: Hirsutism
 implications of age-related decrease in Cr of, for prevention of cardiovascular disease and NIDDM, 469-473
- Hand, arterialized venous blood of, in assessment of glucose metabolism, 1364-1366
- Handgrip exercise
 handgrip strength and insulin levels, 1266-1269
 by SCI subjects, lipolysis regulation by SNS during, 391
- Harg (homoarginine), *see* Serum homoarginine
- Hb (hemoglobin)
 exercise effects on, 1340
 glycosylated, TRG effects on, in normolipidemic non-obese NIDDM subjects, 194
- Hb (hemoglobin) (*Continued*)
 in preeclampsia, 964
see also HbA₁; HbA_{1c}
- HbA₁ (hemoglobin A₁) in IDDM and NIDDM, tolrestat effects on, 635
- HbA_{1c} (hemoglobin A_{1c})
 in acute hyperinsulinemia, 1167
 in FCPD, 2
 in HGPS, 855
 in IDDM, *see* HbA_{1c} in IDDM
 in IGT, 668
 in mitochondrial DM, 794, 1020
 in myocardial infarction, 1471
 in NIDDM, *see* HbA_{1c} in NIDDM
- HbA_{1c} (hemoglobin A_{1c}) in IDDM
 C and plasma apo H levels and, 523, 524
 and changes in renal morphology, 662-664
 with diarrhea and constipation, rectal mucosa SP content and, 732
 GAD antibodies and GH secretion and, 383
 intracellular Ca and [³H]PdBu binding to intact platelets and, 950
- HbA_{1c} (hemoglobin A_{1c}) in NIDDM, 1260
 C and plasma apo H levels and, 523, 524
 diabetic nephropathy and retinopathy and, 979
 with diarrhea and constipation, rectal mucosa SP content and, 732
 with hyperinsulinemia and hypofibrinolysis, effects of short-term continuous insulin infusions on, 1076
 intracellular Ca and [³H]PdBu binding to intact platelets and, 950
 in non-obese subjects with diabetic nephropathy, insulin resistance and, 1014, 1016
 peripheral vasoconstrictor responses to SNS activation and, 236
 polyol pathway activation and GSH redox status and, 1195
- HL, *see* Hypobetalipoproteinemia
- HCO₃ (bicarbonate)-urea method measuring TEE in small-cell lung cancer subjects, 1412-1417
- Hcy (homocysteine), total plasma, in epileptic patients on anticonvulsant therapy, 959-962
- HD, *see* Hemodialysis
- HDL, *see* High-density lipoprotein
- HDL-C, *see* High-density lipoprotein-cholesterol
- Healthy subjects, *see* Normal adult subjects
- Heart
 FAEE synthesis by perfused, 926-929
 insulin inhibition of AMP-activated PK in, resulting in acetyl CoA carboxylase and FA oxidation, 1270-1274
 lactate-induced insulin resistance in, of anesthetized subjects, 684-690
 of STZ-DM subjects, polyol pathway metabolism and F3P production in, 1333-1338
see also entries beginning with terms: Heart, Myocardial and element: Card-
- Heart disease, coronary, I/D polymorphism of ACE gene in hypertension, NIDDM and, 1211-1214
- Heart failure
 daily energy requirements of subjects with, 1294-1298
 EE and plasma leptin concentrations in, 450-453
- Heart rate (HR)
 hypertension and, *see* Heart rate of hypertensive subjects
 and ischemia in STZ-DM, 170
 and MPO during exercise, 283
 of normotensive and hypertensive obese subjects, lipolytic sensitivity and, 1081
 portal adrenergic blockade effects on, 459, 460
- Heart rate of hypertensive subjects
 obese, lipolytic sensitivity and, 1081
 of TAK-044- and hydralazine-treated malignant hypertension subjects, 1033

- Height
- of burned children, and effects of dietary protein intake on urea and protein metabolism, 575
 - of chronic HD patients, pre- and post-HD body composition changes and, 1060
 - of cirrhotic subjects, 841
 - and correlation between visceral AT accumulation and metabolism of uric acid, 1163
 - of elderly women, *see* Height of elderly women
 - of FCPD subjects, 2
 - GH secretion, IGF-I, and IGFBP-3 concentrations in children with ISS, 1241-1245
 - of heart failure subjects, 451, 1296
 - of HIV-infected men, total EE and, 1325
 - of hypertensive subjects, *see* Height of hypertensive subjects
 - of mitochondrial DM subjects with tRNA^{Leu(UUR)} 3243 mutation, 1020
 - and moderate exercise effects on insulin- and non-insulin mediated glucose uptake, 205
 - of non-obese men, and effects of acute hyperinsulinemia on serum T concentrations, 527
 - of obese subjects, *see* Height of obese subjects
 - of premenopausal women, VDR alleles and bone mineral density and, 225
 - race and, and hepatic insulin extraction and clearance, 55, 56
 - and relationship between RMR and FFM composition, 1226
 - and serum Lp(a) levels in endometriosis, 736
 - of small-cell lung cancer subjects, TEE and, 1413
 - time of day and glucose tolerance status effects on serum SCFAs and, 806
 - of Turner's syndrome subjects, 909, 1483
- Height of elderly women
- long-term BW maintenance and, 886
 - and postmenopausal lipolysis and, 1313
- Height of hypertensive subjects
- of hypertensive NIDDM subjects with or without CHD, ACE gene and, 1213
 - obese, lipolytic sensitivity and, 1081
- Height of obese men
- and effects of acute hyperinsulinemia on serum T concentrations, 527
 - and effects of sex hormones on LPL activity, 180
 - hypertensive, lipolytic sensitivity and, 1081
- Height of obese subjects
- insulin secretion, insulin sensitivity, and EE and, 124
 - normotensive, lipolytic sensitivity and, 1081
 - of obese children and adolescents, 865
 - of obese exercising women on weight-reducing diet, BMC changes and, 858
 - see also* Height of obese men
- Hematocrit
- in familial hypertriglyceridemia, 1302
 - in severe malaria, 1436
- Hemodialysis (HD)
- chronic, pre- and post-HD changes in body composition of subjects on, as assessed by DEXA, 1059-1062
 - PAI-1 in chronic renal disease, CAPD and, 36-40
- Hemodynamics
- L-arginine and D-arginine effects on, 1069-1071
 - see also* Blood flow; Blood pressure; Heart rate
- Hemoglobin, *see entries beginning with acronym:* Hb
- Hemorrhology, PP, apo B metabolism and, in familial hypertriglyceridemia, 1299-1304
- Hemostatic abnormalities in obese NIDDM subjects, heparin effects on, 930-934
- Heparan sulfate proteoglycans (HSPGs), LPL enhancing, and apo E saturation improving Lp(a) binding to, 650-655
- Heparin
- effects of, on hemostatic abnormalities in obese NIDDM subjects, 930-934
 - effects of, on lipid concentrations, 654
- Hepatic blood flow (BF), portal adrenergic blockade effects on, 459, 460
- Hepatic glucose-6-phosphatase (G6Pase)
- effects of flux of, on hepatic glucose phosphorylation, cycling, disposal, and net balance, 1390-1398
 - TNF- α effects on, 580
- Hepatic glucose production (HGP)
- in NIDDM, GLP-1 amide effects on, 748
 - in underweight and non-obese subjects with and without cancer, 143
- Hepatic glycogen
- exercise effects on, in transgenic subjects, 1355
 - in STZ-DM, 1351-1352
 - TNF- α effects on, 580
- Hepatic insulin, race and extraction of, 53-58
- Hepatic iron (Fe) overload, hypertriglyceridemia, hypercholesterolemia and, in Cu-deficient subjects, 377-381
- Hepatic ketogenesis, oral MCT effects on, in FCPD, 1-4
- Hepatic lipase (HL)
- deficiency in, short-term stanozolol therapy effects on serum Lps in, 992-996
 - epinephrine effects on secretion of, by hepatocytes, 76-82
- Hepatic splanchnic tissues, contribution of, to NE increase during prolonged exercise in DM, 1327-1332
- Hepatic triglycerides (TGs) in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and EPA-E on, 1460
- Hepatic vein epinephrine (EPI), prolonged exercise in DM and, 1328-1329
- Hepatic very-low-density lipoprotein (VLDL), RE kinetics and PP production of, 585
- Hepatocytes
- activation of MAPK in, by Ca- and PKC-dependent pathway, 548-555
 - epinephrine effects on HL secretion by, 76-82
 - fetal, time-dependent effects of insulin on lipid synthesis in, 345-354
- HepG2 cells, ACTH increases receptor-specific uptake of native LDL, native Lp(a), and oxidized Lp(a), but not of oxidized LDL in, 726-729
- Heterozygotes, SLOS, identification of, by measuring 7-dehydrocholesterol- Δ^7 -reductase activity in fibroblasts, 844-850
- Hexarelin, negative GH autorefeedback on GH-releasing effects of, 83-88
- HF diet, *see* High-fat diet
- HGP, *see* Hepatic glucose production
- HGPS (Hutchinson-Gilford progeria syndrome), response to NT and GH therapy in, 851-856
- High-density lipoprotein (HDL; α -lipoprotein)
- in chronic renal disease, HD, and CAPD subjects, 38
 - diet effects on, *see* High-density lipoprotein, diet effects on exercise and, *see* High-density lipoprotein, and exercise
 - in IGT, effects of fibrinogen, PAI-1, and FVII on levels of, 670
 - LDL oxidation suppressed by, 835
 - in persistent hypobetalipoproteinemia, 630
 - structural and metabolic abnormalities of, in FED, 474-483
 - see also* High-density lipoprotein₂; High-density lipoprotein₃; High-density lipoprotein-cholesterol; Lipoprotein(a)
- High-density lipoprotein (HDL; α -lipoprotein), diet effects on
- of diet high in vegetables, fruit, and nuts on, 533
 - plasma, effects of dietary fat restriction on particle size of, in postmenopausal women, 431-436

- High-density lipoprotein (HDL; α -lipoprotein), and exercise, 1180
 effects of prolonged exercise by obese men without weight loss on metabolism of, 217-223
- High-density lipoprotein₁, *see* Lipoprotein(a)
- High-density lipoprotein₂ (HDL₂)
 dietary fat restriction effects on, 434, 435
see also High-density lipoprotein₂-cholesterol
- High-density lipoprotein-cholesterol (HDL-C)
 abdominal AT/insulin secretion correlation and, 1221, 1222
 and androgenic status in men, 1289
 basal GH levels in women correlated with, 1039-1044
 diet effects on, *see* High-density lipoprotein-cholesterol, diet effects of
 in ECD, 1218
 in elderly postmenopausal women, lipolysis and, 1313
 exercise effects on, *see* High-density lipoprotein-cholesterol, exercise and
 in familial hypertriglyceridemia, 1301, 1302
 heparin effects on concentrations of, 654
 in HL deficiency, short-term stanozolol therapy effects on, 993, 994
 in hypercholesterolemia, *see* High-density lipoprotein-cholesterol in hypercholesterolemia
 in hypobetalipoproteinemia, 627
 in IDDM, C and plasma apo H levels and, 523
 in IGT, *see* High-density lipoprotein-cholesterol in IGT
 insulin resistance, LDL particle size and, 1276, 1278
 in male offspring of CAD parents, 506, 956
 in myocardial infarction, 1471
 niceritrol effects on, 356
 in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM
 in obese men, *see* High-density lipoprotein-cholesterol in obese men
 in PCOS, metformin effects on, 455
 plasma, *see* Plasma high-density lipoprotein-cholesterol
 RE kinetics and PP production of, 585, 586
 and SLDL particles in children, 147
 serum fasting, in young women with endometriosis, 736
 smoking cessation effects on, 713, 714
- High-density lipoprotein-cholesterol (HDL-C), diet effects of
 diet high in vegetables, fruit, and nuts, 533
 dietary fat restriction effects, 434
- High-density lipoprotein-cholesterol (HDL-C), exercise and, 1182
 endurance training by non-obese men and HDL-C increase, 556-561
 lovastatin effects on, 1207
see also High-density lipoprotein-cholesterol in exercising obese men
- High-density lipoprotein-cholesterol (HDL-C) in exercising obese men
 in elderly and middle-aged men, sequential effects of aerobic exercise and weight loss on, 1444
 HDL-C increase with endurance training, 556-561
 with hypercholesterolemia, 187
 without weight loss, 219
- High-density lipoprotein-cholesterol (HDL-C) in hypercholesterolemia
 in hypercholesterolemic trained and sedentary men, 187
 pravastatin effects on RBC deformability and, 289
- High-density lipoprotein-cholesterol (HDL-C) in IGT, 915
 effects of fibrinogen, PAI-1, and FVII on levels of, 668, 670
- High-density lipoprotein-cholesterol (HDL-C) in NIDDM
 C and plasma apo H levels and, 523
 with diabetic nephropathy, *see* High-density lipoprotein-cholesterol in NIDDM with diabetic nephropathy
 in hypertensive NIDDM, 1317
 in non-obese subjects with diabetic nephropathy, insulin resistance and, 1014
 with obesity, heparin effects on hemostatic abnormalities and, 931
 peripheral vasoconstrictor responses to SNS activation and, 236
- High-density lipoprotein-cholesterol (HDL-C) in NIDDM with diabetic nephropathy
 in non-obese subjects, insulin resistance and, 1014
 and retinopathy, 979
- High-density lipoprotein-cholesterol (HDL-C) in obese men
 in elderly and middle-aged men, sequential effects of aerobic exercise and weight loss on, 1444
 in obese hypertensive men, and effects of diltiazem or quinapril on insulin sensitivity, glucose effectiveness, and beta cell function, 174
see also High-density lipoprotein-cholesterol in exercising obese men
- High-density lipoprotein₃ (HDL₃)
 dietary fat restriction effects on, 434, 435
see also High-density lipoprotein₃-cholesterol
- High-density lipoprotein₂-cholesterol (HDL₂-C)
 dietary fat restriction effects on, 434
 in familial hypertriglyceridemia, 1301, 1302
 in HL deficiency, short-term stanozolol therapy effects on, 993, 994
 in obese exercising men without weight loss, 219, 220
 sequential effects of aerobic exercise and weight loss on, in obese elderly and middle-aged men, 1444
 serum fasting, in young women with endometriosis, 736
 smoking cessation effects on, 713, 714
- High-density lipoprotein₃-cholesterol (HDL₃-C)
 dietary fat restriction effects on, 434
 in familial hypertriglyceridemia, 1301, 1302
 in HL deficiency, short-term stanozolol therapy effects on, 993, 994
 in obese exercising men without weight loss, 219, 220
 serum fasting, in young women with endometriosis, 736
 smoking cessation effects on, 713, 714
- High-energy phosphate, generation of, in glucose catabolism, 308
- High-fat (HF) diet
 effects of, on insulin-stimulated posttransport muscle glucose metabolism, 1101-1106
 effects of, on leptin concentrations in non-obese subjects, 420-424
 insulinotropic sensitivity to glucose and carbachol in insulin resistance induced by, 97-106
- Hirsutism with PCOS
 in obese and non-obese subjects, 539
 severe, effects of triptorelin with desogestrel-containing oral contraceptives on hair, bone density, and hormone profile in, 437-440
- Hirsutism in women
 without hyperandrogenemia, adrenal and ovarian steroidogenic abnormalities, 902-907
see also Hirsutism with PCOS; Triptorelin in hirsutism
- Histidine
 in isonitrogenous diet, 786, 790, 791
 plasma, *see* Plasma histidine
 skeletal muscle, in critical illness, 760
- Histopathology of pancreas in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and EPA-E on, 1461, 1463
- HIT-T15 cells, effects of imidazolines and α_2 -adrenergic agonists on insulin secretion by, 1146-1149
- HIV (human immunodeficiency virus)-infected men
 with low adiposity, serum leptin in, 303-305
 total EE by, 1324-1326
- HL, *see* Hepatic lipase
- HMG-CoA (hydroxy-methylglutaryl-coenzyme A) reductase
 fibroblast, in SLOS, 848
 inhibitors of, *see* Lovastatin; Pravastatin; Simvastatin
- Homeostasis, altered Ca, IGT and, 1171-1177
- Homoarginine, *see* Serum homoarginine
- Homocysteine (Hcy), total plasma, in epileptic patients on anticonvulsant therapy, 959-962

- Homocysteinemia
 cortisol and estradiol as nongenetic factors for hyperhomocyst(e)inemia, 247-249
 high PAI-1 activity, resistance to activated protein C and, and myocardial infarction, 1470-1472
- Homozygotes, SLOS, identification of, by measuring 7-dehydrocholesterol- Δ^7 -reductase activity in fibroblasts, 844-850
- Hormones
 effects of triptorelin with desogestrel-containing oral contraceptives on, in PCOS with severe hirsutism, 437-440
 endurance exercise with constant energy intake by identical twins and change over time in, 499-503
see also specific hormones
- HP (hypoparathyroidism), age and response to PTH in HP and PHP, 1246-1251
- HPA (hypothalamic-pituitary-adrenal) axis, hypersensitivity of, to naloxone in opioid withdrawal, 130-134
- HR, *see* Heart rate
- HSPGs (heparan sulfate proteoglycans), Lp(a) binding to, enhanced by LPL and improved by apo E saturation, 650-655
- Human immunodeficiency virus, *see* HIV-infected men
- Hutchinson-Gilford progeria syndrome (HGPS), response to NT and GH therapy in, 851-856
- Hybridoma cells, PQXB 1/2, DCA effects on, 270
- Hydralazine, renoprotective effects of TAK-044 and, in malignant hypertension, compared, 1032-1038
- Hydrolysis of adenosine by ADA, effects of, on progesterone effects on glucose metabolism in adipocytes, 595-604
- β (beta)-Hydroxy-5-androsten-17-one, *see* Dehydroepiandrosterone sulfate
- β (beta)-Hydroxybutyrate (BOHB), portal adrenergic blockade effects on, 461
- Hydroxy-methylglutaryl coenzyme A reductase, *see* HMG-CoA reductase
- 17-Hydroxyprogesterone (17-OHP)
 function of DHEAS, ACTH and, in adrenal masses, 107-113
see also 17-Hydroxyprogesterone in hirsutism, triptorelin effects on; 17-Hydroxyprogesterone in PCOS
- 17-Hydroxyprogesterone (17-OHP) in hirsutism, triptorelin effects on hirsutism without hyperandrogenemia, 905
 with severe hirsutism, effects of triptorelin with desogestrel-containing OCs, 439
- 17-Hydroxyprogesterone (17-OHP) in PCOS
 with and without obesity, long-term NTX therapy effects on, 540
 with severe hirsutism, effects of triptorelin with desogestrel-containing OCs on, 439
- Hydroxyproline, plasma, in uremia, 614
- 25-Hydroxyvitamin D (25-OHD), and association between IGT and altered Ca homeostasis, 1171-1177
- 1 α (alpha)-Hydroxyvitamin D₃ [1 α (OH)D₃], effects of, on levels of serum thyroid hormones in hyperthyroidism with untreated Graves' disease, 1184-1188
- Hyperamylinemia, hyperinsulinemia-associated, in glucose-tolerant and insulin-resistant offspring of Mexican-American NIDDM parents, 1157-1161
- Hyperandrogenemia, adrenal and ovarian steroidogenic abnormalities in hirsute women without, 902-907
- Hypercholesterolemia
 with hypertriglyceridemia, hepatic iron overload and, in Cu-deficient subjects, 377-381
 in men, *see* Men, hypercholesterolemic
- Hyperglycemia, absence of short-term effects of GLP-1 amide and, on plasma leptin levels, 723-725
- Hyperhomocyst(e)inemia, cortisol and estradiol as nongenetic factors for, 247-249
- Hyperinsulinemia
 effects of, on acetyl-L-carnitine association with muscle glucose and lipid metabolism, 1454-1457
 hyperamylinemia associated with, in glucose-tolerant and insulin-resistant offspring of Mexican-American NIDDM parents, 1157-1161
 with hypofibrinolysis in NIDDM, effects of short-term continuous insulin infusion on, 1074-1079
 lack of association between altered venous plasma ET-1 levels and, in healthy subjects, 1137-1139
 sex hormones and, in premenopausal women, obesity and, 1252-1258
 skeletal muscle in, 1269
see also Acute hyperinsulinemia
- Hyperlipidemia
 beta cells and insulin sensitivity in, troglitazone effects on, 273-281
 niceritrol effects on plasma Lp(a) levels in, 355-358
see also Hypercholesterolemia; Hypertriglyceridemia
- Hyperoxaluria due to clofibrate-induced increased oxalate synthesis, 135-139
- Hyperplasia, congenital adrenal, complicated by CPP, GnRH agonist therapy of linear growth during infancy due to, 513-517
- Hypersensitivity of HPA axis to naloxone in opioid withdrawal, 130-134
- Hypertension
 in early pregnancy, preeclampsia development and, 1108
 malignant, renoprotective effects of TAK-044 in, 1032-1038
 mitogen effects on PKC activity and phosphorylation of NHE-1 of lymphoblasts in, 297-302
 in NIDDM, *see* Hypertension in NIDDM
 in obesity, *see* Hypertension in obesity
 smokeless nicotine associated with, but not with glucose tolerance deterioration, 1008-1012
- Hypertension in NIDDM
 with hyperinsulinemia and hypofibrinolysis, 1075
 I/D polymorphism of ACE gene in coronary heart disease and NIDDM, 1211-1214
 Na⁺/H⁺ and Na⁺/Li⁺ CT activity with, 1316-1323
- Hypertension in obesity
 effects of diltiazem or quinapril on insulin sensitivity, glucose effectiveness, and beta cell function in obese hypertensive men, 173-178
 lipolysis sensitivity and response to fasting in obese normotensive and hypertensive subjects, 1080-1084
- Hyperthyroidism
 mild, effects of, on GH and insulin secretion, and on sex hormones in healthy young men, 1424-1428
 1 α (OH)D₃ effects on levels of serum thyroid hormones with untreated Graves' disease and, 1184-1188
 serum guanidino compounds in, 1063-1067
- Hypertriglyceridemia
 familial, PP hemorrheology and apo B metabolism in, 1299-1304
 with hypercholesterolemia, hepatic iron overload and, in Cu-deficient subjects, 377-381
- Hypobetalipoproteinemia (HBL)
 familial, without apo B truncation, normal intestinal dietary fat and cholesterol absorption, intestinal apo B mRNA levels, and apo B-48 synthesis in, 1095-1100
 persistent, in men, 625-633
- Hypocaloric diet
 nitrogen-free, effects of GH and, on postoperative protein synthesis, 796-800
see also specific diets
- Hypofibrinolysis, hyperinsulinemia with, in NIDDM, effects of short-term continuous insulin infusion on, 1074-1079

- Hypoglycemia, idiopathic reactive, alpha cell function in, 639-643
- Hypoparathyroidism (HP), age and response to PTH in, 1246-1251
- Hypothalamic-pituitary-adrenal (HPA) axis, hypersensitivity of, to naloxone in opioid withdrawal, 130-134
- Hypothalamic/pituitary/thyroid axis, imipramine effects on, 1429-1434
- Hypothalamus
ventromedial, effects of stimulation of, on glycogenolysis in liver, in vivo microdialysis in study of, 897-901
see also entries beginning with term: Hypothalamic
- Hypothyroidism
effects of, on thyroid hormones, 154-158
platelet aggregation alteration in Graves' disease an primary, 1128-1132
serum guanidino compounds in, 1063-1067
- Hypoxanthine, *see* Plasma hypoxanthine
- IAPP (islet amyloid polypeptide)/amylin, effects of, on insulin secretion in beta cells, 1044-1051
- IBMX (3-isobutyl-1-methylxanthine), effects of progesterone on cAMP and glycerol in presence of, 596-598, 602
- I/D (insertion/deletion) polymorphism of ACE gene in hypertension, NIDDM, and coronary heart disease, 1211-1214
- IDDM, *see* Insulin-dependent diabetes mellitus
- Identical twins, constant energy intake by endurance training, changes over time in EE and related hormones in, 499-503
- Idiopathic hirsutism in women, 902-907
- Idiopathic reactive hypoglycemia (IRH), alpha cell function in, 639-643
- Idiopathic short stature (ISS), children with, GH secretion, IGF-I, and IGFBP-3 concentrations in, 1241-1245
- IDL (intermediate-density lipoprotein) in hypercholesterolemic trained and sedentary men, 188
- IDL-C (intermediate-density lipoprotein-cholesterol) in hypercholesterolemic trained and sedentary men, 187
- IGF, *see entries beginning with terms:* Insulin-like growth factor
- IGFBPs, *see entries beginning with terms:* Insulin-like growth factor-binding protein
- IgG (immunoglobulin G; gamma-globulin), liver transplantation and, 1004
- IGT, *see* Impaired glucose tolerance
- IL-6, *see* Interleukin-6
- Imidazolines, effects of G-protein, α_2 -adrenergic agonists and, on insulin secretion in beta cells, 1146-1149
- Imipramine, effects of, on hypothalamic/pituitary/thyroid axis, 1429-1434
- Immunoglobulin G (IgG; gamma-globulin), liver transplantation and, 1004
- Immunoreactive glucagon, effects of GLP-1 amide on, in NIDDM, 747
- Immunoreactive insulin (IRI)
in PCOS, metformin effects on, 454-457
plasma, *see* Plasma immunoreactive insulin
- Impaired glucose tolerance (IGT)
Ca homeostasis and, 1171-1777
dietary fat modification effects on fibrinogen, factor VII, and PAI-1 activity in, 666-672
metabolic heterogeneity in, 914-917
- Inborn error of creatine synthesis, GAMT deficiency and, 1189-1193
- Incretin, *see* Glucagon-like peptide-1 (7-36) amide; Glucagon-like peptide-1 (7-36) amide gene
- Indomethacin, effects of, in T-cell leukemia, 359-365
- Infants, 513-521
linear growth of, due to CAH complicated by CPP, GnRH agonist therapy of, 513-517
premature, serum cortisol and cortisone in, 518-521
- Infarction, myocardial, with homocysteinemia, high PAI-1 activity and resistance to activated protein C, 1470-1472
- Infection(s)
HIV, *see* HIV-infected men
in multiple myeloma subjects during anti-IL-6 therapy, 1346-1347
- Injury
nutritional and metabolic effects of mild orotic aciduria during supplementation with arginine after, 785-792
skeletal muscle, during exercise, simvastatin and lovastatin inducing, 1206-1210
spinal cord, *see* Spinal cord injury, SNS regulating lipolysis in
- Insertion allele at ACE gene locus associated with insulin resistance, 395-399
- Insertion/deletion (I/D) polymorphism of ACE gene in hypertension, NIDDM, and coronary heart disease, 1211-1214
- Insulin
acute effects of troglitazone on muscle glucose metabolism in absence or presence of, 716-721
adult GH deficiency and, 813, 815
L-arginine effects on, 69
blood, *see* Blood insulin
in cirrhosis, effects of, on nonoxidative glucose metabolism, 840-843
in cryopreserved pancreatic islets, 645-647
dietary soy protein and ERT effects on, in ovariectomized subjects, 701
differential effects of oxovanadiums and, on glucose metabolism, 562-572
effects of antidiabetic drugs on ability of, to modify force of arterial contractions, 1199-1205
in elderly postmenopausal women, lipolysis and, 1313
ethanol effects on, 752-754
in fasted and fed surgical subjects, GH and, 26
in girls with Turner's syndrome, GH therapy effects on, 1482-1488
glucose uptake and, *see* Glucose uptake, insulin-mediated
handgrip strength and levels of, 1266-1269
in HGPS, 855
immunoreactive, *see* Immunoreactive insulin
inhibition of AMP-activated PK in heart by, resulting in acetyl CoA carboxylase and FA oxidation, 1270-1274
lactate and, *see* Lactate, insulin and
moderate exercise effects of, on non-insulin-mediated glucose uptake in normal subjects, 203-209
in obese children and adolescents, relationship of serum IGFBP-3, serum PICP, and serum IGF-I to sex, pubertal development, growth, nutritional status and, 862-872
plasma, *see* Plasma insulin
posttransport muscle glucose metabolism stimulated by, HF diet effects on, 1101-1106
in premenopausal and postmenopausal women, SHBG and, 8
in SCI subjects, 389
serum, *see* Serum insulin
smokeless nicotine effects on, 1010
time of day and glucose tolerance status effects on serum SCFAs and, 806
time-dependent effects of, on lipid synthesis in fetal hepatocytes, 345-354
unweighted muscle atrophy attenuated by, 673-679
wortmannin converts, from antilipolytic to lipolytic agent in presence of forskolin, 62-66
see also Hyperinsulinemia; Insulin-dependent diabetes mellitus; Insulin receptor; Insulin release and secretion; Insulin resistance; Insulin sensitivity; Non-insulin-dependent diabetes melli-

- Insulin (*Continued*)
tus and entries beginning with terms: Insulin-like growth factor, Insulinotropic
- Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus)
children with, mitochondrial DNA mutation A32443G in, 445-450
correlation between plasma apo H and C levels in, 522-525
with diarrhea and constipation, SP content of rectal mucosa in, 730-734
erythrocyte membrane sialic acid in, aging and, 59-61
genetic susceptibility loci in NIDDM and, 48-52
GH release in, *see* Growth hormone, release and secretion of, in IDDM
incretin gene expression in intestines of subjects with, 261-267
serum AGEs as predictors of changes in renal morphology in, 661-664
tolrestat effects on NRBA in, 634-638
young subjects with, intracellular Ca and [³H]PdBu binding to intact platelets in, 949-953
see also Mitochondrial diabetes mellitus, mutations in
- Insulin-like growth factor-I (IGF-I)
GH and, *see* Insulin-like growth factor-I, GH and
GHRH 1-29 effects on, 91
glucose utilization in TNF-treated subjects improved with, 1052-1058
IGFBP-3 and, *see* Insulin-like growth factor-binding protein-3, IGF-I and
insulin resistance and, 1282
in PCOS with and without obesity, long-term NTX therapy effects on, 540
plasma, *see* Plasma insulin like growth factor-I
PZP effects on, 1309
renal, effects of graded uninephrectomy on IGFBPs and, compensatory renal growth and, 29-35
serum, *see* Serum insulin-like growth factor-I
tissue-specific effects of chronic dietary protein restriction and gastrectomy on pathway of, in liver and colon, 691-697
in underweight and non-obese subjects with and without cancer, 141
- Insulin-like growth factor-I (IGF-I), GH and
in adult GH deficiency, 813
in fasted and fed surgical subjects, 26
in GH-secreting adenoma, 426
GH therapy effects on, in Turner's syndrome, 1484
in HGPS, 853
in SCD children, GH secretion, IGF-I and IGFBP-3 concentration in, 1241-1245
- Insulin-like growth factor-II (IGF-II) in HGPS, 853
- Insulin-like growth factor-binding protein(s) (IGFBP)
effects of graded uninephrectomy on renal and serum IGF-I and, compensatory renal growth and, 29-35
plasma, in protein-restricted diet, 693-694
see also Insulin-like growth factor-binding protein(s) in BRECs, production of; Insulin-like growth factor-binding protein-3
- Insulin-like growth factor-binding protein(s) (IGFBP) in BRECs, production of, 1367-1380
binding studies of, 1369
discussion on, 1374-1377
glucose effects on, 1373-1374
identification and regulation of BREC IGFBPs, 1370-1371
insulin and GFs effects on BREC DNA synthesis and, 1369-1370
Northern blot studies of, 1372-1373
- Insulin-like growth factor-binding protein-3 (IGFBP-3)
GHRH 1-29 effects on, 91
in HGPS, 853
IGF-I and, *see* Insulin-like growth factor-binding protein-3, IGF-I and
- Insulin-like growth factor-binding protein-3 (IGFBP-3) (*Continued*)
in PCOS with and without obesity, long-term NTX therapy effects on, 540
- Insulin-like growth factor-binding protein-3 (IGFBP-3), IGF-I and GH secretion, IGF-I and IGFBP-3 concentrations in SCD children, 1241-1245
measuring clinical activity index in acromegaly, 494-498
relationship of serum PICP, serum IGF-I, and serum IGFBP-3 to sex, pubertal development, growth, insulin, and nutritional status of obese children and adolescents, 862-872
- Insulin receptor (IR) in NIDDM, inhibition of endosomal acidification in normal cells compared with metabolic derangements of, 1259-1265
- Insulin release and secretion
aging effects on, 242-246
in beta cells, *see* Beta cells, insulin secretion in
BK effects on, in pancreatic islets, 1113-1115
CAT scan of abdominal AT distribution and its correlation with anthropometry and, in healthy Asian Indians, 1220-1224
glucose production, insulin sensitivity and, in underweight and normal weight subjects with and without cancer, 140-145
long-term NT therapy effects on secretion of GH and, in non-obese PCOS subjects, 538-543
mild hyperthyroidism effects on GH and, and on sex hormones in healthy young men, 1424-1428
in NIDDM, NE effects on glucose effectiveness and, 1448-1453
in obesity, *see* Insulin release and secretion in obesity
plasma leptin in postmenopausal women correlated with, 1477-1481
regulation of thyroid hormones in, 154-158
from RINm5F cells, effects of 9CRA on, 656-660
- Insulin release and secretion in obesity
long-term NTX therapy effects on secretion of GH and, in obese PCOS subjects, 538-543
in mitochondrial DM with tRNA^{Leu(UUR)} 3243 mutation, 1019-1023
visceral AT effects on, 123-129
- Insulin resistance, 1275-1286
acute glucocorticoid-induced, in adipocytes, RU38486 effects on, 997-1002
association between IGT and Ca homeostasis and, 1175
DHEAS role in relationship between aging and, 1281-1286
HF diet-induced, insulinotropic sensitivity to glucose and carbachol in, 97-106
hyperinsulinemia-associated hyperamylinemia in glucose-tolerant and insulin-resistant offspring of Mexican-American NIDDM parents, 1157-1161
insertion allele at ACE gene locus associated with, 395-399
lactate-induced, in heart and skeletal muscles of anesthetized subjects, 684-690
LDL particle size and, 1275-1280
in limb and trunk lipodystrophy, 159-163
in NIDDM, *see* Insulin resistance in NIDDM
see also Insulin sensitivity
- Insulin resistance in NIDDM
decreased glucose effectiveness but not, in glucose-tolerant offspring of Japanese NIDDM subjects, 880-883
in non-obese NIDDM subjects with diabetic nephropathy, 1013-1018
in spontaneous NIDDM, EPA-E effects on, 1458-1464
- Insulin sensitivity
beta cells, *see* Beta cells, insulin sensitivity and
decreased glucose tolerance but not, in male offspring of parent with CAD, as maturational abnormality, 504-512
insulin secretion, glucose production and, in underweight and normal-weight subjects with and without cancer, 140-145
in mitochondrial DM with tRNA^{Leu(UUR)} 3243 mutation, 1019-1023
in NIDDM, day-to-day variation in, 374-376

- Insulin sensitivity (*Continued*)
 in obesity, *see* Insulin sensitivity in obesity
see also Insulin resistance
- Insulin sensitivity in obesity
 in obese hypertensive men, effects of diltiazem or quinapril on, 173-178
 reduced PTPase in AT and improved, following weight loss, 1140-1145
 visceral AT effects on, 123-129
- Insulinotropic polypeptide gene expression, glucose-dependent, in intestines of NIDDM subjects, 261-267
- Insulinotropic sensitivity to glucose and carbachol in HF diet-induced insulin resistance, 97-106
- Interleukin-6 (IL-6)
 in chronic renal disease, HD, and CAPD subjects, PAI-1 and, 38
 in multiple myeloma, effects of modulation of chronic excessive production of, on T₃ and T₄, 1343-1348
- Intermediate-density lipoprotein (IDL) in hypercholesterolemic trained and sedentary men, 188
- Intermediate-density lipoprotein-cholesterol (IDL-C) in hypercholesterolemic trained and sedentary men, 187
- Interstitial glycerol in SCI, 390-393
 effects of peripheral afferent stimulation of sympathetic neurons on, 1468
- Intestinal absorption of dietary fat and cholesterol, intestinal apo B mRNA levels, and apo B-48 synthesis in FHBL without apo B truncation, 1095-1100
- Intestinal apolipoprotein B (apo B) mRNA (messenger ribonucleic acid), intestinal absorption of dietary fat and cholesterol, apo B-48 synthesis in FHBL without apo B truncation, and levels of, 1095-1100
- Intestinal apolipoprotein B-48 (apo B-48), synthesis of, in FHBL without apo B truncation, apo B mRNA levels, intestinal absorption of dietary fat and cholesterol and, 1095-1100
- Intestines
 of IDDM and NIDDM subjects, expression of incretin genes in, 261-267
see also entries beginning with term: Intestinal
- Intraabdominal adipose tissue (AT), adult GH deficiency and, 813, 815
- Intracellular calcium ([Ca²⁺]_i), [³H]PdBu and, binding to intact platelets in young IDDM and NIDDM subjects, 949-953
- Intravenous glucose tolerance test (IVGTT)
 in bulimia nervosa, 484-486
 of hyperlipidemic subjects on troglitazone therapy, 273-281
 insulin secretion, insulin sensitivity, EE and, in obesity, 125
 of male offspring of CAD parent, 504-512
 in NIDDM, NE effects on, 1448-1453
 in severe malaria, minimal model analysis of, 1435-1440
- In vivo microdialysis, effects of VMH stimulation on glycogenolysis in liver studied with, 897-901
- IR (insulin receptor) in NIDDM, inhibition of endosomal acidification in normal cells compared with metabolic derangements of, 1259-1265
- IRH (idiopathic reactive hypoglycemia), alpha cell function in, 639-643
- IRI, *see* Immunoreactive insulin
- Iron, *see* Fe
- Ischemia
 and mitochondrial disorders, 311-313
 in STZ-DM, myocardial glucose uptake during, 168-172
- 3-Isobutyl-1-methylxanthine (IBMX), effects of progesterone on cAMP and glycerol in presence of, 596-598, 602
- Isoleucine
 cortisol and estradiol effects on, 248
 in isonitrogenous diet, 786, 790, 791
 plasma, *see* Plasma isoleucine
- Isoleucine (*Continued*)
 skeletal muscle, in critically illness, 760
- Isonitrogenous diet following injury, nutritional and metabolic effects of mild orotic aciduria during, 785-792
- Isotopically labeled tracers, *see* Tracers
- ISS (idiopathic short stature), children with, GH secretion, IGF-I, and IGFBP-3 concentrations in, 1241-1245
- IVGTT, *see* Intravenous glucose tolerance test
- Japanese subjects
 with major risk factors for M3243A→G mutation, prevalence of mitochondrial DM in, 793-795
 with NIDDM, decreased glucose effectiveness but not insulin resistance in glucose-tolerant offspring of, 880-883
 Trp64Arg missense mutation of β₃-adrenergic receptor in, prevalence of, 199-202
- K and K⁺ (potassium)
 with diet high in vegetables, fruit, and nuts, 532, 535
 following graded uninephrectomy, 32
 skeletal muscle, in critically illness, 760
see also Kaliuretic peptide; Na⁺/K⁺ ATPase
- Kaliuretic peptide, effects of, on CGRP, 818-825
- KBs (ketone bodies), TRG effects on, in normolipidemic non-obese NIDDM subjects, 194
- Ketogenesis, hepatic, oral MCT effects on, in FCPD, 1-4
- α (alpha)-Ketoglutarate (KG) in isonitrogenous diet following injury, 785-792
- α-Keto-δ-guanidinovaleic acid, *see* Serum α-keto-δ-guanidinovaleic acid
- α (alpha)-Ketoisocaproate (KIC)
 in isonitrogenous diet following injury, 785-792
 splanchnic versus whole-body production of, from leucine in fed state, 164-167
- [1-¹³]-α-Ketoisocaproate (KIC), ethanol effects on plasma levels of, 751-752
- Ketone bodies (KBs), TRG effects on, in normolipidemic non-obese NIDDM subjects, 194
- 6-Keto-prostaglandin F_{1α} (PGF_{1α}) in MCs exposed to high glucose concentrations, D-α-tocopherol effects on, 781, 783
- Ketosis, resistance to, in FCPD, effects of oral MCTs on hepatic ketogenesis and, 1-4
- KG (α-ketoglutarate) in isonitrogenous diet following injury, 785-792
- KIC, *see* α-Ketoisocaproate; [1-¹³]-α-Ketoisocaproate
- Kidneys
 radiation dose from apo tracers to, 1237
see also Diabetic nephropathy of NIDDM entries beginning with term: Renal and element: Reno-
- Kinase
 myosin light chain, in diabetic cardiomyopathy, 73
 serum creatine, effects of simvastatin and lovastatin on skeletal muscle, during exercise, 1206-1210
see also Phosphoenolpyruvate carboxykinase; Phosphokinase; Protein kinase
- Kinetic modeling in molecular cell biology, 1489-1495
 collaboration in, 1494-1495
 practical process for model development and testing, 1490-1491
 procedure for including control in mechanistic rate laws, 1491-1494
- Kinetics
 apo A-I, in FED, 478-479, 481
 apo B, in ECD, 1218
 Ca, in Turner's syndrome, estrogen therapy effects on, 908-913
 glucose, *see* Kinetics, glucose
 glycerol, in normotensive and hypertensive obese subjects, lipolysis and, 1082-1083

Kinetics (*Continued*)

- kinetic analysis of insulin action on glucose uptake and production, 1116-1127
- leucine, *see* Kinetics, leucine
- in obesity, *see* Kinetics in obesity
- plasma Lp, [³H]leucine in study of, 333-342
- protein, lipid, and CHO, stable isotopically labeled tracers in study of, 322-329
- of retinyl esters during PP lipemia, compartmental model of, 584-594
see also Oxidation
- Kinetics, glucose
 - IGF-I effects on, 1055
 - and insulin, in male offspring of CAD parent, 507
 - in NIDDM, aging and, 892
- Kinetics, leucine
 - during fasting, *see* Fasting, leucine kinetics during, GH and
 - during feeding using moderate nitrogenous and caloric diet and GH, 23-28
 - [1-¹³C]leucine, ethanol effects on, 750-755
- Kinetics in obesity
 - of beta cell secretion, insulin sensitivity and, 127-128
 - HDL, in obese exercising men without weight loss, 219-220
- Köbberling-Dunnigan syndrome type 2 (limb and trunk lipodystrophy), insulin resistance in, 159-163
- α (alpha) LA (α lipoic acid), effects of, on glycemia and muscle GLUT4 transporter content in STZ-DM, 763-768
- Lactalbumin in soy protein diet, 699
- Lactate
 - L-arginine effects on, 69
 - in exercising transgenic subjects, 1351
 - insulin resistance in heart and skeletal muscles of anesthetized subjects induced by, 684-690
 - plasma, metformin effects on, in NIDDM, 229
 - portal adrenergic blockade effects on, 460
 - in SCI subjects, 389
- Lactate, insulin and
 - differential effects of oxovanadiums and insulin on lactate metabolism, 562-572
 - troglitazone effects on lactate release in presence or absence of insulin, 718-719
- Lactate dehydrogenase (LDH), clofibrate effects on, 137
- Lactic acid
 - blood, ethanol and fructose effects on, compared, 546
 - muscle, α LA effects on, 766
 - plasma, after exercise, 1340
- Lactic acidosis, 309-310
see also Mitochondrial disorder(s)
- LANPs (long-acting atrial natriuretic peptides), effects of, on level of CGRP, 818-825
- Lard
 - effects of, in spontaneous NIDDM, 1459-1463
 - in soy protein diet, 699
- Lathosterol-5-dehydrogenase, fibroblast, in SLOS, 848
- LCAT (lecithin:cholesterol acyltransferase) in FED, 474-483
- LDH (lactate dehydrogenase), clofibrate effects on, 137
- LDL, *see* Low-density lipoprotein(s)
- LDL-C, *see* Low-density lipoprotein-cholesterol
- Lean body mass, *see* Fat-free mass
- Lean subjects, *see* Non-obese subjects
- Lecithin:cholesterol acyltransferase (LCAT) in FED, 474-483
- Leptin
 - HF diet effects on concentrations of, in non-obese subjects, 420-424
see also Leptin in women; Plasma leptin; Serum leptin

Leptin in women

- release of NPY, galanin and, in obese women and anorexic women, 1384-1389
see also Plasma leptin in women
- Leucine
 - cortisol and estradiol effects on, 248
 - in isonitrogenous diet, 786, 790, 791
 - kinetics of, *see* Kinetics, leucine
 - plasma, *see* Plasma leucine
 - skeletal muscle, in critically illness, 760
 - splanchnic versus whole-body KIC production from, in fed state, 164-167
 - [1-¹³C]Leucine, ethanol effects on kinetics of, 750-755
 - [³H]Leucine in study of plasma Lp kinetics, 333-342
- Leukemia, T-cell, PGs in cachexia induced by, 359-365
- LH, *see* Luteinizing hormone
- Limb and trunk lipodystrophy (type 2 Köbberling-Dunnigan syndrome), insulin resistance in, 159-163
- Linear growth during infancy due to CAH complicated by CPP, GnRH agonist therapy of, 513-517
- Lipase
 - hepatic, *see* Hepatic lipase
 - in obese exercising men without weight loss, HDL metabolism and, 219-220
see also Lipoprotein lipase; Phospholipase A₂
- Lipemia
 - PP, compartmental model of retinyl ester kinetics during, 584-594
see also Hyperlipidemia
- Lipid(s)
 - Cu deficiency effects on peroxidation of, 378
 - effects of hyperinsulinemia on acetyl-L-carnitine association with muscle glucose and lipid metabolism, 1454-1457
 - fasting, effects of endurance exercise by lean and obese men on, 558
 - fetal and maternal modulators of metabolism of, preeclampsia development correlated with, 963-967
 - GHRH 1-29 effects on, 92-93
 - plasma, *see* Plasma lipids
 - serum, *see* Serum lipids
 - stable isotopically labeled tracers in study of kinetics of, 322-329
 - time-dependent effects of insulin on synthesis of, in fetal hepatocytes, 345-354
 - tissue, BRL 49653 effects on availability of, in NIDDM, 935-942
see also Hyperlipidemia; Normolipidemic subjects; Phospholipids and specific lipids
- Lipid peroxide (LPO)
 - Cu promoting generation of, in LDLs, 835
 - MC content of, D-α-tocopherol effects on, 781
- Lipodystrophy, limb and trunk, insulin resistance in, 159-163
- Lipogenesis
 - and lipogenic effects of insulin in fetal hepatocytes, glycogenic effects compared with, 345-354
 - in WAT after starvation-refeeding cycles, 10-17
- α (alpha) Lipoic acid (LA), effects of, on glycemia and muscle GLUT4 transporter content in STZ-DM, 763-768
- Lipolysis
 - effects of adenosine hydrolysis by ADA on progesterone effects on, 595-604
 - in elderly postmenopausal women, 1312-1315
 - in SCI, *see* Spinal cord injury, SNS regulating lipolysis in sensitivity and response of, to fasting in normotensive and hypertension obese subjects, 1080-1084
- Lipolytic agent, wortmannin converting insulin but not oxytocin from antilipolytic agent to, in presence of forskolin, 62-66
- Lipoprotein (Lp)
 - from CAPD subjects, resistance of, to oxidation, 833-839

Lipoprotein (Lp) (*Continued*)

- serum, short-term stanozolol therapy effects on, in HL deficiency, 992-996
- see also* Apolipoprotein(s); High-density lipoprotein; Intermediate-density lipoprotein; Lipoprotein(a); Lipoprotein A-I; Lipoprotein A-I:II; Lipoprotein lipase; Low-density lipoprotein(s); Plasma lipoprotein; Very-low-density lipoprotein(s)
- Lipoprotein(a) [Lp(a); high-density lipoprotein,]
 - binding of, to HSPGs enhanced by LPL and improved by apo E saturation, 650-655
 - in chronic renal disease subjects, HD, and CAPD subjects, 38
 - diet effects on, *see* Lipoprotein(a), diet effects on
 - exercise effects on VLDL subfractions and, in men and women, 1178-1183
 - in FED, 476
 - in hypobetalipoproteinemia, 627
 - in IGT, effects of fibrinogen, PAI-1, and FVII on levels of, 670
 - native, ACTH increases receptor-specific uptake of native LDL, oxidized Lp(a) and, but not of oxidized LDL in HepG2 cells, 726-729
 - in NIDDM with obesity, heparin effects on hemostatic abnormalities and, 931
 - in PCOS, metformin effects on, 454-457
 - plasma, niceritrol effects on levels of, 355-358
 - serum, *see* Serum lipoprotein(a)
- Lipoprotein(a) [Lp(a); high-density lipoprotein,], diet effects on
 - of diet high in vegetables, fruit, and nuts on, 533
 - of dietary fat restriction, 434
- Lipoprotein A-I (Lp A-I), smoking cessation effects on, 711-715
- Lipoprotein A-I:II (Lp A-I:II), smoking cessation effects on, 711-715
- Lipoprotein lipase (LPL)
 - in HL deficiency, short-term stanozolol therapy effects on, 993
 - Lp(a) binding to HSPGs enhanced by, and improved by apo E saturation, 650-655
 - NO-1886 elevates plasma HDL-C levels by increasing, and without effect on CETP activity, 257-260
 - in obese men, sex hormones inhibiting activity of, 179-185
 - postheparin, *see* Plasma postheparin lipoprotein lipase
- Liver
 - effects of chronic dietary protein restriction and gastrectomy on IGF-I pathway in, 691-697
 - portal adrenergic blockade effects on gluconeogenic effects of epinephrine and NE on, 458-465
 - radiation dose received from apo tracers by, 1237
 - VMH stimulation effects on glycogenolysis in, in vivo microdialysis in study of, 897-901
 - see also* Liver transplantation and entries beginning with element: Hepat-
- Liver transplantation, somatostatin response to oral test meal by recipients of, 1003-1007
- Long-acting atrial natriuretic peptides (LANPs), effects of, on level of CGRP, 818-825
- Longitudinal changes
 - in FSH, LH, and testosterone in elderly men, 410-413
 - in skeletal muscle biochemical parameters in critical illness, 756-762
- Long-term body weight (BW) maintenance in older women, energy requirements for, 884-889
- Long-term follow-up of HGPS, 854
- Long-term therapy
 - with NTX, effects of, on GH and insulin secretion in obese and non-obese PCOS subjects, 538-543
 - with RU486, effects of, on pituitary-adrenal and pituitary-thyroid axes, 292-296
 - with vanadium, effects of, on STZ-DM, 769-777
- Lovastatin, skeletal muscle injury in exercise induced by, 1206-1210
- Low-density lipoprotein(s) [LDL; β -lipoprotein]
 - ACTH increases receptor-specific uptake of native Lp(a), and native but not of oxidized LDL in HepG2 cells, 726-729
 - in chronic renal disease, HD, and CAPD subjects, 38
 - diet effects on, *see* Low-density lipoprotein, diet effects on
 - in ECD, 1215-1219
 - exercise and, *see* Low-density lipoprotein, exercise and
 - in hypercholesterolemic sedentary men, 188
 - in IGT, effects of fibrinogen, PAI-1, and FVII on levels of, 670
 - oxidation of, *see* Oxidation, LDL
 - plasma, *see* Plasma low-density lipoprotein(s)
 - receptor-mediated binding to fibroblasts by, in SLOS, 848
 - see also* Hypobetalipoproteinemia; Low-density lipoprotein, particles of; Low-density lipoprotein-cholesterol; Very-low-density lipoprotein(s)
- Low-density lipoprotein (LDL; β -lipoprotein), diet effects on
 - of diet high in vegetables, fruit, and nuts, 533
 - dietary soy protein and ERT effects on LDLs in ovariectomized subjects, 701
- Low-density lipoprotein (LDL; β -lipoprotein), exercise and, 1180
 - in hypercholesterolemic trained men, 188
- Low-density lipoprotein (LDL; β -lipoprotein), particles of
 - insulin resistance and size of, 1275-1280
 - in sedentary and trained hypercholesterolemic men, 186-192
 - size of, as marker for atherogenic risk in male offspring of parent with early CAD, 954-958
 - small dense, in children, 146-148
- Low-density lipoprotein-cholesterol (LDL-C)
 - abdominal AT/insulin secretion correlation and, 1221
 - basal GH levels in women correlated with, 1040, 1041
 - diet effects on, *see* Low-density lipoprotein-cholesterol, diet effects on
 - in elderly postmenopausal women, lipolysis and, 1313
 - exercise and, *see* Low-density lipoprotein-cholesterol, exercise and
 - in familial hypertriglyceridemia, 1301, 1302
 - fasting serum, in young women with endometriosis, 736
 - heparin effects on concentrations of, 654
 - in hypercholesterolemia, *see* Low-density lipoprotein-cholesterol in hypercholesterolemia
 - in hypobetalipoproteinemia, 627
 - in IGT, effects of fibrinogen, PAI-1, and FVII on levels of, 670
 - insulin resistance, LDL particle size and, 1276, 1278
 - in male offspring of CAD parents, 506, 956
 - niceritrol effects on, 356
 - in obese men, *see* Low-density lipoprotein-cholesterol in obese men
 - in PCOS, metformin effects on, 455
 - plasma, in acute hyperinsulinemia, 1167
 - RE kinetics and PP production of, 586
 - and SLDL particles in children, 147
 - smoking cessation effects on, 713, 714
- Low-density lipoprotein-cholesterol (LDL-C), diet effects on
 - of diet high in vegetables, fruit, and nuts, 533, 534
 - of dietary fat restriction, 434
- Low-density lipoprotein-cholesterol (LDL-C), exercise and effects of, 1182
 - lovastatin effects on, 1207
- Low-density lipoprotein-cholesterol (LDL-C) in hypercholesterolemia
 - in hypercholesterolemic trained and sedentary men, 187
 - pravastatin effects on RBC deformability and, 289
- Low-density lipoprotein-cholesterol (LDL-C) in obese men
 - elderly and middle-aged men, sequential effects of aerobic exercise and weight loss on, 1444
 - hypertensive men, and effects of diltiazem or quinapril on insulin sensitivity, glucose effectiveness, and beta cell function, 174

- Low-density lipoprotein-cholesterol (LDL-C) in obese men (*Continued*)
in obese exercising men without weight loss, HDL metabolism and, 219
- Lp, *see* Lipoprotein
- LPL, *see* Lipoprotein lipase
- LPO, *see* Lipid peroxide
- Lung(s), radiation dose from apo tracers to, 1237
- Lung cancer, small-cell, TEE measured with HCO₃-urea method in subjects with, 1412-1417
- Luteinizing hormone (LH)
in CAH complicated by CPP, effects of GnRH agonist therapy on, 514
longitudinal changes in, in healthy older men, 410-413
in premenopausal and postmenopausal women, SHBG and, 8
see also Luteinizing hormone in PCOS
- Luteinizing hormone (LH) in PCOS
long-term NTX therapy effects on, 540
metformin effects on, 455
with severe hirsutism, effects of triptorelin with desogestrel-containing OCs on, 439
- Lymphoblasts, NHE-1 of, in hypertension, mitogen effects on PKC activity and phosphorylation of, 297-302
- Lysine
in isonitrogenous diet, 786, 790, 791
plasma, *see* Plasma lysine
skeletal muscle, in critical illness, 760
- Macroadenoma, pituitary, GH deficiency determination with GHRH stimulation test in subjects with, 680-683
- Macroproteinuria in NIDDM with diabetic nephropathy and retinopathy, 979, 980
- Magnesium (Mg), intake of, with diet high in vegetables, fruit, and nuts, 532
- Magnesium/adenosine triphosphatase (Mg²⁺/ATPase) in diabetic cardiomyopathy, 73
- Malaria, severe, minimal model analysis of IVGTT in, 1435-1440
- Malate in purified and unpurified islet cells, 985
- Male offspring of CAD parent, *see* Coronary artery disease, male offspring of parents with
- Malic enzyme (ME)
Cu deficiency effects on, 378
insulin effects on activities of, in fetal hepatocytes, 350-351
- Malignant hypertension, renoprotective effects of TAK-044 in, 1032-1038
- Malnutrition
effects of, on insulin sensitivity, insulin secretion, and glucose production, 140-145
see also Diet; Nutritional status
- Manganese (Mn), intake of, with diet high in vegetables, fruit, and nuts, 532
- MAPK (mitogen-activated protein kinase), activation of, in hepatocytes, by Ca- and PKC-dependent pathway, 548-555
- Mass isotopomer distribution analysis (MIDA) of protein, lipids, and CHOs, 327
- Mass spectrometry, very low stable isotopically labeled tracers enrichment with GC/MS, and its application to muscle protein synthesis measurement, 943-948
- Maternal and fetal modulators of lipid metabolism, preeclampsia development correlated with, 963-967
- Maturation, *see* Growth and development
- Maximal output power (MPO) during exercise, 283
- Maximum oxygen consumption, *see* $\dot{V}O_{2max}$; exercise effects on
- MCs, *see* Mesangial cells
- MCTs (medium-chain triglycerides), effects of oral, on hepatic ketogenesis in FCPD, 1-4
- ME, *see* Malic enzyme
- Meal
oral test, somatostatin response to, in liver transplant recipients, 1003-1007
see also Diet; Thermic effect of the meal and entries beginning with term: Postprandial
- Mechanistic rate laws, modeling procedure for including control in, 1491-1494
- Medium-chain triglycerides (MCTs), effects of oral, on hepatic ketogenesis in FCPD, 1-4
- Membrane-permeable cysteine protease inhibitor, E64d as, effects of, on PTH action in osteoblasts, 1090-1094
- Men
correlation between visceral AT accumulation and metabolism of uric acid in, 1162-1165
hypobetalipoproteinemic, 625-633
relationship between serum urate, fractional urate excretion and, 1085-1089
see also Cardiovascular disease, risk factors for, in men; Elderly men; HIV-infected men; Men, hypercholesterolemic; Men, obese; Men, sex hormones in; Middle-aged men; Non-obese men; Sex
- Men, exercising
exercise effects on VLDL subfractions and Lp(a), 1178-1183
galanin levels after exercise-induced pituitary hormone secretion in, 282-286
LDL particles in, 186-192
non-obese, increased HDL-C in, 556-561
physical activity and plasma insulin in, 1418-1423
see also Endurance exercise by men; Exercise; Men, obese, exercising; Norepinephrine, exercise effects on, in men; Prolonged exercise by men
- Men, hypercholesterolemic, 625-633
sedentary and exercising men, LDL particles in, 186-192
- Men, obese, 173-185
hypertensive, effects of diltiazem or quinapril on insulin sensitivity, glucose effectiveness and beta cell function in, 173-178
sex hormones inhibiting LPL activity in, 179-185
see also Men, obese, exercising; Testosterone in obese men
- Men, obese, exercising
increase in HDL-C in, 556-561
middle-aged and elderly men, sequential effects of aerobic exercise and weight loss on CV disease risk factors in, 1441-1447
prolonged exercise without weight loss, effects of, on HDL metabolism, 217-223
- Men, sex hormones in
androgenic status and prothrombin factors in, irrespective of age, obesity, and AT distribution, 1287-1293; *see also* Men, obese
LPL activity inhibited by, in men, 179-185
young, effects of mild hyperthyroidism on GH and insulin secretion, and on sex hormones in, 1424-1428
see also Sex hormone-binding globulin in men; Testosterone in obese men and specific sex hormones
- Mental stress, SCI subjects under, lipolysis regulation by SNS during, 390-391
- Mesangial cells (MCs)
exposed to high glucose concentrations, effects of D- α -tocopherol on, 779-784
PKC-signaled increases of TGF- β in, inhibited by antioxidants, 918-925
- Messenger ribonucleic acid, *see* mRNA
- Metformin
effects of, on glucose utilization after OGTT in NIDDM, 227-233
in PCOS, effects of, on plasma PAI-1, Lp(a), and immunoreactive insulin, 454-457

- Methimazole (MMI) for hyperthyroidism with untreated Graves' disease, 1184-1888
- Methionine
cortisol and estradiol effects on, 248
in isonitrogenous diet, 786, 790, 791
plasma, *see* Plasma methionine
in soy protein diet, 699
- DL-Methionine in protein-restricted diet, 692
- Methylguanidine (MG), serum, in nondialyzed patients with chronic renal insufficiency, 1026, 1028
- 3-Methylhistidine, plasma, in uremia, 614
- Methyltransferase, deficiency in guanidinoacetate, guanidino compounds in, 1189-1193
- Mexican-American parents with NIDDM, hyperinsulinemia-associated hyperamylinemia in glucose-tolerant and insulin-resistant offspring of, 1157-1161
- MG (methylguanidine), serum, in nondialyzed patients with chronic renal insufficiency, 1026, 1028
- Mg (magnesium)
intake of, with diet high in vegetables, fruit, and nuts, 532
skeletal muscle, in critical illness, 760
- Mg²⁺/ATPase (magnesium/adenosine triphosphatase) in diabetic cardiomyopathy, 73
- Microalbuminuria in NIDDM with diabetic nephropathy and retinopathy, 979, 980
- Microdialysis study
in vivo, effects of VMH stimulation on glycogenolysis in liver studied with, 897-901
of lipolysis regulation by SNS in normal and spinal-cord injured subjects, 388-394
- MIDA (mass isotopomer distribution analysis) of protein, lipids, and CHOs, 327
- Middle-aged men
obese, sequential effects of aerobic exercise and weight loss on CV disease risk factors in, 1441-1447
physical activity and plasma insulin in, 1418-1423
- Mifepristone (RU486), effects of long-term therapy with, on pituitary-adrenal and pituitary-thyroid axes, 292-296
- Mild hyperthyroidism, effects of, on GH and insulin secretion, and on sex hormones in healthy young men, 1424-1428
- Mild orotic aciduria, nutritional and metabolic effects of, during supplementation with arginine after injury, 785-792
- Minimal model analysis
of bulimia nervosa, 484-486
of IVGTT in severe malaria, 1435-1440
- Mitochondrial diabetes mellitus (DM), mutations in
tRNA^{Leu(UUR)} 3243 mutation, insulin secretion and sensitivity with, 1019-1023
see also Mitochondrial diabetes mellitus, M3243A→G DNA mutation in
- Mitochondrial diabetes mellitus (DM), M3243A→G DNA mutation in
in IDDM children, 445-450
prevalence of major risk factors for, in Japanese patients, 793-795
- Mitochondrial disorder(s), 306-321
aging and, 310
ischemia and, 311-313
lactic acidosis as, 309-310
mitochondrial biology and, 306-308
neurodegenerative diseases and, 313-314
NIDDM and, 310-311
treatment of, 314-316
- Mitochondrial DNA (deoxyribonucleic acid)
respiratory chain activity and content of, in nonpurified and purified islet pancreatic cells, 984-987
- Mitochondrial DNA (deoxyribonucleic acid) (*Continued*)
see also Mitochondrial diabetes mellitus, M3243A→G DNA mutation in
- Mitogen, effects of, on PKC activity and phosphorylation of lymphoblast NHE-1 in hypertension, 297-302
- Mitogen-activated protein kinase (MAPK), activation of, in hepatocytes, by Ca- and PKC-dependent pathway, 548-555
- MLC (myosin light chain), phosphorylation of, in diabetic cardiomyopathy, 71-75
- MLCK (myosin light chain kinase) in diabetic cardiomyopathy, 73
- MMI (methimazole) for hyperthyroidism with untreated Graves' disease, 1184-1888
- Mn (manganese), intake of, with diet high in vegetables, fruit, and nuts, 532
- Model library, accessing whole-body metabolism models on, 330-332
- Moderate exercise, effects of insulin- and non-insulin-mediated glucose uptake in normal subjects, 203-209
- Molecular cell biology, *see* Kinetic modeling in molecular cell biology
- Monocytes, glitazide effects on cell-mediated LDL oxidation and adhesion of, to endothelial cells, 1150-1156
- Monophosphate
adenosine, *see* AMP
8-bromo cyclic guanosine, effects of, on ET-1 production in VSMCs, 492
- Monounsaturated fatty acid (MUFA) intake
in diet high in vegetables, fruit, and nuts, 532, 534
in exercise, 1180
in modified diet of IGT subjects, 668
by smokers, 713
in soy protein diet, 699
- Morphology
changes in renal, in IDDM, serum AGEs as predictors of, 661-664
and reactivity of aorta in STZ-DM, antioxidant and TG-lowering effects of vitamin E associated with prevention of abnormal, 872-879
- Mortality due to cardiovascular disease, serum Ca concentrations and, 1171-1177
- MPO (maximal output power) during exercise, 283
- mRNA (messenger ribonucleic acid)
content of insulin, in beta cells, effects of aging on, 245
GHR gene, during 3T3-L1 preadipocyte differentiation, 114-118
GLUT4, *see* mRNA, GLUT4
G6Pase, TNF-α effects on, 579-583
hepatic and colonic IGF-I, 693
intestinal apo B, intestinal absorption of dietary fat and cholesterol, apo B-48 synthesis, and levels of, in FHBL without apo B truncation, 1095-1100
PEPCK, *see* mRNA, PEPCK
- mRNA (messenger ribonucleic acid), GLUT4
α LA effects on, 765-766
overexpression of, in exercising transgenic subjects, 1349-1357
skeletal muscle, in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and EPA-E on, 1461
- mRNA (messenger ribonucleic acid), PEPCK
aging and endurance training effects on expression of, 414-419
TNF-α effects on, 581
- Mucosa, SP content of rectal, in IDDM and NIDDM with diarrhea and constipation, 730-734
- MUFAs, *see* Monounsaturated fatty acid intake
- Multicompartmental model analysis of protein, lipids, and CHOs, 327-328
- Multiple myeloma, effects of modulation of chronic excessive IL-6 production in, on T₃ and T₄, 1343-1348
- Muscle(s)
atrophy of unweighted, attenuated by insulin, 673-679

Muscle(s) (*Continued*)

- GHRH 1-29 effects on, 91-92
- glucose metabolism in, *see* Muscle glucose metabolism
- α LA effects on glycemia and GLUT4 transporter content of, in STZ-DM, 763-768
- radiation dose received from apo tracers by, 1237
- skeletal, *see* Skeletal muscle
- in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and EPA-E on TGs in, 1460
- see also* Muscle cells; Muscle mass; Muscle protein and entries beginning with element: Myo-
- Muscle cells, vascular, smooth, ET-1 production in, modulated by atrial, brain, and C-type natriuretic peptides, 487-493
- Muscle glucose metabolism
 - acute effects of troglitazone on, in absence or presence of insulin, 716-721
 - HF diet effects on insulin-stimulated posttransport, 1101-1106
 - muscle lipid metabolism and, effects of hyperinsulinemia on acetyl-L-carnitine association with, 1454-1457
- Muscle glycogen in exercising transgenic subjects, 1355
- Muscle mass in underweight and non-obese subjects with and without cancer, 141
- Muscle protein
 - skeletal muscle concentration of, in critical illness, 758
 - synthesis of, very low stable isotopically labeled tracers enrichment measured with GC/MS, and its application to measurement of, 943-948
- Mutation
 - Trp64Arg missense, of β_3 -adrenergic receptor, 199-202
 - see also* Mitochondrial diabetes mellitus, mutations in
- Myeloma, multiple, effects of modulation of chronic excessive IL-6 production in, on T₃ and T₄, 1343-1348
- Myocardial glucose, uptake of, during ischemia in STZ-DM, 168-172
- Myocardial infarction with homocysteinemia, high PAI-1 activity, and resistance to activated protein C, 1470-1472
- Myocyte Na⁺/H⁺ exchanger isoform-1 (NHE-1), vascular, Ca-induced activation of, 250-256
- Myosin light chain (MLC), phosphorylation of, in diabetic cardiomyopathy, 71-75
- Myosin light chain kinase (MLCK) in diabetic cardiomyopathy, 73
- N, *see* Nitrogen
- Na (and Na⁺) (sodium)
 - with diet high in vegetables, fruit, and nuts, 532, 535
 - following graded uninephrectomy, 32
 - skeletal muscle, in critical illness, 760
 - see also* Na⁺/H⁺ exchanger isoform-1; Na⁺/K⁺ ATPase; Na⁺/Li⁺ countertransport activity; Natriuretic factor; Natriuretic peptides
- NADPH (nicotinamide adenine dinucleotide phosphate), erythrocyte, in NIDDM, polyol pathway activation and GSH redox status and, 1195
- Na⁺/H⁺ (sodium/hydrogen) countertransport (CT) activity in hypertensive NIDDM, 1316-1323
- Na⁺/H⁺ (sodium/hydrogen) exchanger isoform-1 (NHE-1)
 - of lymphoblasts in hypertension, mitogen effects on PKC activity and phosphorylation of, 297-302
 - vascular myocyte, Ca-induced activation of, 250-256
- Na⁺/K⁺ ATPase (sodium/potassium adenosine triphosphatase), activity of erythrocyte membrane, in IDDM and NIDDM, aging and, 59-61
- Na⁺/Li⁺ (sodium/lithium) countertransport (CT) activity in hypertensive NIDDM, 1316-1323
- Naloxone, hypersensitivity of HPA axis to, in opioid withdrawal, 130-134

- Naltrexone (NTX), effects of long-term therapy with, on GH and insulin secretion in obese and non-obese PCOS women, 538-543
- Natriuretic factor, atrial, effects of, on CGRP, 818-826
- Natriuretic peptides
 - atrial, *see* Atrial natriuretic peptides
 - brain and C-type, ET-1 production in VSMCs modulated by, 487-493
- NE, *see* Norepinephrine
- NEFAs (nonesterified fatty acids), *see* Free fatty acids
- Nephropathy, diabetic, *see* Diabetic nephropathy of NIDDM
- Nervous system, *see* Spinal cord injury, SNS regulating lipolysis in and entries beginning with element: Neur-
- Net balance of hepatic glucose, effects of G6Pase flux on, 1390-1398
- Neurodegenerative diseases, mitochondrial disorders and, 313-314
- Neuromedin B, pituitary, in fasting and STZ-DM, TSH secretion and, 149-153
- Neurons, lipolysis in SCI activated by peripheral afferent stimulation of decentralized sympathetic, 1465-1469
- Neuropeptide(s), neural expression of pancreatic islet, in HF diet-induced insulin resistance, 103
- Neuropeptide Y (NPY), release of leptin, galanin and, in obese women and anorexic women, 1384-1389
- Neuroregulation by GH, effects of sex and food intake effects on, and physiological role of opioid-cholinergic system interaction in, 740-744
- Neutrophil respiratory burst activity (NRBA), tolrestat effects on, in IDDM and NIDDM, 634-638
- NH₄ (ammonium), plasma, after exercise, 1340
- NHE-1, *see* Na⁺/H⁺ exchanger isoform-1
- NHS (nonhepatic splanchnic) tissues, contribution of, to NE increase during prolonged exercise in DM, 1327-1332
- Niacin, intake of, with diet high in vegetables, fruit, and nuts, 532
- Niceritrol, effects of, on plasma Lp(a) levels, 355-358
- Nicotinamide adenine dinucleotide phosphate (NADPH), erythrocyte, in NIDDM, polyol pathway activation and GSH redox status and, 1195
- Nicotine
 - smokeless, associated with hypertension but not with glucose tolerance deterioration, 1008-1012
 - see also* Smoking
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- Nile red staining, insulin effects on cellular fluorescence produced by, 351
- Nitric oxide (NO)
 - acute hyperinsulinemia stimulating production of, 406-409
 - as mediator for L-arginine, role of, in insulin-mediated glucose uptake, 1068-1073
- Nitrogen (N)
 - blood urea, in hypercholesterolemia, pravastatin effects on RBC deformability and, 289
 - urinary excretion of, surgery and, 798
 - see also* Nitrogen-free diet; Nitrogenous diet
- Nitrogen (N)-free diet, hypocaloric, effects of GH and, on postoperative protein synthesis, 796-800
- Nitrogenous diet
 - isonitrogenous diet following injury, nutritional and metabolic effects of mild orotic aciduria during, 785-792
 - leucine kinetics during fasting and feeding using GH, caloric and, 23-28
- NO, *see* Nitric oxide
- NO₂/NO₃⁻, urinary excretion of, as measure of NO production stimulated by acute hyperinsulinemia, 406-409
- Nocturnal growth hormone (GH), GHRH 1-29 effects on release of, in elderly men, 91
- Nocturnal thyrotropin (TSH), effects of PZP on GH secretion and secretion of, in IDDM, 1305-1311

- NO-1886 (diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl] benzylphosphonate) elevates plasma HDL-C levels by increasing LPL and without effect on CETP activity, 257-260
- Nondiabetic subjects
effects of aging on insulin action in, 890-896
Japanese, prevalence of Trp64Arg missense mutation of β_3 -adrenergic receptor in, 199-202
- Nondialyzed subjects with chronic renal insufficiency, serum and urine guanidino compounds in, 1024-1031
- Nonesterified fatty acids, *see* Free fatty acids
- Nonhepatic splanchnic (NHS) tissues, contribution of, to NE increase during prolonged exercise in DM, 1327-1332
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), 192-202
aging and, *see* Aging, NIDDM and
BRL 49653 effects on systemic FA supply and utilization and on tissue lipid availability in, 935-942
correlation between plasma apo H and C levels in, 522-525
day-to-day variation in insulin sensitivity in, 374-376
diabetic nephropathy of, *see* Diabetic nephropathy of NIDDM
with diarrhea and constipation, substance P content of rectal mucosa in subjects with, 730-734
extrapancreatic action of truncated GLP-1 amide in, 745-749
gene polymorphism in, *see* Polymorphism, gene, in NIDDM
genetic susceptibility loci in IDDM and, 48-52
glucose in, *see* Glucose in NIDDM
glucose tolerance in, *see* Glucose tolerance in NIDDM
hypertension in, *see* Hypertension in NIDDM
hypofibrinolysis with hyperinsulinemia in, effects of short-term continuous insulin infusion on, 1074-1079
IAPP/amylin in, 1044-1051
inhibition of endosomal acidification in normal cells compared with insulin and insulin receptor metabolic derangements in, 1259-1265
insulin resistance in, *see* Insulin resistance in NIDDM
intestinal incretin gene expression in, 261-267
mitochondrial disorders and, 310-311
non-obese subjects with, *see* Non-obese subjects with NIDDM
with obesity, heparin effects on hemostatic abnormalities in, 930-934
peripheral vasoconstrictor responses to sympathetic activation in, rheological disorders and, 235-241
polyol pathway activation and redox status of GSH in, 1194-1198
prevalence of Trp64Arg missense mutation of β_3 -adrenergic receptor in Japanese subjects with, 199-202
tolrestat effects on NRBA in, 634-638
young subjects with, intracellular Ca and [3 H]PdBu binding to intact platelets in, 949-953
see also Mitochondrial diabetes mellitus, mutations in; Parents, NIDDM, of glucose-tolerant offspring
- Non-obese men
acute hyperinsulinemic, serum T concentrations in, 526-529
HDL-C increase in exercising, 556-561
- Non-obese subjects
children and adolescents, relationship of serum IGFBP-3, serum PICP, and serum IGF-I to sex, pubertal development, growth, insulin, and nutritional status of, 862-872
hepatic insulin extraction, insulin clearance, and concentrations of C-peptides in, race and, 53-58
HF diet effects on leptin concentrations in, 420-424
insulin secretion, insulin sensitivity, and glucose production in underweight and, with and without cancer, 140-145
with NIDDM, *see* Non-obese subjects with NIDDM
with PCOS, long-term NTX therapy effects on secretion of GH and insulin in, 538-543
- Non-obese subjects (*Continued*)
visceral AT effects on insulin secretion, insulin sensitivity, and energy expenditure in, 123-129
see also Non-obese men
- Non-obese subjects with NIDDM
and diabetic nephropathy, insulin resistance in, 1013-1018
normolipidemic, TRG in, 192-198
- Nonoxidative glucose metabolism in cirrhosis, insulin effects on, 840-843
- Nonprotein respiratory quotient (npRQ), insulin effects on, in cirrhosis, 843
- Nonpurified pancreatic islet cells, respiratory chain activity and mitochondrial DNA content of, 984-987
- Norepinephrine (NE; noradrenaline)
effects of, on insulin secretion and glucose effectiveness in NIDDM, 1448-1453
effects of, on MAPK activity in hepatocytes, 549
effects of antidiabetic drugs on arterial contractions induced by, 1201-1202
exercise and, *see* Norepinephrine, exercise effects on
in normotensive and hypertensive obese subjects, lipolysis and, 1082
portal adrenergic blockade effects on gluconeogenic effects of, on liver, 458-465
in SCI, 389, 1466-1468
VMH stimulation effects on, 897-901
- Norepinephrine (NE; noradrenaline), exercise effects on
of prolonged exercise in DM, hepatic and nonhepatic splanchnic tissue contribution to NE increase, 1327-1332
see also Norepinephrine, exercise effects on, in men
- Norepinephrine (NE; noradrenaline), exercise effects on, in men
galanin levels after exercise-induced NE secretion, 282-286
on NE kinetics in endurance exercising by identical twins, 501
- Normal adult subjects, 382-394
age of, and response to PTH in HP and PHP, 1246-1251
aging effects on DHEAS in relation to fasting insulin level and body composition in, BIA in assessment of, 826-832
alpha cell function in, 639-643
L-arginine but not D-arginine stimulates insulin-mediated glucose uptake in, 1068-1073
Asian Indian, CAT scan of abdominal AT distribution and its correlation with anthropometry and insulin secretion in, 1220-1224
antithrombin and prothrombin catabolism in, 1406-1411
daily energy requirements of, 1294-1298
EE by, *see* Normal adult subjects, EE by
exercising, *see* Normal adult subjects, exercising
in fed state, splanchnic versus whole-body α -ketoisocaproate production from leucine in, 164-167
GH in, *see* Normal adult subjects, GH in
hepatic ketogenesis after oral MCTs in, 1-4
hyperinsulinemia effects on acetyl-L-carnitine association with muscle glucose and lipid metabolism in, 1454-1457
I/D polymorphism of ACE gene in, 1211-1214
inhibition of endosomal acidification of normal cells in, 1259-1265
IVGTT of glucose effectiveness in, 484-486
lack of association between hyperinsulinemia and altered venous plasma ET-1 levels in, 1137-1139
LANP effects on level of CGRP in, 818-825
leptin in, *see* Normal adult subjects, leptin in
[3 H]leucine tracer in kinetic studies of plasma Lps in, 333-342
with low adiposity, serum leptin concentrations in, 303-305
microdialysis study of lipolysis regulation by SNS in, 388-394
nonoxidative glucose metabolism in, 840-843

- Normal adult subjects, 382-394 (*Continued*)
 PAI-1 activity in, 36-40
 plasma CETP activity and decreased plasma FFAs in, 1166-1170
 plasma uridine levels in, 801-804
 polyol pathway activation and redox status of GSH in, 1194-1198
 PP and starved, glucose production and gluconeogenesis and, 1358-1363
 relationship between RMR and FFM composition in, 1225-1230
 substance P content of rectal mucosa in, 730-734
 time of day and glucose tolerance status effects on SCFA concentrations in, 805-811
 tolrestat effects on NRBA in, 634-638
see also Men; Women and specific conditions
- Normal adult subjects, EE by
 insulin secretion, insulin sensitivity and, 123-129
 and plasma leptin concentrations in, 450-453
 total EE, 1324-1326
- Normal adult subjects, exercising
 galanin levels after exercise-induced pituitary hormone secretion in, 282-286
 moderate exercise effects on insulin- and non-insulin-mediated glucose uptake in, 203-209
see also Men, exercising
- Normal adult subjects, GH in
 GAD antibodies and GH secretion, 382-387
 GHRH stimulation test to determine GH deficiency in, 680-683
- Normal adult subjects, leptin in
 plasma leptin concentrations in, 450-453
 serum leptin, 812-817
- Normal cells, inhibition of endosomal acidification in, compared with insulin and insulin receptor metabolic derangements in NIDDM, 1259-1265
- Normal-weight subjects, *see* Non-obese subjects
- Normolipidemic subjects
 ECD in, 1215-1219
 non-obese NIDDM, TRG in, 192-198
- Normoponderal subjects, *see* Non-obese subjects
- Normotensive subjects, obese
 insulin sensitivity, glucose effectiveness, and beta cell function in, 173-179
 lipolysis sensitivity and response to fasting in, 1080-1084
- Northern blot studies of IGFBP production in BRECs, 1372-1373
- npRQ (nonprotein respiratory quotient), insulin effects on, in cirrhosis, 843
- NPY (neuropeptide Y), release of leptin, galanin and, in obese women and anorexic women, 1384-1389
- NRBA (neutrophil respiratory burst activity), tolrestat effects on, in IDDM and NIDDM, 634-638
- NT, *see* Nutritional therapy
- NTX (naltrexone), effects of long-term therapy with, on GH and insulin secretion in obese and non-obese PCOS women, 538-543
- Nucleic acids, *see* DNA; RNA
- Nutritional status
 of obese children and adolescents, relationship of serum IGFBP-3, serum PICP, and serum IGF-I to sex, insulin, growth and, 862-872
see also Diet; Malnutrition
- Nutritional therapy (NT)
 response to GH and, in HGPS, 851-856
 total parenteral, tumor-bearing subjects on, arginine and glutamine metabolism in, 370-373
see also Diet; Supplementation
- Nuts, effects of diet high in vegetables, fruit and, on serum lipids, 530-537
- O₂ (oxygen), *see* $\dot{V}O_2$
- Obesity
 androgenic status and prothrombin factors in men, irrespective of age, AT distribution and, 1287-1293; *see also* Men, obese; Non-obese men
 brain β -adrenergic receptor binding induced by beef tallow diet in, 18-22
 GH secretion and, *see* Obesity, GH release and secretion in
 hypertension and, *see* Hypertension in obesity
 NIDDM with, heparin effects on hemostatic abnormalities in, 930-934
 obese children and adolescents, relationship of serum IGFBP-3, serum PICP, and serum IGF-I to sex, pubertal development, growth, insulin, and nutritional status of, 862-872
 race and, *see* Obesity, race and
 visceral AT effects on insulin secretion, insulin sensitivity, and energy expenditure in, 123-129
 weight loss in, *see* Weight loss in obesity
see also Normotensive subjects, obese; Women, obese
- Obesity, GH release and secretion in
 long-term NTX therapy effects on secretion of insulin and GH in obese PCOS subjects, 538-543
 in subjects susceptible and/or resistant to obesity, 210-216
- Obesity, race and
 and hepatic insulin extraction, insulin clearance, and C-peptide concentrations, 53-58
 sex and, and insulin-mediated FFA suppression and fasting TG levels in, 400-405
- Occupation of SCI subjects, 389
- OCs, *see* Oral contraceptives
- Octreotide, inhibitory effects of, on GH release in GH-secreting adenoma cells, galanin inhibitory effects compared with, 425-430
- Offspring, *see* Children
- OGTT, *see* Oral glucose tolerance test
- 1 α (OH)D₃ (1 α -hydroxyvitamin D₃), effects of, on levels of serum thyroid hormones in hyperthyroidism with untreated Graves' disease, 1184-1188
- 1,25-(OH)₂D (1,25-dihydroxyvitamin D), and association between IGT and altered Ca homeostasis, 1171-1177
- 25-OHD (25-hydroxyvitamin D), and association between IGT and altered Ca homeostasis, 1171-1177
- 17-OHP, *see* 17-Hydroxyprogesterone
- Oil
 corn, in protein-restricted diet, 692
 fish, *see* n-3 Polyunsaturated fatty acid(s); n-6 Polyunsaturated fatty acids
see also Olive oil; Safflower oil
- Older subjects
 dietary CHO effects on apo A-I expression in, 1132-1136
see also Aging; Elderly men; Elderly women
- Olive oil
 effects of, in spontaneous NIDDM, 1459-1463
 in soy protein diet, 699
- Opioid-cholinergic system interaction, physiological effects of, on GH neuroregulation, 740-744
- Opioid withdrawal, hypersensitivity of HPA axis to naloxone in, 130-134
- Oral contraceptives (OCs)
 desogestrel-containing, effects of triptorelin with, on hair, bone density, and hormone profile in PCOS with severe hirsutism, 437-440
 and quantitative genetics of serum SHBG, 990
- Oral glucose tolerance test (OGTT)
 of IRH subjects, 639-643

- Oral glucose tolerance test (OGTT) (*Continued*)
 metformin effects on glucose utilization after, in NIDDM, 227-233
 in mitochondrial DM subjects, 1019-1023
 in non-obese subjects with PCOS, 538-543
 in obese subjects, *see* Oral glucose tolerance test in obese subjects
 race and hepatic insulin extraction and clearance and, 55
- Oral glucose tolerance test (OGTT) in obese subjects
 insulin secretion, insulin sensitivity, and EE in, 125
 of obese children and adolescents, 865
 with PCOS, 538-543
- Oral medium-chain triglycerides (MCTs), effects of, on hepatic ketogenesis in FCPD, 1-4
- Oral test meal, somatostatin response to, in liver transplant recipients, 1003-1007
- Organ size, relationship between RMR and, 1225-1230
- Organ weight
 colon, protein-restricted diet effects on, 693
 indomethacin and flurbiprofen effects on, in T-cell leukemia, 361-362
 kidney, *see* Organ weight, kidney
 liver, *see* Organ weight, liver
 ventricular, in diabetic cardiomyopathy, 72
- Organ weight, kidney
 and IGF-I and IGF-BPs following graded uninephrectomy, 30
 in renal insufficiency and proximal tubular dysfunction, 612-613
- Organ weight, liver
 and clofibrate-induced hyperoxaluria, 136-137
 protein-restricted diet effects on, 693
- Ornithine
 in isonitrogenous diet, 786, 790, 791
 metabolism of, in tumor-bearing subjects on TPN, 372
 plasma, *see* Plasma ornithine
 skeletal muscle, in critical illness, 760
- Orotic aciduria, mild, nutritional and metabolic effects of, during supplementation with arginine after injury, 785-792
- Orotidine, allopurinol effects on urinary excretion of, 1475
- Oscillatory Ca^{2+} (calcium) signaling in somatostatin-producing pancreatic cells, 366-369
- Osteoblasts, E64d effects on PTH action in, 1090-1094
- Ovarian steroidogenic abnormalities, adrenal and, in hirsute women without hyperandrogenemia, 902-907
- Ovariectomized subjects, ERT and dietary soy protein effects on CV disease risk factors and aortic cholesteryl ester content in, 698-705
- Ovaries
 radiation dose received from apo tracers by, 1237
see also Ovarian steroidogenic abnormalities; Ovariectomized subjects; Polycystic ovary syndrome
- Overweight, *see* Obesity
- Oxalate, clofibrate inducing increased synthesis of, hyperoxaluria and, 135-139
- Oxidation
 AA, in surgical subjects, GH modulating, 23-28
 CHO, metformin effects on, in NIDDM, 229, 230
 DCA inhibiting glutamine, via transamination, by decreasing pyruvate availability, 268-272
 FA, insulin inhibition of AMP-activated PK in heart resulting in activation of acetyl CoA carboxylase activation and, 1270-1274
 glucose, *see* Oxidation, glucose
 LDL, *see* Oxidation, LDL
 resistance of Lps from CAPD patients to, 833-839
see also Peroxidation; Redox status and entries beginning with term: Oxidized
- Oxidation, glucose (*Continued*)
 stimulation of, as treatment of mitochondrial disorders, 314-315
- Oxidation, LDL
 in CAPD patients, 835
 cell-mediated, glial effects on monocyte adhesion to endothelial cells and, 1150-1156
- Oxidized lipoprotein(a) [Ox-Lp(a)], ACTH increases receptor-specific uptake of native LDL, native Lp(a) and, but not of oxidized LDL in HepG2 cells, 726-729
- Oxidized low-density lipoprotein (Ox-LDL), ACTH increases receptor-specific uptake of native LDL, native Lp(a), and oxidized Lp(a) but not of, in HepG2 cells, 726-729
- Oxovanadiums, differential effects of insulin and, on glucose and lactate metabolism, 562-572
- Oxygen, *see* $\dot{V}\text{O}_2$
- Oxymetazoline, effects of, on insulin secretion by beta cells, 1146-1149
- Oxytocin, wortmannin does not convert, from antilipolytic to lipolytic agent in presence of forskolin, 62-66
- P (phosphorus), intake of, on diet high in vegetables, fruit, and nuts, 532
- PA (plasminogen activator), *see* Tissue plasminogen activator
- PaCO_2 , exercise effects on, 1340, 1341
- PAI-1, *see* Plasminogen activator inhibitor-1
- Palmitate, insulin effects on oxidation of, 1271
- Pancreas
 histopathology of, in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and EPA-E on, 1461, 1463
 radiation dose received from apo tracers by, 1237
see also Pancreatic islets and cells; Pancreatic diabetes; Pancreatitis
- Pancreatic diabetes, fibrocalculus, effects of oral MCTs on hepatic ketogenesis and, 1-4
- Pancreatic islets and cells
 BK effects on secretion of insulin, glucagon, and somatostatin in, 1113-1115
 functional properties of cryopreserved, 644-649
 neural expression of neuropeptides of, in insulin resistance induced by HF diet, 103
 purified and nonpurified, respiratory chain activity and mitochondrial DNA content of, 984-987
 somatostatin-producing, oscillatory Ca^{2+} signaling in, 366-369
see also Alpha cells; Beta cells
- Pancreatitis, tropical calcific, beta cell function and insulin sensitivity in, 441-444
- Pantothenic acid, intake of, on diet high in vegetables, fruit, and nuts, 532
- PaO_2 , exercise effects on, 1340, 1341
- Parathyroid hormone (PTH)
 and association between IGT and altered Ca homeostasis, 1171-1177
 effects of age on response to, 1246-1251
 E64d effects on action of, in osteoblasts, 1090-1094
- Parenteral nutrition, total, tumor-bearing subjects on, arginine and glutamine metabolism in, 370-373
- Parents, *see* Coronary artery disease, male offspring of parents with; Parents, NIDDM, of glucose-tolerant offspring and entries beginning with term: Familial
- Parents, NIDDM, of glucose-tolerant offspring
 Japanese, decreased glucose effectiveness but not insulin resistance in offspring, 880-883
 Mexican-American, hyperinsulinemia-associated hyperamylinemia in glucose-tolerant and insulin-resistant offspring, 1157-1161
- PCOS, *see* Polycystic ovary syndrome
- $[^3\text{H}]\text{PdBu}$ ($[^3\text{H}]\text{phorbol 12,12-dibutyrate}$), intracellular Ca and, binding to intact platelets in young IDDM and NIDDM subjects, 949-953

- PDEs (phosphodiesterases), and effects of progesterone on cAMP, 595-604
- Pentaerythritol tetranicotinate (niceritol), effects of, on plasma Lp(a) levels, 355-358
- PEPCK, *see* Phosphoenolpyruvate carboxykinase
- Peptide(s)
regulation of thyroid hormones in GIP secretion, 154-158
see also C-peptides; Glucagon-like peptide-1 (7-36) amide; Glucagon-like peptide-1 (7-36) amide gene; Natriuretic peptides; Neuropeptide(s); Neuropeptide Y; Peptides in IDDM; Polypeptide; Propeptide and specific peptides
- Peptides in IDDM
GH response to GHRP-6 and, 706-710
GLP-1 amide gene expression in intestines of IDDM subjects, 261-267
- Perinatal period, computer model of whole-body metabolism of zinc in, 331
- Peripheral afferent stimulation of decentralized sympathetic neurons, lipolysis in SCI activated by, 1465-1469
- Peripheral vasoconstrictor responses to sympathetic activation in NIDDM, rheological disorders and, 235-241
- Peritoneal dialysis, *see* Continuous ambulatory peritoneal dialysis
- Peroxidation, lipid, Cu deficiency effects on, 378
- Peroxide, *see* Lipid peroxide
- Peroxovanadiums, differential effects of insulin and, on glucose and lactate metabolism, 562-572
- Persistent hypobetalipoproteinemia in men, 625-633
- PG(s) (prostaglandins) in T-cell leukemia-induced cachexia, 359-365
- PGE (prostaglandin E), effects of aldose reductase inhibition on production of, in STZ-DM, 43
- PGF_{1α} (prostaglandin F_{1α}), 6-keto-, in MCs exposed to high glucose concentrations, D-α-tocopherol effects on, 781, 783
- pH, exercise effects on, 1340
- Phenotype
apo A, and serum Lp(a) levels in young women with endometriosis, 737
apo B, in persistent hypobetalipoproteinemia, 630
- Phenylalanine (Phe)
in burned children, effects of dietary protein intake on, 575
cortisol and estradiol effects on, 248
in isonitrogenous diet, 786, 790, 791
plasma, *see* Plasma phenylalanine
skeletal muscle, in critical illness, 760
- [³H]Phorbol 12,12-dibutyrate ([³H]PdBu), intracellular Ca and, binding to intact platelets in young IDDM and NIDDM subjects, 949-953
- Phosphatase
alkaline, MMI and 1α(OH)D₃ effects on, in Graves' disease, 1185
glucose-6-, *see* Glucose-6-phosphatase mRNA; Hepatic glucose-6-phosphatase
reduced AT protein-tyrosine, and improved insulin sensitivity following weight loss in obesity, 1140-1145
- Phosphate
blood, ethanol and fructose effects on, compared, 546
erythrocyte nicotinamide adenine dinucleotide, in NIDDM, polyol pathway activation and GSH redox status, 1195
fructose-3-, and polyol pathway metabolism in heart of STZ-DM subjects, 1333-1338
glycerol-3-, in purified and unpurified islet cells, 985
high-energy, generation of, in glucose catabolism, 308
see also ATP; Diphosphate; Fructose 2,6-bisphosphate; Glucose-6-phosphate dehydrogenase; Monophosphate
- Phosphocreatine, skeletal muscle, in critical illness, 761
- Phosphodiesterases (PDEs), and effects of progesterone on cAMP, 595-604
- Phosphoenolpyruvate carboxykinase (PEPCK)
aging and endurance training effects on, 414-419
TNF-α effects on, 579-583
- Phosphokinase, creatine, in hypercholesterolemia, and lovastatin and simvastatin effects on skeletal muscle injury during exercise, 1207, 1208
- Phospholipase A₂ (PLA₂), effects of aldose reductase inhibition on activation of, in STZ-DM, 41-47
- Phospholipids (PLs)
in FED, 477
in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and EPA-E on, 1460-1462
- Phosphorus (P), intake of, on diet high in vegetables, fruit, and nuts, 532
- Phosphorylase, role of MAPK and Ca in activation of, 549-551
- Phosphorylation
hepatic glucose, effects of G6Pase flux on, 1390-1398
of lymphoblast NHE-1 in hypertension, mitogen effects of, 297-302
MLC, in diabetic cardiomyopathy, 71-75
- PHP (pseudohypoparathyroidism), age and response to PTH in, 1246-1251
- Physical activity in men, relationship between changes in, and plasma insulin, 1418-1423; *see also* Exercise
- Physiological role of opioid-acetylcholine interaction in GH neuroregulation, effects of sex and food intake on, 740-744
- Phytoestrogens in soy protein diet, 699
- PICP (type I procollagen C-terminal propeptide), relationship of serum IGF-I, serum IGFBP-3, and serum, to sex, pubertal development, growth, insulin, and nutritional status of obese children and adolescents, 862-872
- Pirenzepine (PZP), effects of, on nocturnal TSH secretion and GH secretion in IDDM, 1305-1311
- Pituitary-adrenal axis
effects of long-term mifepristone therapy on, 292-296
hypothalamic-, hypersensitivity of, to naloxone in opioid withdrawal, 130-134
- Pituitary hormones
galanin levels after exercise-induced secretion of, 282-286
see also specific pituitary hormones
- Pituitary macroadenoma, GH deficiency determination with GHRH stimulation test in subjects with, 680-683
- Pituitary neuromedin B in fasting and STZ-DM, TSH secretion and, 149-153
- Pituitary-thyroid axis
effects of long-term mifepristone therapy on, 292-296
hypothalamic/, imipramine effects on, 1429-1434
- PKC, *see* Protein kinase C
- PLA₂ (phospholipase A₂), effects of aldose reductase inhibition on activation of, in STZ-DM, 41-47
- Plasma, radiation dose received from apo tracers by, 1235, 1236
- Plasma alanine
in critical illness, 760
in isonitrogenous diet, 790, 791
lactate effects on, in anesthesia, 686
in NIDDM, metformin effects on, 229
in uremia, 614
- Plasma albumin
kinetics of, [³H]leucine in study of, 335
with protein-restricted diet, 693
- Plasma antithrombin III (ATIII), levels of, and androgenic status in men, 1287-1293
- Plasma apolipoprotein(s) (apo)
smoking cessation effects on, 713
see also specific apolipoproteins

- Plasma apolipoprotein A-I (apo A-I)
 kinetics of, [^3H]leucine in study of, 335-336
 and plasma CETP activity in acute hyperinsulinemia, 1167
- Plasma apolipoprotein A-II (apo A-II), and plasma CETP activity in acute hyperinsulinemia, 1167, 1168
- Plasma apolipoprotein B (apo B), and plasma CETP activity in acute hyperinsulinemia, 1167
- Plasma apolipoprotein H (apo H; β_2 -glycoprotein I) in IDDM and NIDDM, C levels correlated with, 522-525
- Plasma arginine (ARG)
 in critical illness, 760
 in uremia, 614
- Plasma asparagine
 in critical illness, 760
 in isonitrogenous diet, 790, 791
 in uremia, 614
- Plasma aspartate
 in critical illness, 760
 in uremia, 614
- Plasma aspartic acid in isonitrogenous diet, 790, 791
- Plasma carnosine in critical illness, 760
- Plasma ceruloplasmin (Cp), erythrocyte, Cu supplementation effects on, in men, 1380-1383
- Plasma cholesterol (C) in STZ-DM, vitamin E effects on, 874
- Plasma cholesteryl ester transfer protein (CETP), decrease in plasma FFAs and acute hyperinsulinemia effects on activity of, 1166-1170
- Plasma citrulline in isonitrogenous diet, 790, 791
- Plasma cortisol, effects of portal adrenergic blockade on, 459
- Plasma C-peptides (connecting peptides)
 fasting, *see* Fasting plasma C-peptides
 reactivity of, in mitochondrial DM, 1021
see also Plasma C-peptides in NIDDM
- Plasma C-peptides (connecting peptides) in NIDDM
 with hyperinsulinemia and hypofibrinolysis, effects of short-term continuous insulin infusions on, 1076
 metformin effects on, 229
 NE effects on, 1450
- Plasma cystine
 in isonitrogenous diet, 790, 791
 in uremia, 614
- Plasma dehydroepiandrosterone (DHEAS), levels of, and androgenic status in men, 1287-1293
- Plasma dihydrotestosterone, effects of, on LPL activity in obese men, 181, 183
- Plasma endothelin-1 (ET-1), venous, lack of association between hyperinsulinemia and altered levels of, in healthy subjects, 1137-1139
- Plasma epinephrine (EPI) in NIDDM, NE effects on, 1450
- Plasma estradiol (E_2), effects of, on LPL activity in obese men, 181, 183
- Plasma estrone, effects of, on LPL activity in obese men, 181, 183
- Plasma ethanol, effects of ethanol infusions on levels of, 751
- Plasma factor VII (FVII), levels of, and androgenic status in men, 1287-1293
- Plasma fibrinogen, levels of, and androgenic status in men, 1287-1293
- Plasma free fatty acids (FFAs; nonesterified fatty acids)
 acute hyperinsulinemia effects on, 1166-1170
 effects of peripheral afferent stimulation of sympathetic neurons in SCI on, 1468
 ethanol effects on, 752-754
 in IGT, 915, 916
 lactate effects on, in anesthesia, 686
 in NIDDM, *see* Plasma free fatty acids in NIDDM
 in preeclampsia, 964
- Plasma free fatty acids (FFAs; nonesterified fatty acids) in NIDDM
 BRL 49653 effects on, 937
 NE effects on, 1450, 1452
 in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and EPA-E on, 1460
- Plasma glucagon (G)
 and HF diet-induced insulin resistance, 101
 in NIDDM, *see* Plasma glucagon in NIDDM
- Plasma glucagon (G) in NIDDM
 metformin effects on, 229
 NE effects on, 1450, 1452
- Plasma glucagon-like peptide-1 (7-36) (GLP-1) amide, effects of truncated GLP-1 infusion on, 747
- Plasma glucose
 CHO intake effects on, in young and older subjects, 1132-1136
 in diabetic cardiomyopathy, 72
 effects of VMH stimulation on, 898
 fasting, *see* Fasting plasma glucose
 of heart failure patients, daily energy requirements and, 1296
 IGF-I effects on, 1054
 in IGT, 668, 915, 916
 lactate effects on, in anesthesia, 686
 in mitochondrial DM, 1021
 in NIDDM, *see* Plasma glucose in NIDDM
 in normotensive and hypertensive obese subjects, lipolysis and, 1082
 with protein-restricted diet, 693
 in severe malaria, 1437, 1438
 in STZ-DM, *see* Plasma glucose in STZ-DM
 in TCP, 443
- Plasma glucose in NIDDM, 1260
 BRL 49653 effects on, 937
 metformin effects on, 229
 NE effects on, 1450
- Plasma glucose in STZ-DM
 vanadium therapy and, 771
 vitamin E effects on, 874
- Plasma glutamate
 in critical illness, 760
 in uremia, 614
- Plasma glutamic acid in isonitrogenous diet, 790, 791
- Plasma glutamine
 in critical illness, 760
 in isonitrogenous diet, 790, 791
 in uremia, 614
- Plasma glycerol in SCI, 390-393, 1468
- Plasma glycine
 in critical illness, 760
 in isonitrogenous diet, 790, 791
 in uremia, 614
- Plasma β_2 -glycoprotein I (apo H) in IDDM and NIDDM, C levels correlated with, 522-525
- Plasma growth hormone (GH) in fasted and fed surgical subjects, 798-799
- Plasma high-density lipoprotein(s) (HDL), effects of dietary fat restriction on particle size of, in postmenopausal women, 431-436
- Plasma high-density lipoprotein-cholesterol (HDL-C)
 in acute hyperinsulinemia, 1167, 1168
 dietary soy protein and ERT effects on, in ovariectomized subjects, 701
 NO-1886 elevates levels of, by increasing LPL and without effect on CETP activity, 257-260
- Plasma histidine
 in critical illness, 760
 in isonitrogenous diet, 790, 791
 in uremia, 614

- Plasma homocysteine (Hcy), total, in epileptic patients on anticonvulsant therapy, 959-962
- Plasma hydroxyproline in uremia, 614
- Plasma hypoxanthine
benzbromarone effects on concentrations of, 1474
ethanol and fructose effects on, compared, 545-546
TGs concentrations and, in gout, 802
- Plasma immunoreactive insulin (IRI)
and CETP activity in acute hyperinsulinemia, 1167
GLP-1 amide effects on, in NIDDM, 747
- Plasma insulin
CHO intake effects on, in young and older subjects, 1132-1136
in diabetic cardiomyopathy, 72
fasting, *see* Fasting plasma insulin
in fed surgical subjects, 789-799
hypothyroidism effects on, 155
IGF-I effects on, 1054
immunoreactive, *see* Plasma immunoreactive insulin
lactate effects on, in anesthesia, 686
in NIDDM, *see* Plasma insulin in NIDDM
in obesity-susceptible and obesity-resistant subjects, 212
physical activity and, in men, 1418-1423
peripheral afferent stimulation of sympathetic neurons in SCI effects on, 1468
with protein-restricted diet, 693
relationship between changes in physical activity and, in men, 1418-1423
in STZ-DM, vanadium therapy and, 771
in TCP, 443
- Plasma insulin in NIDDM, 1260
aging and, 892, 893
metformin effects on, 229
NE effects on, 1450
with obesity, heparin effects on hemostatic abnormalities and, 931
- Plasma insulin-like growth factor-I (IGF-I)
in fasted and fed surgical subjects, 798-799
in protein-restricted diet, 693
- Plasma insulin-like growth factor-binding proteins (IGFBPs) in protein-restricted diet, 693-694
- Plasma isoleucine
in critical illness, 760
in isonitrogenous diet, 790, 791
in uremia, 614
- Plasma [1-¹³C]- α -ketoisocaproate (KIC), ethanol effects on levels of, 751-752
- Plasma lactate, metformin effects on, in NIDDM, 229
- Plasma lactic acid after exercise, 1340
- Plasma leptin
absence of short-term effects of GLP-1 amide and hyperglycemia on levels of, 723-725
EE and concentrations of, in heart failure subjects, 450-453
see also Plasma leptin in women
- Plasma leptin in women
correlation of, with glucagon and insulin secretion in postmenopausal women, 1477-1481
relationship of body composition, age, and race to, 1399-1405
- Plasma leucine
in critical illness, 760
in isonitrogenous diet, 790, 791
with protein-restricted diet, 693
in uremia, 614
- Plasma lipids
and insulin resistance induced by HF diet, 102
NO-1886 effects on, 258, 259
- Plasma lipids (*Continued*)
smoking cessation effects on, 713
in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and EPA-E on, 1460
see also specific plasma lipids
- Plasma lipoprotein (Lp)
dietary fat restriction effects on particle size of, in postmenopausal women, 431-436
kinetics of, [³H]leucine in study of, 333-342
smoking cessation effects on, 713
see also specific lipoproteins
- Plasma lipoprotein(a) [Lp(a)], niceritrol effects on levels of, 355-358
- Plasma low-density lipoprotein(s) (LDL), effects of dietary fat restriction on particle size of, in postmenopausal women, 431-436
- Plasma low-density lipoprotein-cholesterol (LDL-C) in acute hyperinsulinemia, 1167
- Plasma lysine
in critical illness, 760
in isonitrogenous diet, 790, 791
in uremia, 614
- Plasma membrane fatty acids (FAs), effects of dietary fat on composition of, 19-20
- Plasma methionine
in critical illness, 760
in isonitrogenous diet, 790, 791
in uremia, 614
- Plasma 3-methylhistidine in uremia, 614
- Plasma NH₄ (ammonium) after exercise, 1340
- Plasma norepinephrine (noradrenaline; NE), peripheral afferent stimulation of sympathetic neurons in SCI effects on, 1468
- Plasma ornithine
in critical illness, 760
in isonitrogenous diet, 790, 791
in uremia, 614
- Plasma phenylalanine (Phe)
in critical illness, 760
in isonitrogenous diet, 790, 791
in uremia, 614
- Plasma phospholipids (PLs) in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and EPA-E on, 1460
- Plasma plasminogen activator inhibitor-1 (PAI-1)
levels of, and androgenic status in men, 1287-1293
in NIDDM with hyperinsulinemia and hypofibrinolysis, 1074-1079
in PCOS, metformin effects on, 454-457
- Plasma polyunsaturated fatty acids (PUFAs), n-3 and n-6, and resistance to tuberculosis, 622
- Plasma postheparin lipoprotein lipase (LPL)
NO-1886 effects on, 258, 259
sex hormone effects on, in obese men, 181-182
- Plasma proline
in isonitrogenous diet, 790, 791
in uremia, 614
- Plasma protein C, levels of, and androgenic status in men, 1287-1293
- Plasma prothrombin factors, androgenic status and, in men, irrespective of age, obesity, and AT distribution, 1287-1293
- Plasma purine bases
exercise effects on, 1339-1341
fructose and ethanol effects on, compared, 544-547
see also Plasma hypoxanthine; Plasma uric acid; Plasma xanthine
- Plasma retinol (vitamin A) in CAPD patients, 836, 837
- Plasma serine
in isonitrogenous diet, 790, 791
in uremia, 614

- Plasma taurine
 in critical illness, 760
 in isonitrogenous diet, 790, 791
 in uremia, 614
- Plasma testosterone (T), and effects of sex hormones on LPL activity in obese men, 181, 183
- Plasma threonine
 in critical illness, 760
 in isonitrogenous diet, 790, 791
 in uremia, 614
- Plasma thyroxine (T₄), effects of endurance training on, in identical twins, 502
- Plasma tissue plasminogen activator (tPA), levels of, and androgenic status in men, 1287-1293
- Plasma total amino acids (AAs) in critical illness, 760
- Plasma total homocysteine (Hcy) in epileptic patients on anticonvulsant therapy, 959-962
- Plasma total protein, cortisol and estradiol effects on, 248
- Plasma triglycerides (TGs)
 fasting, relationship between insulin-mediated suppression of FFAs and levels of, in obese African American subjects, 400-405
 in NIDDM, BRL 49653 effects on, 937, 938
 NO-1886 effects on, 258, 259
 plasma uridine level relationship to level of, in gout, 802
 in preeclampsia, 964
 in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and EPA-E on, 1460
- Plasma triiodothyronine (T₃)
 endurance training effects on, in identical twins, 502
 hypothyroidism effects on, 155
- Plasma tryptophan in critical illness, 760
- Plasma tyrosine
 in critical illness, 760
 in isonitrogenous diet, 790, 791
 in uremia, 614
- Plasma urea in burned children, dietary protein intake effects on, 575
- Plasma uric acid
 benzbromarone effects on concentrations of, 1474
 ethanol and fructose effects on, compared, 545-546
 in gout, 802
- Plasma uridine and uridine bases
 exercise effects on, 1339-1341
 fructose and ethanol effects on, compared, 544-547
 in gout, *see* Gout, plasma uridine in
- Plasma valine
 in critical illness, 760
 in isonitrogenous diet, 790, 791
 in uremia, 614
- Plasma very-low-density lipoproteins (VLDLs), dietary fat restriction effects on particle size of, in postmenopausal women, 431-436
- Plasma vitamin A (retinol) in CAPD patients, 836, 837
- Plasma vitamin E (α -tocopherol) in CAPD patients, 836, 837
- Plasma von Willebrand factor (vWF), levels of, and androgenic status in men, 1287-1293
- Plasma xanthine
 benzbromarone effects on concentrations of, 1474
 concentrations of TGs and, in gout, 802
 ethanol and fructose effects on, compared, 545-546
- Plasminogen activator, *see* Plasminogen activator inhibitor-1; Tissue plasminogen activator
- Plasminogen activator inhibitor-1 (PAI-1)
 in chronic renal disease, CAPD, and HD, 36-40
 effects of dietary fat modification on fibrinogen, factor VII, and activity of, in IGT, 666-672
- Plasminogen activator inhibitor-1 (PAI-1) (*Continued*)
 myocardial infarction with homocysteinemia, resistance to activated protein C, and high activity of, 1470-1472
 in obese NIDDM subjects, heparin effects on hemostatic abnormalities and, 932
 plasma, *see* Plasma plasminogen activator inhibitor-1
- Platelet(s)
 altered aggregation of, in Graves' disease and primary hypothyroidism, 1128-1131
 intact, intracellular Ca and [³H]PdBu binding to, in young IDDM and NIDDM subjects, 949-953
- Platelet count in chronic renal disease, HD, and CAPD subjects, 37
- PLs, *see* Phospholipids
- Polycystic ovary syndrome (PCOS)
 hirsutism with, *see* Hirsutism with PCOS
 metformin effects on plasma PAI-1, Lp(a), and IRI in, 454-457
 in obese and non-obese subjects, long-term NTX therapy effects on secretion of GH and insulin in, 538-543
- Polymorphism, ACE gene, in NIDDM
 I/D, in hypertension, coronary heart disease, and NIDDM, 1211-1214
 lack of relationship between diabetic nephropathy and retinopathy and, 976-980
- Polymorphism, gene, in NIDDM
 of AGT gene, lack of relationship between diabetic nephropathy and retinopathy and, 976-980
 of GS gene in Russian NIDDM population, 121-122
 see also Polymorphism, ACE gene, in NIDDM
- Polyol pathway
 metabolism of, and F3P production in heart of STZ-DM subjects, 1333-1338
 redox status of GSH and activation of, in NIDDM, 1194-1198
- Polypeptide
 gastric inhibitory, regulation of thyroid hormones in secretion of, 154-158
 IAPP/amylin effects on insulin secretion in beta cells, 1044-1051
 in IDDM and NIDDM, *see* Polypeptide in IDDM and NIDDM
- Polypeptide in IDDM and NIDDM
 expression of glucose-dependent insulinotropic, in intestines, 261-267
 rectal mucosa content of VIP in, with diarrhea and constipation, 730-734
- Polyunsaturated fatty acid(s) (PUFA)
 smoking cessation effects on, 713
 see also Polyunsaturated fatty acid(s), diet and; n-3 Polyunsaturated fatty acid(s); n-6 Polyunsaturated fatty acids
- Polyunsaturated fatty acid(s) (PUFA), diet and
 in diet high in vegetables, fruit, and nuts, 532, 534
 in modified diet of IGT subjects, 668
 PUFA intake in exercise, 1180
 in soy protein diet, 699
- n-3 Polyunsaturated fatty acid(s) (PUFA)
 effects of, on resistance to tuberculosis, 619-624
 EPA-E as, effects of, on insulin resistance in spontaneous NIDDM, 1468-1464
- n-6 Polyunsaturated fatty acids (PUFAs), effects of, on resistance to tuberculosis, 619-624
- Portal adrenergic blockade, effects of, on gluconeogenic effects of epinephrine and NE on liver, 458-465
- Postabsorptive conditions
 acute protein-sparing effects of ethanol in, 750-755
 see also entries beginning with term: Postprandial
- Postheparin lipoprotein lipase, *see* Plasma postheparin lipoprotein lipase

- Postmenopausal women
 dietary fat restriction effects on particle size of plasma Lps in, 431-436
 with different estrogen status, SHBG in, 5-9
 elderly, lipolysis in, 1312-1315
 insulin and glucagon secretion correlated with plasma leptin in, 1477-1481
 relationship between serum urate, TGs, and fractional urate excretion in, 1085-1089
- Postprandial (PP) glucose, incretin effects on, 262
- Postprandial (PP) glycemia in NIDDM, peripheral vasoconstrictor responses to SNS activation and, 236
- Postprandial (PP) hemorrheology, apo B metabolism and, in familial hypertriglyceridemia, 1299-1304
- Postprandial (PP) hypoglycemia, idiopathic, alpha cell function in, 639-643
- Postprandial (PP) lipemia, compartmental model of retinyl ester kinetics during, 584-594
- Postprandial (PP) state, glucose production and gluconeogenesis in STZ-DM subjects in, 1358-1363
- Potassium, *see* K and K⁺
- PP, *see* entries beginning with term: Postprandial
- PQXB 1/2 hybridoma cells, DCA effects on, 270
- Pravastatin, effects of, on RBC deformability, in hypercholesterolemia, 287-291
- Preadipocytes, 3T3-L1, mRNA expression for GHR gene during differentiation of, 114-118
- Precocious puberty, central, complicating CAH, GnRH agonist therapy of linear growth during infancy due to, 513-517
- Preeclampsia
 correlated with maternal and fetal modulators of lipid metabolism, 963-967
 urinary excretion of Ca and creatinine in early pregnancy and development of, 1107-1108
- Pregnancy, *see* Preeclampsia
- Premature infants, serum cortisol and cortisone in, 518-521
- Premenopausal women
 with different estrogen status, SHBG in, 5-9
 obese, hyperinsulinemia, sex hormones and, 1252-1258
 relationship between serum urate, TGs, and fractional urate excretion in, 1085-1089
 vitamin D receptor alleles and bone mineral density in, race and, 224-226
- Prevalence
 of mitochondrial DM in Japanese population with risk factors for M3243A→G mutation, 793-795
 of Trp64Arg missense mutation of β_3 -adrenergic receptor in Japanese subjects, 199-202
see also specific conditions
- Prevention
 of abnormal reactivity and morphology of aorta in STZ-DM, antioxidant and TG-lowering effects of vitamin E associated with, 872-879
 of cardiovascular disease and NIDDM, implications of age-related Cr decrease in hair, sweat, and serum samples for, 469-473
- Primary hypothyroidism, platelet aggregation alterations in, 1128-1131
- PRL, *see* Prolactin
- Procollagen C-terminal propeptide (PICP), relationship of serum IGF-I, serum IGFBP-3, and serum type I, to sex, pubertal development, growth, insulin, and nutritional status of obese children and adolescents, 862-872
- Progeria syndrome, Hutchinson-Gilford, response to NT and GH therapy in, 851-856
- Progesterone, effects of, on glucose metabolism in adipocytes, androstane and, 595-604
- Prolactin (PRL)
 galanin levels after exercise-induced secretion of, in men, 282-286
 in GH-secreting adenoma, 426
 in PCOS, *see* Prolactin in PCOS
 serum, long-term RU486 therapy effects on, 292-296
- Prolactin (PRL) in PCOS
 with and without obesity, effects of long-term NTX therapy on, 540
 with severe hirsutism, effects of triptorelin with desogestrel-containing OCs on, 439
- Proline
 cortisol and estradiol effects on, 248
 in isonitrogenous diet, 786, 790, 791
 plasma, *see* Plasma proline
- Prolonged exercise
 in DM, hepatic and nonhepatic splanchnic tissue contribution to NE increase in, 1327-1332
see also Prolonged exercise by men
- Prolonged exercise by men
 effects of, on serum leptin, 1109-1112
 by obese men without weight loss, effects of, on HDL metabolism, 217-223
- Propeptide, serum type I procollagen C-terminal, serum IGF-I, and serum IGFBP-3 in obese children and adolescents, relationship of, to sex, pubertal development, growth, insulin, and nutritional status of, 862-872
- Propionic acid, effects of time of day and glucose tolerance status on concentrations of, 805-811
- Prostaglandin(s) (PGs) in T-cell leukemia-induced cachexia, 359-365
- Prostaglandin E (PGE), effects of aldose reductase inhibition on production of, in STZ-DM, 43
- Prostaglandin F_{1 α} (PGF_{1 α}), 6-keto-, in MCs exposed to high glucose concentrations, D- α -tocopherol effects on, 781, 783
- Protease inhibitor, E64d as membrane-permeable cysteine, effects of, on PTH on osteoblasts, 1090-1094
- Protein(s)
 acute protein-sparing effects of ethanol in postabsorptive but not anabolic conditions, 805-811
 binding, *see* Growth hormone-binding proteins; Insulin-like growth factor-binding protein(s)
 cholesteryl ester transfer, *see* Cholesteryl ester transfer protein
 C-reactive, in small-cell lung cancer subjects, TEE and, 1413
 dietary, *see* Dietary protein intake
 G-, effects of imidazolines, α_2 -adrenergic agonists and, on insulin secretion in beta cells, 1146-1149
 GH and hypocaloric N-free diet effects on synthesis of, following surgery, 796-800
 insulin attenuates atrophy of unweighted muscle by amplifying inhibition of degradation of, 673-679
 muscle, *see* Muscle protein
 stable isotopically labeled tracers and, *see* Stable isotopically labeled tracers, proteins and
 total, *see* Total protein
see also Lipoprotein; Protein C; Protein kinase; Protein-tyrosine phosphatase; Proteinuria and *specific proteins*
- Protein C
 activated, myocardial infarction with homocysteinemia, high PAI-1 activity, and resistance to, 1470-1472
 plasma levels of, and androgenic status in men, 1287-1293
- Protein kinase (PK)
 activation of mitogen-activated, in hepatocytes, by Ca- and PKC-dependent pathway, 548-555
 insulin inhibition of AMP-activated, in heart resulting in acetyl CoA carboxylase and FA oxidation, 1270-1274
see also Protein kinase C

- Protein kinase C (PKC)
 activation of MAPK in hepatocytes by PKC- and Ca-dependent pathway, 548-555
 ET-1 production in VSMCs and, 488-489
 in MCs exposed to high glucose concentrations, D- α -tocopherol effects on, 781, 782
 mesangial cell TGF- β increases signaled by, antioxidants inhibiting, 918-925
 mitogen effects on phosphorylation of NHE-1 of lymphoblasts and activity of, in hypertension, 297-302
 RU38486 effects on, 999
 in STZ-DM, effects of aldose reductase inhibition on, 41-47
- Protein-tyrosine phosphatase (PTPase), reduced AT, and improved insulin sensitivity following weight loss in obesity, 1140-1145
- Proteinuria
 in early pregnancy, preeclampsia development and, 1108
 in NIDDM, *see* Proteinuria in NIDDM
 in preeclampsia, 964
see also Albuminuria
- Proteinuria in NIDDM
 in hypertensive NIDDM, 1317
 macroproteinuria in NIDDM with diabetic nephropathy and retinopathy, 979, 980
- Proteoglycans, heparan sulfate, Lp(a) binding to, enhanced by LPL and improved by apo E saturation, 650-655
- Prothrombin, catabolism of antithrombin and, in alloxan-induced DM, 1406-1411
- Prothrombin factors, androgenic status and plasma, in men, irrespective of age, obesity, and AT distribution, 1287-1293
- Proximal tubular dysfunction, citrulline as marker of, 611-618
- Pseudohypoparathyroidism (PHP), age and response to PTH in, 1246-1251
- PTH, *see* Parathyroid hormone
- PTPase (protein-tyrosine phosphatase), reduced AT, and improved insulin sensitivity following weight loss in obesity, 1140-1145
- Puberty
 central precocious, complicating CAH, GnRH agonist therapy of linear growth during infancy due to, 513-517
 relationship of serum IGFBP-3, serum PICP, and serum IGF-I to sex, growth, nutritional status, and pubertal development of obese adolescents, 862-872
- PUFAs, *see* Polyunsaturated fatty acid(s)
- Pulse rate, *see* Heart rate
- Purified pancreatic islet cells, respiratory chain activity and mitochondrial DNA content of, 984-987
- Purine bases, *see* Plasma purine bases
- Pyrimidines, ATP consumption-induced degradation of, 1339-1341
- Pyruvate
 DCA inhibiting glutamine oxidation via transamination by decreasing availability of, 268-272
 in purified and unpurified islet cells, 985
 troglitazone effects on release of, in presence or absence of insulin, 718-719
- Pyruvic acid, blood, ethanol and fructose effects on, compared, 546
- PZP (pirenzepine), effects of, on nocturnal TSH and GH secretion in IDDM, 1305-1311
- Quantitative genetics of serum SHBG, 989-991
- Quinapril, effects of, on insulin sensitivity, glucose effectiveness, and beta cell function in obese hypertensive men, 173-178
- Quinine in severe malaria, 1437, 1438
- RA (retinoic acid), induction of GHR mRNA blocked by, 26
- Ra, *see* Rate of appearance
- Race and ethnicity
 CAT scan of abdominal AT distribution and its correlation with anthropometry and insulin secretion in healthy Asian Indians, 1220-1224
 of HGPS subjects, 852
 of NIDDM subjects, *see* Race and ethnicity of NIDDM subjects and obesity, *see* Obesity, race and
 relationship of plasma leptin to age, body composition and, in women, 1399-1405
 serum insulin, C-peptide concentrations, hepatic insulin extraction, and insulin clearance in subjects of West African ancestry, 53-58
 of Turner's syndrome subjects, 909
 and vitamin D receptor alleles and bone mineral density in premenopausal women, 224-226
see also Japanese subjects
- Race and ethnicity of NIDDM subjects
 hypertensive NIDDM, 1317
 I/D polymorphism of ACE gene in hypertension, NIDDM, and coronary heart disease in Taiwanese population, 1211-1214
 Mexican-American NIDDM parents, hyperinsulinemia-associated hyperamylinemia in glucose-tolerant and insulin-resistant offspring of, 1157-1161
 polymorphism of GS gene in Russian NIDDM subjects, 121-122
- Radiation dose from apo tracers, measurement of, 1231-1239
- Rate of appearance (Ra)
 of glycerol, and lipolysis sensitivity and response to fasting in obese normotensive and hypertensive subjects, 1080-1084
 of protein, lipids, and CHOs, determination of, 325-326
 of urea and phenylalanine in burned children, 575
- RBCs (red blood cells), *see entries beginning with term*: Erythrocyte
- RE(s) (retinyl esters), kinetics of, during PP lipemia, compartmental model of, 584-594
- Reactive (postprandial) hypoglycemia, idiopathic, alpha cell function in, 639-643
- Reactivity of aorta in STZ-DM, antioxidant inhibiting TG-lowering effects of vitamin E associated with prevention of abnormal, 872-879
- Recombinant growth hormone, *see* Growth hormone
- RECs (retinal endothelial cells), *see* Insulin-like growth factor-binding protein(s) in BRECs, production of
- Rectal mucosa in IDDM and NIDDM with diarrhea and constipation, substance P content of, 730-734
- Red blood cells, *see entries beginning with term*: Erythrocyte
- Red bone marrow, radiation dose received from apo tracers by, 1235-1237
- Redox status
 GSH, polyol pathway activation and, in NIDDM, 1194-1198
see also Oxidation
- Reductase
 aldose, *see* Aldose reductase inhibition
 fibroblast dehydrocholesterol- Δ^7 -, measuring activity of, to identify SLOS homozygotes and heterozygotes, 844-850
see also HMG-CoA reductase
- REE, *see* Resting energy expenditure
- Refeeding
 effects of cycles of starvation and, on lipogenesis in WAT, 10-17
see also Diet
- Renal clearance of CGRP, effects of LANPs, vessel dilator, ANF, and kaliuretic peptide on, 822, 823
- Renal disease, chronic, PAI-1 in CAPD, HD and, 36-40
- Renal failure, *see* Hemodialysis
- Renal insufficiency
 chronic, serum and urine guanidino compounds in nondialyzed subjects with, 1024-1031
 citrulline as marker of, 611-618

- Renal insulin-like growth factor-I (IGF-I), effects of graded uninephrectomy on IGFBPs and serum, compensatory renal growth and, 29-35
- Renal morphology, changes in, in IDDM, serum AGEs as predictors of, 661-664
- Renoprotective effects of TAK-044 in malignant hypertension, 1032-1038
- Respiratory chain activity, mitochondrial DNA content and, of nonpurified and purified pancreatic cells and, 984-987
- Respiratory quotient (RQ)
ethanol effects on, 754
in fasted and fed surgical subjects, GH and, 26, 799
nonprotein, insulin effects on, in cirrhosis, 843
- Resting energy expenditure (REE)
ethanol effects on, 752, 754
by heart failure subjects, *see* Resting energy expenditure by heart failure subjects
by HIV-infected men, 1325
insulin effects on, in cirrhosis, 843
by older women, 886
time of day and glucose tolerance status effects on serum SCFAs and, 806
- Resting energy expenditure (REE) by heart failure subjects
daily energy requirements and, 1297
plasma leptin concentrations and, 451
- Resting metabolic rate (RMR)
effects of endurance training on, in identical twins, 499-503
relationship between FFM composition and, 1225-1230
- Resting spinal cord injury (SCI) subjects, lipolysis regulation by SNS in, 390, 391
- Retinal endothelial cells, *see* Insulin-like growth factor-binding protein(s) in BRECs, production of
- Retinoic acid (RA), induction of GHR mRNA blocked by, 115
- all-*trans*-Retinoic acid (ATRA), effects of, on insulin secretion from RINm5F, 656-660
- 9-*cis*-Retinoic acid (9CRA), effects of, on insulin secretion from RINm5F cells, 656-660
- Retinoid-X receptors (RXRs), and effects of 9CRA on insulin secretion from RINm5F cells and, 656-660
- Retinol, *see* Vitamin A
- Retinopathy, diabetic, with NIDDM, lack of relationship between AGT and ACE gene polymorphism and, 976-980
- Retinyl esters (REs), kinetics of, during PP lipemia, compartmental model of, 584-594
- rGH (recombinant growth hormone), *see* Growth hormone
- Rheological disorders, peripheral vasoconstrictor responses to sympathetic activation in NIDDM and, 235-241
- Riboflavin (vitamin B₂), intake of, on diet high in vegetables, fruit, and nuts, 532
- Ribonucleic acid, *see* RNA
- RINm5F cells, effects of 9CRA on insulin secretion from, RXRs and, 656-660
- Risk and risk factors
atherogenic, in male offspring of parent with early CAD, LDL particle size as marker for, 954-958
for CV disease, *see* Cardiovascular disease, risk factors for
for M3243A→G mutation, prevalence of mitochondrial DM in Japanese population with, 793-795
of radiation exposure, 1238
- RMR, *see* Resting metabolic rate
- RNA (ribonucleic acid)
beta cell insulin, effects of aging on content of, 245
skeletal muscle concentration of, in critical illness, 758, 759
see also mRNA; tRNA
- RQ, *see* Respiratory quotient
- RU486 (mifepristone), effects of long-term therapy with, on pituitary-adrenal and pituitary-thyroid axes, 292-296
- RU38486, effects of, on acute glucocorticoid-induced insulin resistance in adipocytes, 997-1002
- Russian subjects with NIDDM, polymorphism of GS gene and, 121-122
- RXRs (retinoid-X receptors), and effects of 9CRA on insulin secretion from RINm5F cells, 656-660
- S, *see* Sucrose
- Safflower oil
effects of, in spontaneous NIDDM, 1459-1463
in soy protein diet, 699
- Saturated fatty acid(s) (SFA)
diet and, *see* Saturated fatty acid intake
smoking cessation effects on, 713
- Saturated fatty acid(s) (SFA) intake
in diet high in vegetables, fruit, and nuts, 532, 534
exercise and, 1180
and modified diet in IGT, 668
in soy protein diet, 699
- SCD (sickle cell disease), children with, GH secretion, IGF-I, and IGFBP-3 concentrations in, 1241-1245
- SCFAs (short-chain fatty acids), serum, effects of time of day and glucose tolerance status on concentrations of, 805-811
- SCI, *see* Spinal cord injury, SNS regulating lipolysis in
- SDLDL (small dense low-density lipoprotein) particles in children, 146-148
- SDMA (symmetrical dimethylarginine), serum, in nondialyzed subjects with chronic renal insufficiency, 1024-1031
- Secreted glucuronate (GlcUA) technique measuring effects of G6Pase flux on hepatic glucose phosphorylation, cycling, disposal, and net balance, 1390-1398
- Sedentary men, hypercholesterolemic, LDL particles in, 186-192
- Sequential effects of aerobic exercise and weight loss on CV disease risk factors in obese middle-aged and elderly men, 1441-1447
- Serine
cortisol and estradiol effects on, 248
in isonitrogenous diet, 786, 790, 791
plasma, *see* Plasma serine
portal adrenergic blockade effects on, 461, 464
- Serum advanced glycation end products (AGEs), as predictors of changes in renal morphology in IDDM, 661-664
- Serum albumin
effects of diet high in vegetables, fruit, and nuts on, 535
in heart failure, daily energy requirements and, 1296
- Serum androstenedione, effects of long-term RU486 therapy on, 292-296
- Serum apolipoprotein A-I (apo A-I), fasting, in young women with endometriosis, 736
- Serum apolipoprotein A-II (apo A-II), fasting, in young women with endometriosis, 736
- Serum apolipoprotein B (apo B), fasting, in young women with endometriosis, 736
- Serum arginine acid in nondialyzed patients with chronic renal insufficiency, 1026, 1028
- Serum arginine (ARG)
in nondialyzed patients with chronic renal insufficiency, 1026, 1028
in thyroid dysfunction, 1063-1067
- Serum asymmetrical (and symmetrical) dimethylarginine (ADMA; SDMA) in nondialyzed subjects with chronic renal insufficiency, 1024-1031
- Serum bilirubin in severe malaria subjects, 1436
- Serum Ca (calcium), concentrations of, and cardiovascular disease mortality, 1171-1177

- Serum cholesterol (C)
 fasting, *see* Fasting serum cholesterol
 in hypercholesterolemia, 187, 629
 in IGT, 668
- Serum chromium (Cr), implications of age-related decrease in, for prevention of cardiovascular disease and NIDDM, 469-473
- Serum cortisol
 long-term RU486 therapy effects on, 292-296
 in premature infants, 518-521
- Serum cortisone in premature infants, 518-521
- Serum C-peptides (connecting peptides)
 GH therapy effects on, in Turner's syndrome, 1484-1486
 in IGT, 915, 916
- Serum creatine
 in nondialyzed chronic renal insufficiency subjects, 1026, 1028, 1029
 in thyroid dysfunction, 1063-1067
- Serum creatine kinase (CK), effects of simvastatin and lovastatin on skeletal muscle, during exercise, 1206-1210
- Serum creatinine
 effects of diet high in vegetables, fruit, and nuts on, 535
 following graded uninephrectomy, 32, 33
 in hypercholesterolemia, pravastatin effects on RBC deformability and, 289
 in nondialyzed chronic renal insufficiency subjects, 1026, 1028, 1029
 in severe malaria, 1436
 in thyroid dysfunction, 1063-1067
- Serum fasting total cholesterol (TC) in young women with endometriosis, 736
- Serum free fatty acids (FFAs; nonesterified fatty acids), exercise and effects of prolonged exercise on, in men, 1110, 1111
 by transgenic subjects, 1351-1354
- Serum γ (gamma)-guanidinobutyric acid in nondialyzed patients with chronic renal insufficiency, 1026, 1028
- Serum glucose
 in exercising transgenic subjects, 1354
 fasting, *see* Fasting serum glucose
 pituitary, in STZ-DM, 152
 TNF- α effects on, 580
- Serum guanidine
 in nondialyzed patients with chronic renal insufficiency, 1026, 1028
 in thyroid dysfunction, 1063-1067
- Serum guanidino compounds
 in nondialyzed chronic renal insufficiency subjects, 1024-1031
 in thyroid dysfunction, 1063-1067
- Serum guanidinoacetic acid (GAA)
 in nondialyzed subjects with chronic renal insufficiency, 1024-1031
 in thyroid dysfunction, 1063-1067
- Serum γ -guanidinobutyric acid (GBA) in nondialyzed patients with chronic renal insufficiency, 1026, 1028
- Serum guanidosuccinic acid (GSA)
 in nondialyzed subjects with chronic renal insufficiency, 1024-1031
 in thyroid dysfunction, 1063-1067
- Serum high-density lipoprotein-cholesterol (HDL-C), fasting, in young women with endometriosis, 736
- Serum high-density lipoprotein₂-cholesterol (HDL₂-C), fasting, in young women with endometriosis, 736
- Serum high-density lipoprotein₃-cholesterol (HDL₃-C), fasting, in young women with endometriosis, 736
- Serum homoarginine (Harg)
 in nondialyzed patients with chronic renal insufficiency, 1026, 1028
 in thyroid dysfunction, 1063-1067
- Serum immunoreactive insulin (IRI) in mitochondrial DM, 1021
- Serum insulin
 fasting, *see* Fasting serum insulin
 GH therapy effects on, in Turner's syndrome, 1484
- Serum insulin (*Continued*)
 in IGT, 915, 916
 immunoreactive, in mitochondrial DM, 1021
 race and ethnicity determining hepatic insulin extraction, insulin clearance, C-peptide concentrations and, 53-58
 in severe malaria, 1437
 TNF- α effects on, 580
- Serum insulin-like growth factor-I (IGF-I)
 effects of graded uninephrectomy on IGF-BPs, renal IGF-I, compensatory renal growth and, 29-35
 relationship of serum PICP, serum IGFBP-3, and serum, to sex, pubertal development, growth, insulin, and nutritional status in obese children and adolescents, 862-872
- Serum insulin-like growth factor-binding protein-3 (IGFBP-3), relationship of serum PICP, serum IGF-I, and serum, to sex, pubertal development, growth, insulin, and nutritional status in obese children and adolescents, 862-872
- Serum K (potassium), effects of diet high in vegetables, fruit, and nuts on, 535
- Serum α (alpha)-keto- δ -guanidinovaleric acid (GVA)
 in nondialyzed subjects with chronic renal insufficiency, 1026, 1028
 in thyroid dysfunction, 1063-1067
- Serum leptin
 in adults, body composition relationship to GH deficiency effects on, 812-817
see also Serum leptin in men
- Serum leptin in men
 in HIV-infected men with low adiposity, 303-305
 prolonged exercise effects on, 1109-1112
- Serum lipids
 effects of diet high in vegetables, fruit, and nuts on, 530-537
 in obese exercising men without weight loss, HDL metabolism and, 219-220
see also specific serum lipids
- Serum lipoprotein (Lp), short-term stanozolol therapy effects on, in HL deficiency, 992-996
- Serum lipoprotein(a) [Lp(a)]
 levels of, in young women with endometriosis, 735-739
 short-term stanozolol therapy effects on, in HL deficiency, 993
- Serum low-density lipoprotein-cholesterol (LDL-C), fasting, in young women with endometriosis, 736
- Serum methylguanidine (MG) in nondialyzed patients with chronic renal insufficiency, 1026, 1028
- Serum Na (sodium), effects of diet high in vegetables, fruit, and nuts on, 535
- Serum prolactin (PRL), effects of long-term RU486 therapy on, 292-296
- Serum sex hormone-binding globulin (SHBG), quantitative genetics of, 989-991
- Serum short-chain fatty acids (SCFAs), effects of time of day and glucose tolerance status on concentrations of, 805-811
- Serum symmetrical dimethylarginine (SDMA) in nondialyzed subjects with chronic renal insufficiency, 1024-1031
- Serum testosterone (T), concentrations of, in acutely hyperinsulinemic obese and non-obese men, 526-529
- Serum thyroid hormones
 1 α (OH) D_3 effects on levels of, in hyperthyroidism with untreated Graves' disease, 1184-1188
see also Serum thyrotropin; Serum thyroxine; Serum triiodothyronine
- Serum thyrotropin (TSH; thyroid-stimulating hormone), effects of long-term RU486 therapy on, 292-296
- Serum thyroxine (T₄)
 effects of long-term RU486 therapy on, 292-296
 imipramine effects on, 1429-1434
 pituitary, in fasting and STZ-DM, 150, 152

- Serum total cholesterol (TC), fasting, in young women with endometriosis, 736
- Serum triglycerides (TGs)
fasting, *see* Fasting serum triglycerides
in IGT, 668
relationship between serum urate, fractional urate excretion and, 1085-1089
- Serum triiodothyronine (T₃)
effects of long-term RU486 therapy on, 292-296
imipramine effects on, 1429-1434
pituitary, in fasting and STZ-DM, 150, 152
- Serum type I procollagen C-terminal propeptide (PICP), relationship of serum IGF-I, and serum IGFBP-3 to sex, pubertal development, growth, insulin, and nutritional status of obese children and adolescents, 862-872
- Serum urate, relationship between serum TGs, fractional urate excretion and, 1085-1089
- Serum urea
effects of diet high in vegetables, fruit, and nuts on, 535
following graded uninephrectomy, 32, 33
in nondialyzed subjects with chronic renal insufficiency, 1026, 1028, 1028
in thyroid dysfunction, 1063-1067
- Serum uric acid
effects of diet high in vegetables, fruit, and nuts on, 535
in preeclampsia, 964
- Severe hirsutism, PCOS with, effects of triptorelin with desogestrel-containing oral contraceptives on hair, bone density, and hormone profile in, 437-440
- Severe malaria, minimal model analysis of IVGTT in, 1435-1440
- Sex
abdominal AT/insulin secretion/anthropometry correlation and, 1221-1223
of acromegalic subjects, 495
of adrenal mass subjects, 109
and adult GH-deficiency effects on serum leptin, 813, 815
and aging effects, *see* Sex, aging effects and
and association between IGT and Ca homeostasis, 1172-1175
of cirrhotic subjects, 841
and clofibrate-induced hyperoxaluria, 137
of critically ill subjects, 757
of ECD subjects, 1218
effects of food intake and, on neuroregulation by GH, 740-744
of epileptic patients on anticonvulsant therapy, 961
of FCPD subjects, 2
of GH-secreting adenoma subjects, 426
of Graves' disease subjects, 1185
of HD subjects, *see* Sex of HD subjects
of HGPS subjects, 852, 853
of hypercholesterolemic subjects, pravastatin effects on RBC deformability and, 289
of hyperlipidemic subjects, nickeritol effects on plasma Lp(a) and, 356
of IDDM subjects, *see* Sex of IDDM subjects
of IGT subjects, 668, 915
insulin resistance and, *see* Sex, insulin resistance and
of liver transplant recipients, 1004
of mitochondrial DM subjects, 1020
and moderate exercise effects on insulin- and non-insulin mediated glucose uptake, 205
of multiple myeloma subjects, 1344
of NIDDM subjects, *see* Sex of NIDDM subjects
of obese subjects, *see* Sex of obese subjects
and quantitative genetics of SHBG, 990
race and, *see* Sex, race and
- Sex (*Continued*)
and relationship between RMR and FFM composition, 1226, 1228
of SCI subjects, 389, 1466
of severe malaria subjects, 1436
of small-cell lung cancer subjects, TEE and, 1413
of smokers, smoking cessation and, 712
of TCP subjects, 442
and time of day and glucose tolerance status effects on serum SCFAs, 806
and Trp64Arg missense mutation of β_3 -adrenergic receptor, 200
see also Men; Women
- Sex, aging effects and
on DHEAS in relation to fasting insulin level and body composition, 828-830
insulin resistance and, 1284
- Sex, insulin resistance and
ACE gene and, 396, 397
aging and, 1284
- Sex, race and
and hepatic insulin extraction and clearance, 55, 56
of obese subjects, and insulin-mediated suppression of FFAs, 400-405
- Sex of HD subjects
of chronic HD subjects, pre- and post-HD body composition changes and, 1060
chronic renal disease subjects and CAPD subjects, 37, 38
- Sex hormone(s)
hyperinsulinemia and, in obese premenopausal women, 1252-1258
in men, *see* Men, sex hormones in
see also specific sex hormones
- Sex hormone-binding globulin (SHBG)
in men, *see* Sex hormone-binding globulin in men
in obese hyperinsulinemic women, 1253, 1255
in PCOS, *see* Sex hormone-binding globulin in PCOS
in premenopausal and postmenopausal women with different estrogen status, 5-9
serum, quantitative genetics of, 989-991
- Sex hormone-binding globulin (SHBG) in men
in elderly men, longitudinal changes in, 410-413
in young men, effects of mild hyperthyroidism on, 1424-1428
- Sex hormone-binding globulin (SHBG) in PCOS
with and without obesity, effects of long-term NTX therapy on, 540
with severe hirsutism, effects of triptorelin with desogestrel-containing OCs on, 439
- Sex of hyperinsulinemic subjects
with hyperamylinemia, 1158
and plasma CETP activity in acute hyperinsulinemia, 1167
- Sex of IDDM subjects
C and plasma apo H levels and, 523
with diarrhea and constipation, 731
GAD antibodies and GH secretion and, 383
intracellular Ca and [³H]PdBu binding to intact platelets and, 950
- Sex of NIDDM subjects
C and plasma apo H levels and, 523
with or without CHD and hypertension, ACE gene and, 1213
diabetic nephropathy, *see* Sex of NIDDM subjects with diabetic nephropathy
with diarrhea and constipation, 731
with hyperinsulinemia and hypofibrinolysis, 1075
hypertensive NIDDM, 1317
intracellular Ca and [³H]PdBu binding to intact platelets and, 950
obese, heparin effects on hemostatic abnormalities and, 931

- Sex of NIDDM subjects with diabetic nephropathy
non-obese, insulin resistance and, 1014, 1016
and retinopathy, 978, 979
- Sex of obese subjects
and insulin secretion, insulin sensitivity, and EE, 124, 125
with NIDDM, heparin effects on hemostatic abnormalities and, 931
race and, and insulin-mediated FFA suppression, 400-405
relationship of serum IGFBP-3, serum PICP, and serum IGF-I to sex,
pubertal development, growth, insulin, and nutritional status of
children and adolescents, 862-872
- SFAs, *see* Saturated fatty acid(s)
- SHBG, *see* Sex hormone-binding globulin
- Short-chain fatty acids (SCFAs), serum, effects of time of day and
glucose tolerance status on concentrations of, 805-811
- Short stature, idiopathic, children with, GH secretion, IGF-I, and
IGFBP-3 concentrations in, 1241-1245
- Short-term therapy
with continuous insulin infusion, effects of, on hypofibrinolysis with
hyperinsulinemia in NIDDM, 1074-1079
with stanozolol, effects of, on serum Lps in HL deficiency, 992-996
- Sialic acid, erythrocyte membrane, in IDDM and NIDDM, aging and,
59-61
- Sickle cell disease (SCD), children with, GH secretion, IGF-I, and
IGFBP-3 concentrations in, 1241-1245
- Side effects
of GHRH 1-29, 93
of hexarelin, 86
see also specific drugs
- Simvastatin, skeletal muscle injury in exercise induced by, 1206-1210
- Skeletal muscle
of anesthetized subjects, lactate-induced insulin resistance in, 684-
690
hyperinsulinemia and, 1269
longitudinal changes in biochemical parameters of, during critical
illness, 756-762
simvastatin and lovastatin inducing injury of, during exercise,
1206-1210
in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and
EPA-E on, 1460-1462
- Skin, radiation dose received from apo tracers by, 1237
- SLOS (Smith-Lemli-Opitz syndrome) homozygotes and heterozygotes,
identification of, by measuring fibroblast 7-dehydrocholesterol- Δ^7 -
reductase activity, 844-850
- Small-cell lung cancer, TEE measured with HCO₃-urea method in
subjects with, 1412-1417
- Small dense low-density lipoprotein (SDLDL) particles in children,
146-148
- Smith-Lemli-Opitz syndrome (SLOS) homozygotes and heterozygotes,
identification of, by measuring fibroblast 7-dehydrocholesterol- Δ^7 -
reductase activity, 844-850
- Smokeless nicotine associated with hypertension but not with glucose
tolerance deterioration, 1008-1012
- Smoking
and association between IGT and Ca homeostasis, 1174
effects of cessation of, on Lp A-I and Lp A-I:II, 711-715
and heparin effects on hemostatic abnormalities in obese NIDDM
subjects, 931
hyperinsulinism, sex hormones, obesity and, 1255
by male offspring of CAD parent, 506
plasma insulin, physical activity and, 1421
and quantitative genetics of SHBG, 990
- Smooth muscle cells, vascular, ET-1 production in, modulated by atrial,
brain, and C-type natriuretic peptides, 487-493
- SNS (sympathetic nervous system), *see* Spinal cord injury, SNS
regulating lipolysis in
- SOD (superoxide dismutase), erythrocyte, Cu supplementation effects
on, in men, 1380-1383
- Sodium, *see* Na
- Somatostatin
BK effects on secretion of, in pancreatic islets, 1113-1115
oscillatory Ca²⁺ signaling in pancreatic cells producing, 366-369
rectal mucosa content of, in IDDM and NIDDM with diarrhea and
constipation, 730-734
response of, to oral test meal, in liver transplant recipients, 1003-
1007
role of, in GH secretion suppression in IDDM, 1305-1311
- Somatotropes in obesity-susceptible and obesity-resistant subjects, 213
- Sorbitol
aldose reductase inhibition effects on production of, in STZ-DM, 43
erythrocyte, in NIDDM, polyol pathway activation and GSH redox
status and, 1195
- Soy protein, ERT and dietary, decrease aortic cholesteryl ester content
and risk factors for CV disease in ovariectomized subjects,
698-705
- SP (substance P), rectal mucosa content of, in IDDM and NIDDM with
diarrhea and constipation, 730-734
- Spectrometry, very low stable isotopically labeled tracers enrichment
measured with GC/MS, and its application to measurement of
muscle protein synthesis, 943-948
- Spinal cord injury (SCI), SNS regulating lipolysis in
microdialysis study of, 388-394
peripheral afferent stimulation of decentralized sympathetic neurons
activating lipolysis, 1465-1469
- Splanchnic production of KIC from leucine in fed state, whole-body
production versus, 164-167
- Splanchnic tissues, hepatic and nonhepatic, contribution of, to NE
increase during prolonged exercise, 1327-1332
- Spleen, radiation dose received from apo tracers by, 1237
- Spontaneous non-insulin-dependent diabetes mellitus (NIDDM), EPA-E
effects on, 1458-1464
- Stable isotopically labeled tracers
lipid and CHO kinetics studied with, 322-329
see also Stable isotopically labeled tracers, proteins and
- Stable isotopically labeled tracers, proteins and
protein kinetics studied with, 322-329
very low, GC/MS measuring enrichment of, and its application in
measurement of muscle protein synthesis, 943-948
- Stanozolol therapy, effects of short-term, on serum Lps in HL defi-
ciency, 992-996
- Starvation
effects of cycles of refeeding and, on lipogenesis in WAT, 10-17
of normal and STZ-DM subjects, glucose production and glucone-
genesis and, 1358-1363
see also Diet
- Stature, children with idiopathic short, GH secretion, IGF-I, and
IGFBP-3 concentrations in, 1241-1245
- Steroid(s), *see* Glucocorticoids; Steroidogenic abnormalities and *spe-*
cific steroids
- Steroidogenic abnormalities, adrenal and ovarian, in hirsute women
without hyperandrogenemia, 902-907
- Strength of handgrip, insulin levels and, 1266-1269
- Strenuous exercise, *see* Prolonged exercise
- Streptozotocin-induced diabetes mellitus (STZ-DM), 763-777
abnormal reactivity and morphology of aorta in, antioxidant and
TG-lowering effects of vitamin E associated with prevention of,
872-879
aldose reductase inhibition effects on DAG formation, PKC, and
phospholipase A₂ activation in, 41-47
glucose in, *see* Glucose in STZ-DM

- Streptozotocin-induced diabetes mellitus (STZ-DM), 763-777
 (Continued)
 α LA effects on glycemia and muscle GLUT4 transporter content in, 763-768
 partial beta cell preservation by vanadium in, 769-777
 pituitary neuromedin B in fasting and, TSH secretion and, 149-153
 polyol pathway metabolism and F3P production in heart of subjects with, 1333-1338
 PP and starved subjects with, glucose production and gluconeogenesis in, 1358-1363
 troglitazone effects on albuminuria in, 981-983
 Stress, mental, lipolysis regulation by SNS in SCI subjects under, 390-391
 STZ-DM, *see* Streptozotocin-induced diabetes mellitus
 Subcutaneous adipose tissue (AT)
 adult GH deficiency and, 813, 815
 correlation between anthropometry, insulin secretion and, 1220-1224
 Substance P (SP), rectal mucosa content of, in IDDM and NIDDM with diarrhea and constipation, 730-734
 Succinate in purified and unpurified islet cells, 985
 Sucrose (S)
 in protein-restricted diet, 692
 in soy protein diet, 699
 Sulfonyleurea therapy of hypertensive NIDDM, 1317
 Superoxide dismutase (SOD), erythrocyte, Cu supplementation effects on, in men, 1380-1383
 Supplementation
 with arginine after injury, nutritional and metabolic effects of mild orotic aciduria during, 785-792
 Cu, effects of, on blood Cu enzyme and CV disease risk in men, 1380-1383
 Surgery, *see* Surgery, GH and; Uninephrectomy
 Surgery, GH and
 GH and hypocaloric N-free diet effects on postoperative protein synthesis, 796-800
 GH modulating AA oxidation in surgery, 23-28
 Sweat chromium (Cr), implications of age-related decrease in, for prevention of cardiovascular disease and NIDDM, 469-473
 Symmetrical dimethylarginine (SDMA), serum, in nondialyzed subjects with chronic renal insufficiency, 1024-1031
 Symmetrically excessive xanthomatosis (Erdheim-Chester disease), LDL levels in, 1215-1219
 Sympathetic nervous system, *see* Spinal cord injury, SNS regulating lipolysis in
 Synthase
 fatty acid, insulin effects on, in fetal hepatocytes, 350-351
 glycogen, polymorphism of gene of, and NIDDM in Russian subjects, 121-122
 Systemic fatty acids (FAs), BRL 49653 effects on supply and on utilization of, and on tissue lipid availability, in NIDDM, 935-942

 T, *see* Testosterone
 T₃, *see* Triiodothyronine
 T₄, *see* Thyroxine
 TAG (triacylglycerol), and VLDL subfraction composition and metabolism in AT, 606, 607
 Taiwanese population, I/D polymorphism of ACE gene in hypertension, NIDDM, coronary heart disease in, 1211-1214
 TAK-044 (combined ET type A/type B receptor antagonist), renoprotective effects of, in malignant hypertension, 1032-1038
 TAT (thrombin-antithrombin III) in obese NIDDM subjects, heparin effects on, 932
 Taurine
 plasma, *see* Plasma taurine
 skeletal muscle, in critical illness, 760
 TBA (thiobarbituric acid), vitamin E effects on reactivity of, 872, 874
 TC, *see* Total cholesterol
 T-cell leukemia, PGs in cachexia induced by, 359-365
 TCP (tropical calcific pancreatitis), beta cell function and insulin sensitivity in, 441-444
 TEE, *see* Total energy expenditure
 TEM, *see* Thermic effect of the meal
 Temperature, colonic, effects of indomethacin and flurbiprofen on, in T-cell leukemia, 360-361
 Testes, radiation dose received from apo tracers by, 1237
 Testing, molecular cell biology model, practical process for, 1490-1491
 Testosterone (T)
 in CAH complicated by CPP, effects of GnRH agonist therapy on, 514
 longitudinal changes in, in healthy older men, 410-413
 mild hyperthyroidism effects on, in young men, 1425
 in obese men, *see* Testosterone in obese men
 in premenopausal and postmenopausal women with different estrogen status, 8
 serum concentrations of, in acutely hyperinsulinemic non-obese men, 526-529
 total, in insulin resistance, 1282, 1284
 see also Testosterone in hirsutism, triptorelin effects on; Testosterone in PCOS
 Testosterone (T) in hirsutism, triptorelin effects on
 in hirsutism without hyperandrogenemia, 905
 with severe hirsutism, effects of triptorelin with desogestrel-containing OCs, 439
 Testosterone (T) in obese men
 plasma, and effects of sex hormones on LPL activity in, 181, 183
 serum, in acutely hyperinsulinemic men, 526-529
 Testosterone (T) in PCOS
 long-term NTX therapy effects on, 540
 metformin effects on, 455
 with severe hirsutism, effects of triptorelin with desogestrel-containing OCs on, 439
 TGF- β (transforming growth factor- β), PKC-signaled increases of, in mesangial cells, inhibited by antioxidants, 918-925
 TGs, *see* Triglycerides
 Therapy and management
 of mitochondrial disorders, 314-316
 see also Long-term therapy *specific treatment modalities and conditions*
 Thermic effect of the meal (TEM)
 in endurance training identical twins, 501
 see also Caloric diet and intake
 Thiamine, intake of, on diet high in vegetables, fruit, and nuts, 532
 Thiobarbituric acid (TBA), vitamin E effects on reactivity of, 872, 874
 3T3-L1 preadipocytes, induction of mRNA for GHR gene during differentiation of, 114-118
 Threonine
 cortisol and estradiol effects on, 248
 in isonitrogenous diet, 786, 790, 791
 plasma, *see* Plasma threonine
 portal adrenergic blockade effects on, 461, 464
 skeletal muscle, in critical illness, 760
 Thrombin-antithrombin III (TAT) in obese NIDDM subjects, heparin effects on, 932
 Thromboxane B₂ (TXB₂) in MCs exposed to high glucose concentrations, D- α -tocopherol effects on, 781, 783

- Thyroid
 dysfunction of, serum guanidino compounds in, 1063-1067; *see also*
 Hyperthyroidism; Hypothyroidism
 radiation dose received from apo tracers by, 1235-1237
see also Pituitary-thyroid axis and entries beginning with element:
 Thyro-
- Thyroid hormones
 regulation of, in insulin and GIP secretion, 154-158
 serum, $1\alpha(\text{OH})\text{D}_3$ effects on levels of, in hyperthyroidism with
 untreated Graves' disease, 1184-1188
see also Thyroxine; Triiodothyronine
- Thyrotropin (TSH; thyroid-stimulating hormone)
 effects of modulation of chronic excessive IL-6 production in
 multiple myeloma on, 1345
 hypothyroidism effects on, 155
 imipramine effects on, 1429-1434
 in obese men, effects of sex hormones on LPL activity and, 180
 pituitary neuromedin B in fasting and STZ-DM and secretion of,
 149-153
 PZP effects on secretion of GH and nocturnal, in IDDM, 1305-1311
 serum, effects of long-term RU486 therapy on, 292-296
see also Thyrotropin in Graves' disease
- Thyrotropin (TSH) in Graves' disease
 MMI and $1\alpha(\text{OH})\text{D}_3$ effects on hyperthyroidism and untreated
 Graves' disease, 1185
 and primary hypothyroidism, 1129
- Thyrotropin-releasing hormone (TRH), inhibitory effects of, on GH
 release in GH-secreting adenoma cells, galanin inhibitory
 effects compared with, 425-430
- Thyroxine (T_4)
 effects of modulation of chronic excessive IL-6 production in
 multiple myeloma on, 1343-1348
 in Graves' disease and primary hypothyroidism, 1129
 in obese men, and effects of sex hormones on LPL activity, 180
 plasma, effects of endurance training on, in identical twins, 502
 serum, *see* Serum thyroxine
 in underweight and normoponderal subjects with and without cancer,
 141
- Time of day, effects of glucose tolerance status and, on serum SCFA
 concentrations, 805-811
- Time-dependent effects of insulin on lipid synthesis in fetal hepato-
 cytes, 345-354
- Tissue lipids, BRL 49653 effects on availability of, in NIDDM, 935-942
- Tissue mass, relationship between RMR and, 1226, 1228
- Tissue plasminogen activator (tPA)
 in PCOS, metformin effects on, 455
 plasma levels of, and androgenic status in men, 1287-1293
- Tissue-specific effects of chronic dietary protein restriction and gastros-
 tomy on IGF-I pathway in liver and colon, 691-697
- TNF, *see* Tumor necrosis factor; Tumor necrosis factor- α
- Tobacco, *see* Smoking
- α (alpha)-Tocopherol (vitamin E)
 antioxidant and TG-lowering effects of, associated with prevention of
 abnormal reactivity and morphology of aorta in STZ-DM,
 872-879
 intake of, with diet high in vegetables, fruit, and nuts, 532
 plasma and LDL, in CAPD patients, 836, 837
- D- α (alpha)-Tocopherol (vitamin E), effects of, on MCs exposed to high
 glucose concentrations, 779-784
- Tolrestat, effects of, on NRBA in IDDM and NIDDM, 634-638
- Total amino acids (AAs), skeletal muscle and plasma, in critical illness,
 760
- Total body radiation dose from apo tracers, 1235-1237
- Total cholesterol (TC)
 abdominal AT/insulin secretion correlation and, 1221, 1222
- Total cholesterol (TC) (*Continued*)
 in acute hyperinsulinemia, 1167
 and basal GH levels in women correlated with HDL-C, 1041
 in chronic renal disease, HD, and CAPD subjects, 38
 diet effects on, *see* Total cholesterol, diet effects on
 in ECD, 1218
 exercise and, *see* Total cholesterol, exercise and
 fasting serum, *see* Fasting serum total cholesterol
 in hypobetalipoproteinemia, 627, 630
 in IDDM, intracellular Ca and [^3H]PdBu binding to intact platelets
 and, 950
 in IGT, effects of fibrinogen, PAI-1, and FVII on levels of, 670
 insulin resistance, LDL particle size and, 1276
 niceritrol effects on, 356
 in NIDDM, *see* Total cholesterol in NIDDM
 in obese men, *see* Total cholesterol in obese men
 in PCOS, metformin effects on, 455
 and SLDL particles in children, 147
 smoking cessation effects on, 713, 714
- Total cholesterol (TC), diet effects on
 of diet high in vegetables, fruit, and nuts, 533, 534
 dietary soy protein and ERT effects on TC in ovariectomized
 subjects, 701
- Total cholesterol (TC), exercise and, 1179
 and lovastatin effects, 1207
 in obese exercising men without weight loss, 219
- Total cholesterol (TC) in NIDDM
 fasting serum, Trp64Arg missense mutation of β_3 -adrenergic recep-
 tor and, 202
 in hypertensive NIDDM, 1317
 intracellular Ca and [^3H]PdBu binding to intact platelets and, 950
 in non-obese subjects with diabetic nephropathy, insulin resistance
 and, 1014
 peripheral vasoconstrictor responses to SNS activation and, 236
 with obesity, heparin effects on hemostatic abnormalities and, 931;
see also Total cholesterol in obese men
 in spontaneous NIDDM, effect of lard, olive oil, safflower oil, and
 EPA-E on, 1460
- Total cholesterol (TC) in obese men
 in obese exercising men without weight loss, HDL metabolism and,
 219
 in obese hypertensive men, and effects of diltiazem or quinapril on
 insulin sensitivity, glucose effectiveness, and beta cell function,
 174
- Total energy expenditure (TEE)
 by HIV-infected and healthy men, 1324-1326
 in small-cell lung cancer subjects, HCO_3 -urea method measuring,
 1412-1417
- Total homocysteine (Hcy), plasma, in epileptic patients on anticonvul-
 sant therapy, 959-962
- Total parenteral nutrition (TPN), tumor-bearing subjects on, arginine
 and glutamine metabolism in, 370-373
- Total protein
 effects of diet high in vegetables, fruit, and nuts on, 535
 plasma, cortisol and estradiol effects on, 248
- Total testosterone (T) in insulin resistance, 1282, 1284
- Total triglycerides (TGs)
 exercise effects on, 1181
 in IGT, effects of fibrinogen, PAI-1, and FVII on levels of, 670
- tPA, *see* Tissue plasminogen activator
- TPN (total parenteral nutrition), tumor-bearing subjects on, arginine and
 glutamine metabolism in, 370-373
- Tracers
 apo, radiation dose received from, 1231-1239
see also Stable isotopically labeled tracers and specific tracers

- Training, *see* Exercise
- Transamination, DCA inhibiting glutamine oxidation via, by decreasing pyruvate availability, 268-272
- Transcription, *see* RNA
- Transfer protein, *see* Cholesteryl ester transfer protein
- Transfer ribonucleic acid (tRNA) ^{Leu(UUR)} 3243 mutation in mitochondrial DM, insulin secretion and sensitivity with, 1019-1023
- Transforming growth factor- β (TGF- β), PKC-signaled increases of, in mesangial cells, antioxidants inhibiting, 918-925
- Transgenic subjects, GLUT4 overexpression in exercising, 1349-1357
- Transplantation, liver, somatostatin response to oral test meal in recipients of, 1003-1007
- TRG, *see* Troglitazone
- TRH (thyrotropin-releasing hormone), inhibitory effects of, on GH release in GH-secreting adenoma cells, galanin inhibitory effects compared with, 425-430
- Triacylglycerol (TAG), and VLDL subfraction composition and metabolism in AT, 606
- Triglycerides (TGs)
- abdominal AT/insulin secretion correlation and, 1221, 1222
 - and androgenic status in men, 1289
 - and basal GH levels in women correlated with HDL-C, 1040, 1041
 - in children, 147
 - in chronic renal disease, HD, and CAPD subjects, 38
 - diet effects on, *see* Triglycerides, diet effects on
 - in ECD, 1218
 - in elderly postmenopausal women, lipolysis and, 1313
 - exercise effects on, *see* Triglycerides, exercise and
 - fasting, *see* Fasting triglycerides
 - in FED, 476, 477
 - GH therapy effects on, in Turner's syndrome, 1484
 - heparin effects on concentrations of, 654
 - in HL deficiency, short-term stanozolol therapy effects on, 993, 994
 - in hypercholesterolemia, *see* Triglycerides in hypercholesterolemia
 - in hypobetalipoproteinemia, 627, 630
 - in IDDM, *see* Triglycerides in IDDM
 - in IGT, *see* Triglycerides in IGT
 - and insulin resistance induced by HF diet, 99
 - in male offspring of parent with CAD, 506
 - in myocardial infarction, 1471
 - niceritrol effects on, 356
 - in NIDDM, *see* Triglycerides in NIDDM
 - in obese men, *see* Triglycerides in obese men
 - oral medium-chain, effects of, on hepatic ketogenesis in FCPD, 1-4
 - in PCOS, metformin effects on, 455
 - plasma, *see* Plasma triglycerides
 - RE kinetics and PP production of, 585, 586
 - serum, *see* Serum triglycerides
 - smoking cessation effects on, 713, 714
 - in STZ-DM, antioxidant and TG-lowering effects of vitamin E associated with prevention of abnormal reactivity and morphology of aorta, 872-879
 - see also* Hypertriglyceridemia
- Triglycerides (TGs), diet effects on
- of diet high in vegetables, fruit, and nuts on, 533
 - of dietary fat restriction, 434, 435
 - dietary soy protein and ERT effects on TGs in ovariectomized subjects, 701
 - of HF diet, 422
- Triglycerides (TGs), exercise and, 1179
- and lovastatin effects, 1207
 - in obese exercising men without weight loss, 219, 220
- Triglycerides (TGs) in hypercholesterolemia
- in hypercholesterolemic trained and sedentary men, 187
 - pravastatin effects on RBC deformability and, 289
- Triglycerides (TGs) in hypercholesterolemia (*Continued*)
- Triglycerides (TGs) in IDDM
- C and plasma apo H levels and, 523, 524
 - intracellular Ca and [³H]PdBu binding to intact platelets and, 950
- Triglycerides (TGs) in IGT, 915
- effects of fibrinogen, PAI-1, and FVII on levels of, 668, 670
- Triglycerides (TGs) in NIDDM
- C and plasma apo H levels and, 523, 524
 - with or without CHD and hypertension, ACE gene and, 1213
 - diabetic nephropathy, *see* Triglycerides in NIDDM with diabetic nephropathy
 - in hypertensive NIDDM, 1317
 - intracellular Ca and [³H]PdBu binding to intact platelets and, 950
 - with obesity, heparin effects on hemostatic abnormalities and, 931
 - peripheral vasoconstrictor responses to SNS activation and, 236
 - TRG effects on, in normolipidemic non-obese NIDDM subjects, 194
- Triglycerides (TGs) in NIDDM with diabetic nephropathy
- and diabetic retinopathy, 979
 - in non-obese subjects, insulin resistance and, 1014
- Triglycerides (TGs) in obese men
- in obese exercising men without weight loss, HDL metabolism and, 219, 220
 - in obese hypertensive men, and effects of diltiazem or quinapril on insulin sensitivity, glucose effectiveness, and beta cell function, 174
 - and sex hormone effects on LPL activity, 180
 - sequential effects of aerobic exercise and weight loss on, in obese middle-aged and elderly men, 1444
- Triiodothyronine (T₃)
- effects of modulation of chronic excessive IL-6 production in multiple myeloma on, 1343-1348
 - in Graves' disease and primary hypothyroidism, 1129
 - in underweight and non-obese subjects with and without cancer, 141
 - see also* Plasma triiodothyronine; Serum triiodothyronine
- Triphosphatase, *see* ATPase
- Triphosphate, *see* ATP
- Triptorelin in hirsutism
- with desogestrel-containing oral contraceptives, effects of, on hair, bone density, and hormone profile in PCOS with severe hirsutism, 437-440
 - without hyperandrogenemia, 902-907
- tRNA (transfer ribonucleic acid) ^{Leu(UUR)} 3243 mutation in mitochondrial DM, insulin secretion and sensitivity with, 1019-1023
- Troglitazone (TRG; CS-045)
- acute effects of, on muscle glucose metabolism in absence or presence of insulin, 716-721
 - effects of, on insulin sensitivity and beta cell function in hyperlipidemia, 273-281
 - in non-obese normolipidemic NIDDM subjects, 192-198
 - in STZ-DM, effects of, on albuminuria, 981-983
- Tropical calcific pancreatitis (TCP), beta cell function and insulin sensitivity in, 441-444
- Trp64Arg missense mutation of β_3 -adrenergic receptor in Japanese subjects, prevalence of, 199-202
- Trunk and limb lipodystrophy (type 2 Köbberling-Dunnigan syndrome), insulin resistance in, 159-163
- Tryptophan
- to arginine missense mutation of β_3 -adrenergic receptor in Japanese subjects, prevalence of, 199-202
 - in isonitrogenous diet, 786, 790, 791
 - plasma, in critical illness, 760
- TSH, *see* Thyrotropin
- Tuberculosis, effects of n-3 and n-6 PUFAs on resistance to, 619-624

- Tumor(s)
 arginine and glutamine metabolism in tumor-bearing subjects on TPN, 370-373
see also Cancer and specific tumors
- Tumor necrosis factor (TNF)
 IGF-I effects on glucose utilization in subjects treated with, 1052-1058
see also Tumor necrosis factor- α
- Tumor necrosis factor- α (TNF- α)
 effects of, on G6Pase mRNA, 579-583
 in underweight and non-obese subjects with and without cancer, 141
- Turner's syndrome, girls with
 estrogen therapy effects on Ca absorption, Ca retention, and bone turnover in, 908-913
 GH therapy effects on glucose turnover and insulin clearance in, 1482-1488
- Twins, identical, constant energy intake by endurance training, and changes over time in EE and related hormones in, 499-503
- TXB₂ (thromboxane B₂) in MCs exposed to high glucose concentrations, D- α -tocopherol effects on, 781, 783
- Type I diabetes mellitus, *see* Insulin-dependent diabetes mellitus
- Type I procollagen C-terminal propeptide (PICP), relationship of serum IGF-I, serum IGFBP-3, and serum, to sex, pubertal development, growth, insulin, and nutritional status of obese children and adolescents, 862-872
- Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
- Type 2 Köbberling-Dunnigan syndrome (limb and trunk lipodystrophy), insulin resistance in, 159-163
- Tyrosine
 in isonitrogenous diet, 786, 790, 791
 plasma, *see* Plasma tyrosine
 reduced AT PTPase and improved insulin sensitivity following weight loss in obesity, 1140-1145
 skeletal muscle, in critical illness, 760
- Underweight subjects, insulin secretion, insulin sensitivity, and glucose production of, in normoponderal and, with and without cancer, 140-145
- Uninephrectomy, effects of graded, on renal IGF-I, serum IGF-I, and IGFBPs, compensatory renal growth and, 29-35
- Untreated Graves' disease, 1 α (OH)D₃ effects on levels of serum thyroid hormones in hyperthyroidism with, 1184-1188
- Unweighted muscle atrophy attenuated by insulin, 673-679
- Urate, serum, relationship between serum TGs, fractional urate excretion and, 1085-1089
- Urea
 dietary protein intake effects on metabolism of, in burned children, 573-578
 HCO₃-urea method measuring TEE in small-cell lung cancer subjects, 1412-1417
 urinary excretion of, with isonitrogenous diet, 787
see also Serum urea
- Urea nitrogen, blood, in hypercholesterolemia, pravastatin effects on RBC deformability and, 289
- Uremia, AA handling in, 611-618
- Uric acid
 correlation between visceral AT accumulation and metabolism of, in healthy men, 1162-1165
 overproduction of, in gout, plasma uridine level as marker of, 801-804
see also Plasma uric acid; Serum uric acid; Uricemia
- Uricemia, peripheral vasoconstrictor responses to SNS activation and, in NIDDM, 236
- Uridine, *see* Plasma uridine and uridine bases
- Urinary excretion
 of albumin, *see* Urinary excretion of albumin
 CGRP, effects of LANPs, vessel dilator, ANF, and kaliuretic peptide on, 821-822
 creatinine, *see* Creatinine, urinary excretion of
 fractional urate, relationship between serum TGs, serum urate and, 1085-1089
 of guanidino compounds in nondialyzed subjects with chronic renal insufficiency, 1024-1031
 of hypoxanthine, xanthine, and uric acid, *see* Urinary excretion of hypoxanthine, xanthine, and uric acid
 with isonitrogenous diet, 787
 of nitrogen, surgery and, 798
 NO₂/NO₃⁻, as measure of NO production stimulated by acute hyperinsulinemia, 406-409
 of orotidine, allopurinol effects on, 1475
 oxalate, in clofibrate-induced hyperoxaluria, 136
 urea, by burned children, effects of dietary protein intake on, 575
 uridine, *see* Urinary excretion of uridine
see also entries ending with suffix: -uria
- Urinary excretion of albumin
 in IDDM, 662
 in NIDDM, peripheral vasoconstrictor responses to SNS activation and, 236
see also Albuminuria; Proteinuria
- Urinary excretion of hypoxanthine, xanthine, and uric acid
 allopurinol and benzbromarone effects on, 1474, 1475
 ethanol and fructose effects on, compared, 545-546
- Urinary excretion of uridine
 ethanol and fructose effects on, compared, 545-546
 in gout, 802, 803
- Uterus, radiation dose received from apo tracers by, 1237
- $\dot{V}CO_2$
 ethanol effects on, 754
 GH in surgery and, 26, 799
- $\dot{V}O_2$
 ethanol effects on, 752, 754
 GH in surgery and, 26, 799
 of heart failure patients, 1296
 indomethacin and flurbiprofen effects on, in T-cell leukemia, 360-361
 during ischemia in STZ-DM, 170
 during prolonged exercise, 1110
 troglitazone effects on, in presence or absence of insulin, 718
see also $\dot{V}O_{2max}$, exercise effects on
- $\dot{V}O_{2max}$, exercise effects on, 1179, 1182
 increase in HDL-C with endurance exercise by non-obese men, 557
 moderate exercise effects on insulin- and non-insulin mediated glucose uptake, 205
see also $\dot{V}O_{2max}$ in obese exercising subjects
- $\dot{V}O_{2max}$ in obese exercising subjects
 increase in HDL-C with endurance training, 557
 without weight loss, 218
- Valine
 cortisol and estradiol effects on, 248
 in isonitrogenous diet, 786
 plasma, *see* Plasma valine
- Vanadate, differential effects of insulin and, on metabolism of, 562-572
- Vanadium, partial beta cell preservation by, in STZ-DM, 769-777
- Vascular myocyte Na⁺/H⁺ (sodium/hydrogen) exchanger isoform-1 (NHE-1), Ca-induced activation of, 250-256
- Vascular smooth muscle cells (VSMCs), ET-1 production in, modulated by atrial, brain, and C-type natriuretic peptides, 487-493
- Vasoconstrictor responses, peripheral, to sympathetic activation in NIDDM, rheological disorders and, 235-241

- Vasointestinal polypeptide (VIP), rectal mucosa content of, in IDDM and NIDDM with diarrhea and constipation, 730-734
- Vasopressin
 AVP, ET-1 production in VSMCs and, 488-490
 effects of, on hepatocyte MAPK activity, 549
- Vegetables, effects of diet high in fruit, nuts and, on serum lipids, 530-537
- Venous blood, arterialized hand and foot, in assessment of glucose metabolism, 1364-1366
- Venous plasma endothelin-1 (ET-1), lack of association between hyperinsulinemia and altered levels of, in healthy subjects, 1137-1139
- Ventricles, *see* Cardiac ventricles
- Ventromedial hypothalamus (VMH), effects of stimulation of, on glycogenolysis in liver, in vivo microdialysis in study of, 897-901
- Very-low-density lipoprotein(s) (VLDL)
 in AT, subfractions and metabolism of, 605-610
 in chronic renal disease, HD, and CAPD subjects, 38
 Cu supplementation effects on, 1382
 exercise and, *see* Very-low-density lipoprotein(s), exercise and hepatic, RE kinetics and production of, 585
 in hypercholesterolemic sedentary men, 188
 in IGT, effects of fibrinogen, PAI-1, and FVII on levels of, 670
 kinetics of, [³H]leucine in study of, 335-341
 plasma, effects of dietary fat restriction on particle size of, in postmenopausal women, 431-436
- Very-low-density lipoprotein(s) (VLDL), exercise and exercise effects on Lp(a) and subfractions of, in men and women, 1178-1183
 in hypercholesterolemic men, 188
- Very-low-density lipoprotein-cholesterol (VLDL-C)
 in ECD, 1218
 in hypercholesterolemic trained and sedentary men, 187
 in IGT, effects of fibrinogen, PAI-1, and FVII on levels of, 670
 in male offspring of CAD parents, 506, 956
- Very low stable isotopically labeled tracers, GC/MS measuring enrichment of, and its application to measurement of muscle protein synthesis, 943-948
- Vessel dilator, effects of, on CGRP, 818-825
- VIP (vasointestinal polypeptide), rectal mucosa content of, in IDDM and NIDDM with diarrhea and constipation, 730-734
- Visceral adipose tissue (AT)
 correlation between uric acid metabolism and accumulation of, in healthy men, 1162-1165
 effects of, on insulin secretion, insulin sensitivity, and energy expenditure in obesity, 123-129
see also Abdominal adipose tissue
- Vitamin A (retinol)
 intake of, with diet high in vegetables, fruit, and nuts, 532
 plasma and LDL, in CAPD patients, 836, 837
- Vitamin B₂ (riboflavin), intake of, with diet high in vegetables, fruit, and nuts, 532
- Vitamin B₆, intake of, with diet high in vegetables, fruit, and nuts, 532
- Vitamin B₁₂ (cyanocobalamin), intake of, with diet high in vegetables, fruit, and nuts, 532
- Vitamin C (ascorbic acid), intake of, with diet high in vegetables, fruit, and nuts, 532
- Vitamin D receptor alleles, and BMD in premenopausal women, race and, 224-226
- Vitamin E, *see* α -Tocopherol; D- α -Tocopherol
- Vitamin mix
 in protein-restricted diet, 692
 in soy protein diet, 699
- VLDL(s), *see* Very-low-density lipoprotein(s)
- VLDL-C, *see* Very-low-density lipoprotein-cholesterol
- VMH (ventromedial hypothalamus), effects of stimulation of, on glycogenolysis in liver, in vivo microdialysis in study of, 897-901
- Voiding frequency, and radiation dose from apo tracers received by bladder, 1237-1238
- Von Willebrand factor (vWF), plasma levels of, and androgenic status in men, 1287-1293
- VSMCs (vascular smooth muscle cells), ET-1 production in, modulated by atrial, brain, and C-type natriuretic peptides, 487-493
- Waist-to-hip ratio (WHR)
 abdominal AT/insulin secretion correlation and, 1221, 1222
 adult GH deficiency and, 813
 aging effects on DHEAS in relation to fasting insulin level and, 828-830
 and androgenic status in men, 1289
 exercise and, *see* Waist-to-hip ratio, exercise effects on of FCPD subjects, 2
 of IGT subjects, 668, 670, 915, 1174
 insulin resistance and, *see* Waist-to-hip ratio, insulin resistance and of male offspring of CAD parents, 506, 956
 of NIDDM subjects, Waist-to-hip ratio of NIDDM subjects of obese subjects, *see* Waist-to-hip ratio of obese subjects of PCOS subjects, *see* Waist-to-hip ratio in PCOS
 of postmenopausal women, *see* Waist-to-hip ratio of postmenopausal women
 race and hepatic insulin extraction and clearance and, 55
- Waist-to-hip ratio (WHR), exercise effects on, 1179, 1182
 endurance training effects in non-obese men, 557
 plasma insulin, physical activity and, 1420
- Waist-to-hip ratio (WHR), insulin resistance and
 ACE gene and, 396, 397
 LDL particle size and, 1276, 1278
 relationship between, 1282, 1284
- Waist-to-hip ratio (WHR) of NIDDM subjects
 with or without CHD and hypertension, ACE gene and, 1213
 non-obese, with diabetic nephropathy, insulin resistance and, 1014
 obese, heparin effects on hemostatic abnormalities and, 931
 peripheral vasoconstrictor responses to SNS activation and, 236
- Waist-to-hip ratio (WHR) of obese men
 endurance training effects on, 557
 of obese hypertensive men, and effects of diltiazem or quinapril on insulin sensitivity, glucose effectiveness, and beta cell function, 174
 and sex hormone effects on LPL activity, 180
- Waist-to-hip ratio (WHR) of obese subjects
 with NIDDM, heparin effects on hemostatic abnormalities and, 931
see also Waist-to-hip ratio of obese men; Waist-to-hip ratio of obese women
- Waist-to-hip ratio (WHR) of obese women
 with PCOS, long-term NTX therapy effects on GH and insulin secretion and, 539
 postmenopausal, with different estrogen status, 7, 8
 premenopausal, hyperinsulinism, sex hormones and, 1253, 1255
- Waist-to-hip ratio (WHR) in PCOS
 metformin effects on, 455
 in non-obese subjects, long-term NTX therapy effects on GH and insulin secretion and, 539
- Waist-to-hip ratio (WHR) of postmenopausal women
 with different estrogen status, 7, 8
 plasma leptin and, 1479
- WAT (white adipose tissue), lipogenesis in, after starvation-refeeding cycles, 10-17
- Water, skeletal muscle, in critical illness, 759, 760

- WBCs, *see* White blood cell count
- Weight gain
with isonitrogenous diet, 787
and vanadium therapy of STZ-DM, 771
- Weight loss by obese men
effects of prolonged exercise by obese men without, on HDL metabolism, 217-223
sequential effects of aerobic exercise and, on CV disease risk factors in obese middle-aged and older men, 1441-1447
- Weight loss in obesity
by adolescents and children, 867
reduced AT PTPase and improved insulin sensitivity following, 1140-1145
see also Weight loss by obese men; Weight-reducing diet, obese women on
- Weight-reducing diet, obese women on
exercising women, BMC changes in, 857-861
FM loss during, *see* Fat mass in obese women on weight-reducing diet
- West African ancestry, serum insulin, C-peptide concentrations, hepatic insulin extraction, and insulin clearance in African Americans of, 53-58
- Wheat bran in soy protein diet, 699
- Wheat flour in soy protein diet, 699
- White adipose tissue (WAT), lipogenesis in, after starvation-refeeding cycles, 10-17
- White Americans, *see* Race and ethnicity
- White blood cell (WBC) count
in chronic renal disease, HD, and CAPD subjects, 37
in T-cell leukemia, indomethacin and flurbiprofen effects on, 362
- Whole-body metabolism, computers models in exploration of, 330-332
- Whole-body production of KIC from leucine in fed state, splanchnic production versus, 164-167
- WHR, *see* Waist-to-hip ratio
- Women
with eating disorders, *see* Anorexia nervosa; Bulimia nervosa
levels of basal GH in, correlated with HDL-C, 1039-1044
- Women (*Continued*)
non-obese PCOS, long-term NTX therapy effects on secretion of GH and insulin in, 538-543; *see also* Polycystic ovary syndrome
young, with endometriosis, serum Lp(a) levels in, 735-739
see also Elderly women; Hirsutism in women; Leptin in women; Normal adult subjects; Postmenopausal women; Preeclampsia; Premenopausal women; Sex; Women, exercising; Women, obese
- Women, exercising
effects of fitness on VLDL subfractions and Lp(a) in, 1178-1183
obese, on weight-reducing diet and, BMC changes in, 857-861
see also Exercise
- Women, obese
NPY, leptin, and galanin release in, 1384-1389
with PCOS, and NTX effects in insulin and GH secretion, 538-543
premenopausal, hyperinsulinemia, sex hormones and, 1252-1258
on weight-reducing diet, *see* Weight-reducing diet, obese women on
see also Obesity
- Wortmannin, conversion of insulin, but not oxytocin, from antilipolytic to lipolytic agent by, in presence of forskolin, 62-66
- Xanthine, *see* Plasma xanthine
- Xanthomatosis, symmetrically excessive, LDL levels in, 1215-1219
- X-ray absorptiometry, dual-energy, pre- and post-HD changes in body composition of subjects on chronic HD as assessed by, 1059-1062
- Young men, effects of mild hyperthyroidism on GH and insulin secretion, and on sex hormones in, 1424-1428
- Young subjects
CHO effects on Apo A-I expression in older and, 1132-1136
with IDDM and NIDDM, intracellular Ca and [³H]PdBu binding to intact platelets in, 949-953
see also Young men; Young women
- Young women, with endometriosis, serum Lp(a) levels in, 735-739
- Zinc (Zn), whole-body metabolism of, computer model of, 330-332